

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:32:22 ; Search time 125 Seconds
(without alignments)
716.540 Million cell updates/sec

Title: US-09-211-315-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	1685	100.0	317	2	AAW83195	Aaw83195 Human ost
2	1685	100.0	317	2	AAW69957	Aaw69957 NF-kB rec
3	1685	100.0	317	2	AAW68293	Aaw68293 NF-kB rec
4	1685	100.0	317	2	AAE08738	Aae08738 Human rec
5	1685	100.0	317	3	AAY84417	Aay84417 Amino aci
6	1685	100.0	317	4	AAE04426	Aae04426 Human rec
7	1685	100.0	317	4	AAE01993	Aae01993 Human ful
8	1685	100.0	317	5	ABB08134	Abb08134 Human RAN
9	1685	100.0	317	5	AAE26103	Aae26103 Human RAN

10	1685	100.0	317	5	ABG31631	Abg31631	Human	RAN
11	1685	100.0	317	5	AAU78285	Aau78285	Human	TRA
12	1685	100.0	317	5	AAO19096	Aao19096	C neoform	
13	1685	100.0	317	6	ABP55108	Abp55108	Human	ost
14	1685	100.0	317	6	AAE34364	Aae34364	Human	rec
15	1685	100.0	317	6	ABR42314	Abr42314	Human	RAN
16	1685	100.0	317	7	ADB16988	Adb16988	Human	rec
17	1685	100.0	317	7	ADC35204	Adc35204	Human	TNF
18	1685	100.0	317	7	ADC73002	Adc73002	Human	RAN
19	1685	100.0	317	7	ADC78268	Adc78268	Human	RAN
20	1677	99.5	317	2	AAW83018	Aaw83018	Osteoclas	
21	1417.5	84.1	316	2	AAW83017	Aaw83017	Osteoclas	
22	1417.5	84.1	316	2	AAW83194	Aaw83194	Human	ost
23	1417.5	84.1	316	2	AAW59654	Aaw59654	Amino	aci
24	1417.5	84.1	316	2	AAyl7874	Aayl7874	Murine	TR
25	1417.5	84.1	316	3	AAy91024	Aay91024	Mouse	OBM
26	1417.5	84.1	316	3	AAy84418	Aay84418	Amino	aci
27	1417.5	84.1	316	3	AAy84419	Aay84419	Amino	aci
28	1417.5	84.1	316	5	AAU78289	Aau78289	Mouse	TRA
29	1417.5	84.1	316	6	ABR42071	Abr42071	Human	RAN
30	1417.5	84.1	316	6	ABB99477	Abb99477	Amino	aci
31	1417.5	84.1	316	6	ABU08463	Abu08463	Amino	aci
32	1417.5	84.1	316	6	ABR55560	Abr55560	Amino	aci
33	1396.5	82.9	318	4	AAB82092	Aab82092	Rat	osteo
34	1326.5	78.7	294	2	AAW69956	Aaw69956	NF-kB	rec
35	1326.5	78.7	294	2	AAW68292	Aaw68292	NF-kB	rec
36	1326.5	78.7	294	2	AAE08737	Aae08737	Murine	re
37	1326.5	78.7	294	4	AAE04425	Aae04425	Murine	re
38	1326.5	78.7	294	4	AAE01992	Aae01992	Murine	RA
39	1326.5	78.7	294	5	AAE26102	Aae26102	Mouse	RAN
40	1326.5	78.7	294	7	ADB16986	Adb16986	Murine	re
41	1326.5	78.7	294	7	ADC73000	Adc73000	Murine	RA
42	1326.5	78.7	294	7	ADC78266	Adc78266	Murine	RA
43	1325	78.6	250	6	ADA50079	Ada50079	Human	wil
44	1322	78.5	250	6	ADA50095	Ada50095	Human	RAN
45	1322	78.5	250	6	ADA50094	Ada50094	Human	RAN

ALIGNMENTS

RESULT 1

AAW83195

ID AAW83195 standard; protein; 317 AA.

XX

AC AAW83195;

XX

DT 11-FEB-1999 (first entry)

XX

DE Human osteoprotegerin binding protein from the pcDNA/huOPGbp1.insert.

XX

KW Human; osteoprotegerin binding protein; OPG binding protein; arthritis;

KW osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;

KW hypercalcaemia; osteoclast differentiation and activation receptor;

KW Paget's disease.

XX

OS Homo sapiens.

XX
 PN WO9846751-A1.
 XX
 PD 22-OCT-1998.
 XX
 PF 15-APR-1998; 98WO-US007584.
 XX
 PR 16-APR-1997; 97US-00842842.
 PR 23-JUN-1997; 97US-00880855.
 PR 30-MAR-1998; 98US-00052521.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Boyle WJ;
 XX
 DR WPI; 1998-594578/50.
 DR N-PSDB; AAV70285.
 XX
 PT Nucleic acid encoding osteoprotegrin binding protein - useful for, e.g.
 PT treating bone diseases by modulating osteoclast differentiation and for
 PT diagnosis.
 XX
 PS Claim 19; Fig 4; 47pp; English.
 XX
 CC The present sequence is human osteoprotegerin (OPG) binding protein. Host
 CC cells transfected with vectors containing nucleic acid molecules encoding
 CC OPG binding protein are used to produce recombinant OPG binding protein.
 CC OPG binding protein is used in binding assays to determine osteoprotegrin
 CC (OG) in biological samples; to screen for specific binding agents
 CC (particularly agonists and antagonists, including intracellular proteins)
 CC ; to raise Ab (useful in immunoassays for detection of OPG binding
 CC protein) and to identify compounds that modulate binding of OPG binding
 CC protein to osteoclast differentiation and activation receptor (ODAR). The
 CC nucleic acid molecule encoding OPG binding protein can be used to detect
 CC OPG binding protein-encoding sequences, e.g. screening for related
 CC sequences, also to produce transgenic animal models, while complementary
 CC sequences are used for antisense regulation of OPG binding protein
 CC expression. Modulators of OPG binding protein, particularly soluble forms
 CC of OPG binding protein or Ab, are used to treat or prevent bone diseases,
 CC e.g. osteoporosis, bone loss caused by arthritis or metastases,
 CC hypercalcaemia, Paget's disease, periodontal disease, osteoporosis,
 CC loosening of prostheses, optionally in combination with agents that
 CC promote bone growth
 XX
 SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 4.3e-154;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

 Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 2

AAW69957

ID AAW69957 standard; protein; 317 AA.

XX

AC AAW69957;

XX

DT 08-OCT-1998 (first entry)

XX

DE NF-kB receptor activator RANK ligand (RANKL).

XX

KW RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;

KW immune response; inflammatory response; toxic shock; sepsis; RANKL;

KW RANK ligand; tumour necrosis factor; TNF.

XX

OS Homo sapiens.

XX

PN WO9828426-A2.

XX

PD 02-JUL-1998.

XX

PF 22-DEC-1997; 97WO-US023775.

XX

PR 23-DEC-1996; 96US-0059978P.

PR 07-MAR-1997; 97US-00813509.

PR 14-OCT-1997; 97US-0064671P.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Anderson DM, Galibert LJ, Maraskovsky E;

XX

DR WPI; 1998-377657/32.

DR N-PSDB; AAV41378.

XX

PT New isolated ligand for receptor activator of NF-kappa B - used to

PT develop products for augmenting an immune response for inhibiting an

PT inflammatory response and for protection of cells.

XX

PS Claim 27; Page 59-60; 80pp; English.

XX

CC This represents a human RANKL, a ligand for the RANK (receptor activator
 CC of necrosis factor-kappaB (NF-kB)) polypeptide. RANK is a member of the
 CC tumour necrosis factor (TNF) family. A soluble RANK may be used for
 CC inhibiting activation of NF-kB, by contacting a cell expressing membrane-
 CC associated RANK with a soluble RANK which binds to RANK ligand (RANKL).
 CC RANKL polypeptides can activate RANK and can be used to induce maturation
 CC of dendritic cells and enhance their allo-stimulatory capacity, thereby
 CC augmenting an immune response. The soluble RANK polypeptide composition
 CC may also be used for regulating an immune or inflammatory response.
 CC Inhibition of NF-kB by RANK antagonists may be useful in ameliorating
 CC negative effects of an inflammatory response that result from triggering
 CC of RANK, e.g. in treating toxic shock or sepsis, graft-versus-host
 CC reactions, or acute inflammatory reactions. They can also be used in
 CC adjunct therapy for disease characterised by neoplastic cells that
 CC express RANK. RANKL polypeptides can also be used to identify inhibitors
 CC of RANK and thus inhibitors of an inflammatory response, and also for
 CC protecting RANK-expressing cells from the negative effects of
 CC chemotherapy or the presence of high levels of TNF-alpha. The products
 CC can also be used for detection and drug screening
 XX
 SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 4.3e-154;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Db	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 3
 AAW68293
 ID AAW68293 standard; protein; 317 AA.
 XX
 AC AAW68293;
 XX

```
DT      08-OCT-1998   (first entry)
XX
DE      NF-kB receptor activator RANK ligand (RANKL).
XX
KW      RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;
KW      immune response; inflammatory response; toxic shock; sepsis; RANKL;
KW      RANK ligand; tumour necrosis factor; TNF.
XX
OS      Homo sapiens.
XX
PN      WO9828424-A2.
XX
PD      02-JUL-1998.
XX
PF      22-DEC-1997;    97WO-US023866.
XX
PR      23-DEC-1996;    96US-0059978P.
PR      07-MAR-1997;    97US-00813509.
PR      14-OCT-1997;    97US-0064671P.
XX
PA      (IMMV ) IMMUNEX CORP.
XX
PI      Anderson DM, Galibert LJ, Maraskovsky E;
XX
DR      WPI; 1998-377655/32.
DR      N-PSDB; AAV41372.
XX
PT      New isolated receptor activator of necrosis factor-kappa B - useful for,
PT      e.g. developing products for regulating an immune or inflammatory
PT      response, treating toxic shock or sepsis.
XX
PS      Example 7; Page 59-60; 80pp; English.
XX
CC      This represents a human RANKL, a ligand for the RANK (receptor activator
CC      of necrosis factor-kappaB (NF-kB)) polypeptide. RANK is a member of the
CC      tumour necrosis factor (TNF) family. Host cells transformed or
CC      transfected with an expression vector comprising the RANK encoding
CC      nucleic acid can be used to produce recombinant RANK protein. The soluble
CC      RANK may be used for inhibiting activation of NF-kB, by contacting a cell
CC      expressing membrane-associated RANK with a soluble RANK which binds to
CC      RANK ligand (RANKL). The soluble RANK polypeptide composition may also be
CC      used for regulating an immune or inflammatory response. Inhibition of NF-
CC      kB by RANK antagonists may be useful in ameliorating negative effects of
CC      an inflammatory response that result from triggering of RANK, e.g. in
CC      treating toxic shock or sepsis, graft-versus-host reactions, or acute
CC      inflammatory reactions. They can also be used in adjunct therapy for
CC      disease characterised by neoplastic cells that express RANK. The products
CC      can also be used for detection and drug screening
XX
SQ      Sequence 317 AA;

Query Match          100.0%; Score 1685; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPAAASRSMFVALLGLGLGQV 60

Db	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 4

AAE08738

ID AAE08738 standard; protein; 317 AA.

XX

AC AAE08738;

XX

DT 15-NOV-2001 (first entry)

XX

DE Human receptor activator of NF kappaB ligand (RANKL) protein.

XX

KW Human; receptor activator of nuclear factor kappaB ligand; RANKL; NF;

KW tumour necrosis factor; TNF; TNF receptor associated factor; TRAF;

KW immune response; inflammatory response; graft-versus-host reaction;

KW toxic shock; sepsis; acute inflammatory reaction; bone resorption;

KW anti-apoptotic signal; therapy; immunosuppressant; anti-inflammatory.

XX

OS Homo sapiens.

XX

PN US6271349-B1.

XX

PD 07-AUG-2001.

XX

PF 17-DEC-1998; 98US-00215649.

XX

PR 23-DEC-1996; 96US-0059978P.

PR 23-DEC-1996; 96US-00772330.

PR 07-MAR-1997; 97US-0077181P.

PR 07-MAR-1997; 97US-00813509.

PR 14-OCT-1997; 97US-0064671P.

PR 22-DEC-1997; 97US-00996139.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Dougall WC, Galibert L;

XX
DR WPI; 1998-377655/32.
DR N-PSDB; AAD15311.
XX
PT New isolated receptor activator of necrosis factor-kappa B - useful for,
PT e.g. developing products for regulating an immune or inflammatory
PT response, treating toxic shock or sepsis.
XX
PS Example 15; Col 71-72; 47pp; English.
XX
CC The patent discloses novel receptor activator of nuclear factor (NF)-
CC kappaB (RANK) proteins and their corresponding DNAs. RANK is a member of
CC the tumour necrosis factor (TNF) receptor superfamily and associates with
CC TNF receptor associated factor (TRAF) 2 and 3 which are important in the
CC regulation of immune and inflammatory response. The receptors are useful
CC for regulating immune response and in screening for inhibitors of these
CC receptors. The cytoplasmic domain of RANK is used in developing assays
CC for inhibitors of signal transduction, e.g. for screening the molecules
CC that inhibit interaction of RANK with TRAF1, TRAF2, TRAF3, TRAF5 and
CC particularly TRAF6. NF-kappaB inhibition by RANK antagonists are useful
CC in ameliorating the negative effects of an inflammatory response that
CC result from triggering of RANK, e.g. in treating toxic shock or sepsis,
CC graft-versus-host reactions, acute inflammatory reactions and the effects
CC of bone resorption. RANK acts as an anti- apoptotic signal and rescue the
CC cells that express RANK from apoptosis. Soluble forms of the receptor are
CC used in vivo or in vitro based screening tests for agonists or
CC antagonists of RANK activity, as antagonists of RANK-mediated NF-kappa B
CC activation, or to inhibit transduction of a signal via RANK. RANK
CC compositions are used in the development of both agonistic and
CC antagonistic antibodies, or as an adjunct therapy for disease
CC characterised by neoplastic cells that express RANK. Compounds that
CC interfere with RANK/TRAF6 interactions are useful for modulating the
CC formation of osteoclasts from osteoclast precursors and for modulating
CC osteoclast function and activities. They are used as inhibitors of
CC diseases associated with excess bone resorption and as immunosuppressants
CC or anti-inflammatory agents. The RANK DNAs are useful for the expression
CC of recombinant proteins, as probes for analysis of the presence or
CC distribution of RANK transcripts, while the proteins are useful in
CC preparing kits for the detection of soluble RANK, or monitor RANK-related
CC activity. The present sequence is RANK ligand (RANKL) protein from human
XX
SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
|
Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
|
Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
|

Db 121 QAFQGA VQKELQHIVGSQH IRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180
 QY 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
 QY 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
 QY 301 PDQDATYFGAFKVRDID 317
 ||||||||||||||||
 Db 301 PDQDATYFGAFKVRDID 317

RESULT 5

AAAY84417

ID AAY84417 standard; protein; 317 AA.

XX

AC AAY84417;

XX

DT 25-JUL-2000 (first entry)

XX

DE Amino acid sequence of a human osteoprotegerin ligand (OPGL).

XX

KW Osteoprotegerin ligand; OPGL; osteoprotegerin; osteoclastogenesis;

KW tumour necrosis factor receptor; type II transmembrane protein;

KW osteoclast differentiation; CSF-1; osteoclast activator; immune response;

KW osteoporosis; bone resorption.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Region 49. .69

FT /note= "transmembrane region"

FT Domain 70. .157

FT /note= "extracellular stalk domain"

FT Region 158. .317

FT /note= "active ligand moiety"

XX

PN WO200015807-A1.

XX

PD 23-MAR-2000.

XX

PF 13-SEP-1999; 99WO-DK000481.

XX

PR 15-SEP-1998; 98DK-00001164.

PR 02-OCT-1998; 98US-0102896P.

XX

PA (MEBI-) M & E BIOTECH AS.

XX

PI Halkier T, Haaning J;

XX

DR WPI; 2000-271444/23.

DR N-PSDB; AAZ99964.

XX

PT In vivo down-regulation of osteoprotegerin ligand (OPGL) activity used to

PT treat, prevent and ameliorate osteoporosis.

XX

PS Claim 19; Page 78-79; 110pp; English.

XX

CC The present sequence represents a human osteoprotegerin ligand (OPGL).

CC Osteoprotegerin is a secreted member of the tumour necrosis factor

CC receptor family, which blocks osteoclastogenesis in a dose dependent

CC manner. The OPGL protein is synthesised as a type II transmembrane

CC protein. The murine and human OPGL polypeptides are 87% homologous. OPGL

CC is a potent osteoclast differentiation factor when combined with CSF-1.

CC It is not capable of inducing osteoclast differentiation in the absence

CC of CSF-1. OPGL is also an activator of mature osteoclasts. The

CC specification describes a method for the in vivo down-regulation of OPGL

CC activity in an animal. The method comprises using at least one OPGL

CC polypeptide or subsequence, and/or at least one OPGL analogue to induce

CC an immune response in the animal. The method and OPGL polypeptide are

CC useful for treating, preventing and ameliorating osteoporosis or other

CC diseases or conditions characterised by excessive bone resorption

XX

SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 3; Length 317;

Best Local Similarity 100.0%; Pred. No. 4.3e-154;

Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

|||||

Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

|||||

Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTINATDIPSGSH 180

|||||

Db 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTINATDIPSGSH 180

Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

|||||

Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

|||||

Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy 301 PDQDATYFGAFKVRDID 317

|||||

Db 301 PDQDATYFGAFKVRDID 317

RESULT 6

AAE04426

ID AAE04426 standard; protein; 317 AA.

XX

AC AAE04426;

XX

DT 04-SEP-2001 (first entry)

```

XX      Human receptor activator of NF-chi B ligand (huRANKL) protein.
XX
KW      Human; receptor activator of NF-chi B; RANK; tumour necrosis factor; TNF;
KW      CD40; TNF receptor-associated factor; TRAF; ligand; immune response;
KW      chromosome 18q22.1; huRANKL; chromosome 13q14; transmembrane protein.
XX
OS      Homo sapiens.
XX
FH      Key                Location/Qualifiers
FT      Region            162. .317
FT                        /note= "Receptor binding region"
XX
PN      US6242213-B1.
XX
PD      05-JUN-2001.
XX
PF      22-DEC-1997;      97US-00995659.
XX
PR      23-DEC-1996;      96US-0059978P.
PR      23-DEC-1996;      96US-00772330.
PR      07-MAR-1997;      97US-0077181P.
PR      14-OCT-1997;      97US-0064671P.
XX
PA      (IMMV ) IMMUNEX CORP.
XX
PI      Anderson DM;
XX
DR      WPI; 2001-407216/43.
DR      N-PSDB; AAD08715.
XX
PT      New DNA molecules, useful for producing ligands (which are useful for
PT      regulating immune response and in screening for inhibitors of NF-chi B
PT      receptor activator) of the receptor activator of NF-chi B (RANK).
XX
PS      Claim 1; Col 65-66; 43pp; English.
XX
CC      The present invention relates to receptor activator of NF-chi B (RANK)
CC      DNA. RANK is mapped to chromosome 18q22.1 and its ligand (RANKL) to
CC      chromosome 13q14. RANK and RANKL are type 1 and type 2 transmembrane
CC      proteins respectively. RANK is a member of the tumour necrosis factor
CC      (TNF) superfamily and it closely resembles CD40 in the extracellular
CC      region. RANK associates with TNF receptor-associated factor (TRAF) 2 and
CC      TRAF3. The DNA molecules are useful for producing ligands of RANK. The
CC      ligands are useful for regulating immune response and in screening for
CC      inhibitors of RANK. The present sequence is human RANKL (huRANKL) protein
XX
SQ      Sequence 317 AA;

Query Match                100.0%;  Score 1685;  DB 4;  Length 317;
Best Local Similarity      100.0%;  Pred. No. 4.3e-154;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

```

Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 7

AAE01993

ID AAE01993 standard; protein; 317 AA.

XX

AC AAE01993;

XX

DT 31-JUL-2001 (first entry)

XX

DE Human full-length RANKL (receptor activator of NF-kappaB ligand).

XX

KW Human; receptor activator of NF-kappaB; RANK; nuclear factor-kappaB;
 KW NF-kappaB; tumour necrosis factor; TNF; type I transmembrane protein;
 KW TNF receptor-associated factor; TRAF; RANK ligand; RANKL; osteopathic;
 KW inflammatory reaction; bone resorption; gene therapy; immunomodulator;
 KW immune system dysfunction; familial expansile osteolysis; FEO;
 KW early onset Paget's disease of bone; EP; cytostatic; chromosome 13q14.

XX

OS Homo sapiens.

XX

PN WO200136637-A1.

XX

PD 25-MAY-2001.

XX

PF 14-NOV-2000; 2000WO-US031459.

XX

PR 17-NOV-1999; 99US-00442029.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Anderson DM, Hughes AE;

XX

DR WPI; 2001-329222/34.

DR

N-PSDB; AAD05904.

XX

PT New DNA encoding a receptor activator of NF-kappaB polypeptide for the

PT treatment of Pagets disease and Familial Expansile Osteolysis (FEO).

XX
PS Disclosure; Page 76-77; 96pp; English.

XX
CC The present invention relates to a novel receptor, referred to as RANK
CC (receptor activator of NF (nuclear factor)-kappaB), a member of TNF
CC (tumour necrosis factor) receptor superfamily. RANK is a Type I
CC transmembrane protein that interacts with TNF receptor-associated factors
CC (TRAFs). Triggering of RANK by overexpression or co-expression of RANK
CC and membrane bound RANK ligand (RANKL) results in upregulation of the
CC transcription factor NF-kappaB, a ubiquitous transcription factor that is
CC most extensively utilised in cells of the immune system. Inhibition of NF-
CC -kappaB by RANK antagonists is useful in ameliorating negative effects of
CC inflammatory reactions, and the effects of excess bone resorption. The
CC RANK DNAs, proteins and their analogues are useful for the preparation of
CC pharmaceutical compositions, for infecting target cells for use in gene
CC therapy applications in diagnosing diseases associated with RANK, and as
CC targets for use in screening assays. They may be used in the treatment or
CC diagnosis of immune system dysfunction. The present invention also
CC encompasses gene therapy methods to correct gene-activating mutations,
CC associated with e.g. familial expansile osteolysis (FEO) and early onset
CC Paget's disease of bone (EP). The present amino acid sequence is full-
CC length human RANKL (huRANKL) protein. The RANKL gene is located in
CC chromosome 13q14

XX
SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
|
Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
|
Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
|
Db 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
|
Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRS GEEISIEVSNPSLLD 300
|
Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRS GEEISIEVSNPSLLD 300

Qy 301 PDQDATYFGAFKVRDID 317
|
Db 301 PDQDATYFGAFKVRDID 317

RESULT 8
ABB08134

ID ABB08134 standard; protein; 317 AA.
XX
AC ABB08134;
XX
DT 10-SEP-2002 (first entry)
XX
DE Human RANKL polypeptide.
XX
KW Dendritic cell; mobilisation factor; T cell; adjuvant; antibacterial;
KW fungicide; protozoacide; virucide; anti-inflammatory; anti-HIV;
KW tuberculostatic; cytostatic; human; RANKL.
XX
OS Homo sapiens.
XX
PN WO200236141-A2.
XX
PD 10-MAY-2002.
XX
PF 30-OCT-2001; 2001WO-US044834.
XX
PR 02-NOV-2000; 2000US-0245721P.
XX
PA (IMMV) IMMUNEX CORP.
XX
PI Lynch DH, De Smedt TN, Maliszewski CR, Butz EA, Miller RE;
PI Thomas EK;
XX
DR WPI; 2002-500114/53.
XX
PT Treating an individual suffering from infection, e.g. inflammation,
PT chickenpox or AIDS, by administering a combination of dendritic cell
PT mobilization factor or maturation agent, T cell enhancing factor and
PT antigen-specific T cells.
XX
PS Disclosure; Page 42-43; 43pp; English.
XX
CC The invention relates to treating an individual at risk for or suffering
CC from infection with a pathogenic or opportunistic organism. The method
CC involves administering a combination of two to five agents comprising:
CC (a) dendritic cell mobilisation factor; (b) dendritic cell maturation
CC agent; (c) dendritic cell activation agent; (d) T cell enhancing factor;
CC or (e) activated, antigen-specific T cells. The methods are useful for
CC treating an individual at risk for or suffering from infection with a
CC pathogenic or opportunistic organism, e.g. viruses (e.g. HIV), bacteria
CC (e.g. M. tuberculosis), yeast, fungi (e.g. C. albicans) or protozoa (e.g.
CC T. cruzi, which causes Chaga's disease). The methods are especially
CC useful for treating an individual suffering from immunosuppression by
CC enhancing a lymphocyte-mediated immune response. In particular, the
CC method is useful for treating inflammations, chickenpox, oral or genital
CC herpes, mononucleosis, multifocal leukoencephalopathy, hepatitis, AIDS, T
CC cell leukemia or T cell lymphoma. The activated antigen-presenting
CC dendritic cells are useful as a vaccine adjuvant. The present sequence
CC represents a human RANKL polypeptide fragment
XX
SQ Sequence 317 AA;

Query Match

100.0%; Score 1685; DB 5; Length 317;

Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDIAKRSKLEAQPFAHLTINATDIPSGSH 180
        |||
Db    121 QAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDIAKRSKLEAQPFAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 9

AAE26103

ID AAE26103 standard; protein; 317 AA.

XX

AC AAE26103;

XX

DT 14-NOV-2002 (first entry)

XX

DE Human RANK ligand (RANKL) protein.

XX

KW Human; RANK; receptor activator of nuclear factor-kappaB; NF-kB; sepsis;

KW immune response; toxic shock; graft-versus-host reaction; therapy; TRAF;

KW tumour necrosis factor receptor-associated factor; immunosuppressive;

KW antibacterial; antiinflammatory; chromosome 13.

XX

OS Homo sapiens.

XX

PN US2002086827-A1.

XX

PD 04-JUL-2002.

XX

PF 30-MAY-2001; 2001US-00871291.

XX

PR 23-DEC-1996; 96US-0059978P.

PR 07-MAR-1997; 97US-0077181P.

PR 14-OCT-1997; 97US-0064671P.

PR 22-DEC-1997; 97US-00996139.

PR 17-DEC-1999; 99US-00466496.

PR 24-MAY-2000; 2000US-00577800.

XX
PA (IMMV) IMMUNEX CORP.
XX
PI Anderson DM;
XX
DR WPI; 2002-642254/69.
DR N-PSDB; AAD43213.
XX
PT A novel RANK (receptor activator of nuclear factor-kappaB (NF-kB))
PT polypeptide, useful for inhibiting activation of NF-kB and for regulating
PT an immune or inflammatory response in an individual.
XX
PS Example 15; Page 35; 49pp; English.
XX
CC The invention relates to novel RANK (receptor activator of nuclear factor
CC -kappaB (NF-kB)) proteins and polynucleotides encoding them. Sequences of
CC the invention are useful for inhibiting activation of NF-kappaB. They are
CC useful for regulating an immune or inflammatory response in an individual
CC at risk for an immune or inflammatory response. Inhibition of NF-kappaB
CC by RANK antagonists is useful in ameliorating negative effects of an
CC inflammatory response that results from triggering of RANK, for e.g. in
CC treating toxic shock or sepsis, graft-versus-host reactions or acute
CC inflammatory reactions. Soluble RANK is useful as an adjunct therapy for
CC diseases characterised by neoplastic cells that express RANK. Soluble
CC forms of the receptor are useful in vitro to screen for agonists or
CC antagonists of RANK activity. The cytoplasmic domain of RANK is useful in
CC developing assays for inhibitors of signal transduction, to screen for
CC molecules that inhibit interaction of RANK with tumour necrosis factor
CC receptor-associated factor (TRAF) 2 or TRAF3. The present sequence is
CC human RANK ligand (RANKL) protein. RANKL gene is located on chromosome 13
XX
SQ Sequence 317 AA;

```
Qy      301 PDQDATYFGAFKVRDID 317
          |||||
Db      301 PDODATYFGAFKVRDID 317
```

RESULT 10

ABG31631

ID ABG31631 standard; protein; 317 AA.

XX

AC ABG31631;

XX

DT 29-NOV-2002 (first entry)

XX

DE Human RANKL protein.

XX

KW Tumour; cancer; dendritic cell mobilisation factor; tumour-killing agent;

KW dendritic cell maturation agent; T cell enhancing factor; skin cancer;

KW antigen-specific T cell; prostate cancer; liver cancer; bone tumour;

KW brain tumour; spinal cord tumour; cervical intraepithelial neoplasia;

KW actinic keratosis; dendritic cell maturation stimulator; cytostatic;

KW dendritic cell activator; T cell enhancer; human; RANKL.

XX

OS Homo sapiens.

XX

PN WO200266044-A2.

XX

PD 29-AUG-2002.

XX

PF 23-OCT-2001; 2001WO-US046254.

XX

PR 24-OCT-2000; 2000US-0242868P.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Thomas EK, Lyman SD, Lynch DH, De Smedt TN, Maliszewski CR;

XX

DR WPI; 2002-674891/72.

XX

PT Treating an individual with tumors or cancers, e.g. liver cancer or brain

PT tumor, by administering a combination of dendritic cell populations, T

PT cell enhancing factors and activated, antigen-specific T cells.

XX

PS Disclosure; Page 43-44; 44pp; English.

XX

The present invention relates to a new method for treating a tumour-bearing subject. The method involves administering a combination of 2 to 5 agents comprising dendritic cell mobilisation factor, dendritic cell maturation agent, tumour-killing agent, T cell enhancing factor or activated, antigen-specific T cells. The method is useful for treating tumours or cancers in a subject e.g. skin cancer, prostate cancer, liver cancer, tumours of the bone, brain or spinal cord, actinic keratosis, or cervical intraepithelial neoplasia. The present amino acid sequence represents the human RANKL protein that was used in the method of the invention

XX

SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 5; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
      |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

QY     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
      |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

QY    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180
      |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180

QY    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
      |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

QY    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEIEISIEVSNPSLLD 300
      |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEIEISIEVSNPSLLD 300

QY    301 PDQDATYFGAFKVRDID 317
      |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 11

AAU78285

ID AAU78285 standard; protein; 317 AA.

XX

AC AAU78285;

XX

DT 18-JUN-2002 (first entry)

XX

DE Human TRANCE protein splice variant 1.

XX

KW Human; tumour necrosis factor-related activation induced cytokine;

KW TRANCE; dwarfism; osteopetrosis; craniofacial-skeletal discrepancy;

KW bone damage; cartilage damage; traumatic injury; surgery; osteoarthritis;

KW rheumatoid arthritis; acromegaly; gigantism; exostosis; carilaginea;

KW exostosis bursata; multiple osteocartilaginous exostosis; chondrocyte;

KW cartilage growth; skeletal growth.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Region 126. .317

FT /note= "Specifically claimed in claims 17 and 18"

FT Region 137. .317

FT /note= "Specifically claimed in claims 17 and 18"

FT Region 140. .317

FT /note= "Specifically claimed in claims 17 and 18"

FT Region 145. .317

FT /note= "Specifically claimed in claims 17 and 18"

FT Region 158. .317
 FT /note= "Specifically claimed in claims 17 and 18"
 FT Domain 159. .317
 FT /note= "TNF core domain, specifically claimed in claims
 FT 17 and 18"
 XX
 PN WO200216551-A2.
 XX
 PD 28-FEB-2002.
 XX
 PF 20-AUG-2001; 2001WO-US026101.
 XX
 PR 18-AUG-2000; 2000US-0226197P.
 XX
 PA (UYMA-) UNIV MASSACHUSETTS MEDICAL CENT.
 XX
 PI Choi Y, Odgren PR, Marks SC;
 XX
 DR WPI; 2002-304119/34.
 DR N-PSDB; ABK12876.
 XX
 PT Treating mammal having disorder characterized by abnormal
 PT cartilage/skeletal growth such as dwarfism, acromegaly, by administering
 PT tumor necrosis factor-related activation induced cytokine-modulating
 PT agent to mammal.
 XX
 PS Disclosure; Fig 10; 55pp; English.
 XX
 CC The present invention relates to a new method of treating a mammal having
 CC a disorder comprising insufficient or excessive cartilage or skeletal
 CC growth. The method of the invention involves administering to the mammal
 CC a tumour necrosis factor-related activation induced cytokine (TRANCE)-
 CC modulating agent. The method is useful for treating a mammal having a
 CC disorder comprising insufficient or excessive cartilage or skeletal
 CC growth, where the disorder comprising insufficient cartilage or skeletal
 CC growth is selected from dwarfism, osteopetrosis, craniofacial-skeletal
 CC discrepancies and bone or cartilage damage resulting from traumatic
 CC injury, surgery, osteoarthritis or rheumatoid arthritis, and disorders
 CC comprising excessive cartilage or skeletal growth are selected from
 CC acromegaly, gigantism, exostosis, carilaginea, exostosis bursata and
 CC multiple osteocartilaginous exostoses. The method is useful for
 CC inhibiting chondrocyte differentiation. The present amino acid sequence
 CC represents the human TRANCE protein, splice variant 1, of the invention.
 CC TRANCE is a member of the tumour necrosis factor family and acts directly
 CC on cartilage-producing cells (chondrocytes)
 XX
 SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 5; Length 317;
 Best Local Similarity 100.0%; Pred. No. 4.3e-154;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMEVALLGLGLGQV 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMEVALLGLGLGQV 60
 Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

```

Db          |||||
61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy          121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180
          |||||
Db          121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180

Qy          181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
          |||||
Db          181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy          241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300
          |||||
Db          241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300

Qy          301 PDQDATYFGAFKVRDID 317
          |||||
Db          301 PDQDATYFGAFKVRDID 317

```

RESULT 12

AAO19096

ID AAO19096 standard; protein; 317 AA.

XX

AC AAO19096;

XX

DT 22-NOV-2002 (first entry)

XX

DE C neoformans antigen expressing dendritic cell related protein #5.

XX

KW Human; fungicide; fungal infection; dendritic cell; antigen;

KW Cryptococcus neoformans; vaccine; immunostimulant.

XX

OS Homo sapiens.

XX

PN WO200266053-A2.

XX

PD 29-AUG-2002.

XX

PF 14-DEC-2001; 2001WO-US048288.

XX

PR 04-JAN-2001; 2001US-0259653P.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Thomas EK;

XX

DR WPI; 2002-674896/72.

XX

PT Producing a population of activated, Cryptococcus neoformans antigen-

PT presenting dendritic cells for preventing or treating C. neoformans

PT infection comprises causing the obtained dendritic cells to present the

PT antigen.

XX

PS Disclosure; Page 30-32; 32pp; English.

XX

CC The present invention relates to a method of producing a population of

CC activated, Cryptococcus neoformans antigen-presenting dendritic cells,
CC comprising causing the obtained dendritic cells to present the antigen
CC and maturing the dendritic cells. The activated, C. neoformans antigen-
CC expressing dendritic cells are useful for treating, or as vaccines or
CC vaccine adjuvants against, C. neoformans infection, or for generating
CC antigen-specific T cells. The present sequence is a human protein shown
CC in the exemplification of the invention

XX

SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 5; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
          |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
          |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
          |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
          |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVG GFFKLRS GEEISIEVSNPSLLD 300
          |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVG GFFKLRS GEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
          |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 13

ABP55108

ID ABP55108 standard; protein; 317 AA.

XX

AC ABP55108;

XX

DT 05-FEB-2003 (first entry)

XX

DE Human osteoprotegerin ligand.

XX

KW Osteoprotegerin ligand; OPG ligand; OPGL; human; autoimmune disease;

KW rheumatoid arthritis; diabetes; osteoarthritis; psoriasis;

KW inflammatory bowel disease; transplant rejection; allergy;

KW immunosuppressive; antirheumatic; antiarthritic; antidiabetic;

KW antipsoriatic; immunosuppressive; antiallergic; antiinflammatory;

KW osteopathic; antiulcer; monocyte.

XX

OS Homo sapiens.

XX
FH Key Location/Qualifiers
FT Domain 1. .47
FT /note= "putative cytoplasmic domain"
FT Domain 48. .68
FT /note= "putative transmembrane signal-anchor"
FT Domain 69. .317
FT /note= "putative extracellular domain"
FT Modified-site 171
FT /note= "potential N-glycosylation site"
FT Modified-site 198
FT /note= "potential N-glycosylation site"
XX
PN WO200276507-A2.
XX
PD 03-OCT-2002.
XX
PF 06-FEB-2002; 2002WO-US001238.
XX
PR 23-MAR-2001; 2001US-0278215P.
XX
PA (GETH) GENENTECH INC.
XX
PI Grewal I;
XX
DR WPI; 2003-058352/05.
DR N-PSDB; ABV75842.
XX
PT Stimulating mammalian monocytes by exposing to an OPG ligand polypeptide,
PT useful for treating immune related disorders such as autoimmune disease,
PT rheumatoid arthritis, diabetes, osteoarthritis, psoriasis, and allergy.
XX
PS Claim 1; Fig 1B; 111pp; English.
XX
CC The present sequence is the protein sequence of human osteoprotegerin
CC ligand (OPGL), a member of the tumour necrosis factor (TNF) family of
CC molecules that has been reported to bind to at least 2 receptors, RANK
CC and OPG. In the present invention, OPGL was shown to activate human
CC monocytes, and to activate such monocytes to secrete certain cytokines
CC such as interleukin-1 (IL-1), IL-6, IL-12, MIP-1alpha and TNF-alpha and
CC chemokines such as IL-8. OPGL may function in up-regulation of co-
CC stimulatory molecules such as ICAM-a and VCAM-1, LFA, and B7.1, B7.3 and
CC B7h. OPGL may also serve as an antigen presenting molecule which enhances
CC T-cell activation. The invention provides methods of using OPGL to
CC activate monocytes to secrete chemokines or cytokines by exposing a
CC mammalian cell (in cell culture or in a mammal) to OPGL. Also provided
CC are methods of using OPGL to treat conditions or diseases in mammals
CC associated with, or resulting from lack of, or decreased, chemokine or
CC cytokine secretion by monocytes. The invention also provides agonist and
CC antagonist molecules to modulate immune activity. These may include
CC antibodies to the OPG or RANK receptors. An antagonist comprising an anti
CC -OPGL antibody, an anti-OPG receptor antibody, an anti-RANK receptor
CC antibody, an OPG receptor immunoadhesin or a RANK receptor immunoadhesin
CC is used in a claimed method of treating an immune-related condition,
CC especially an autoimmune disease, rheumatoid arthritis, insulin dependent
CC diabetes, osteoarthritis, inflammatory bowel disease (especially
CC ulcerative colitis or Crohn's disease), psoriasis, transplant rejection

CC or allergy
XX
SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 6; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 14

AAE34364

ID AAE34364 standard; protein; 317 AA.

XX

AC AAE34364;

XX

DT 14-MAY-2003 (first entry)

XX

DE Human receptor activator of NF-kappa B ligand (RANKL).

XX

KW Human; acute septic arthritis; osteomalacia; hyperparathyroidism;

KW Cushing's syndrome; receptor activator of NF-kappa B ligand; cancer;

KW bone formation; rickets; Langerhan's cell histiocytosis; gene therapy;

KW monoostotic fibrous dysplasia; radiation therapy; spinal cord injury;

KW RANKL; Gaucher's disease; polyostotic fibrous dysplasia; scurvy.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Domain 1. .47

FT /note= "Intracellular domain"

FT Domain 48. .68

FT /note= "Transmembrane domain"

FT Domain 69. .317

```

FT          /note= "Extracellular domain"
FT    Binding-site  162..317
FT          /note= "RANK-binding domain"

```

XX

PN WO200292016-A2.

XX

PD 21-NOV-2002.

XX

PF 17-MAY-2002; 2002WO-US016002.

XX

PR 17-MAY-2001; 2001US-0291919P.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Dougall WC, Anderson DM;

XX

DR WPI; 2003-129220/12.

DR N-PSDB; AAD52598.

XX

PT Treating patients having e.g. acute septic arthritis, osteomalacia,
PT hyperparathyroidism, Cushing's syndrome or spinal cord injury, comprises
PT administering a receptor activator of NF-kappa B antagonist to increase
PT bone formation.

XX

PS Claim 1; Page 51-52; 52pp; English.

XX

CC The invention relates to a method of treating a patient having e.g. acute
CC septic arthritis, osteomalacia, hyperparathyroidism, Cushing's syndrome
CC or spinal cord injury. The method involves administering a receptor
CC activator of NF-kappa B (RANK) antagonist to stimulate an increase in the
CC rate for formation of new bone. RANK antagonist is capable of inhibiting
CC the ability of RANK to induce NF-kappa B. The method is useful for
CC stimulating bone formation, or for treating patients having acute septic
CC arthritis, osteomalacia (including rickets and scurvy),
CC hyperparathyroidism, Cushing's syndrome, monoostotic fibrous dysplasia,
CC polyostotic fibrous dysplasia, Gaucher's disease, Langerhan's cell
CC histiocytosis, spinal cord injury, patients requiring periodontal
CC reconstruction, or patients who have completed a course or radiation
CC therapy for cancer. The method is also useful for treating a patient who
CC is a prosthetic joint recipient, a bone graft recipient, or a ligament
CC graft recipient. The invention is useful in gene therapy. The present
CC sequence is human RANK ligand (RANKL) protein

XX

SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 6; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.3e-154;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRRASRDYTKYLRGSEEMGGGGPAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Db	1	MRRASRDYTKYLRGSEEMGGGGPAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120

Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 15

ABR42314

ID ABR42314 standard; protein; 317 AA.

XX

AC ABR42314;

XX

DT 11-AUG-2003 (first entry)

XX

DE Human RANKL protein.

XX

KW Human; RANKL; tumour necrosis factor; ligand; cytostatic;

KW immunomodulator; osteopathic.

XX

OS Homo sapiens.

XX

PN WO2003040307-A2.

XX

PD 15-MAY-2003.

XX

PF 25-JUL-2002; 2002WO-US023782.

XX

PR 27-JUL-2001; 2001US-0307838P.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Hilbert DH, Rosen CA;

XX

DR WPI; 2003-430659/40.

XX

PT New heteromultimeric complex having a first polypeptide member of the
PT tumor necrosis factor (TNF) ligand family, and a second different member
PT of TNF ligand family, useful for treating cancer, osteoporosis or an
PT autoimmune disease.

XX

PS Disclosure; Page 366-367; 388pp; English.

XX

CC The present sequence is the protein sequence of human RANKL protein. The
CC invention relates to compositions comprising heterotrimeric complexes of
CC tumour necrosis factor (TNF) ligand family members, and their use in the
CC detection, prevention and treatment of disease. In one embodiment, the

CC heterotrimeric complex comprises full-length or extracellular portions of
 CC RANKL and full-length or extracellular portions of other TNF ligand
 CC family members, preferably TRAIL. The heterotrimeric complexes of the
 CC invention are useful for treating an autoimmune disease, cancer or
 CC osteoporosis, and particularly for inhibiting cancer cell proliferation,
 CC increasing B cell proliferation, or inducing apoptosis of T cells. A
 CC claimed method of inhibiting cancer cell proliferation comprises
 CC administering a heterotrimeric complex consisting of TRAIL and CD40L or
 CC RANKL. A claimed method of treating osteoporosis comprises administering
 CC an antibody against a complex comprising RANKL and TRAIL
 XX
 SQ Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 6; Length 317;
 Best Local Similarity 100.0%; Pred. No. 4.3e-154;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Db	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

Search completed: September 15, 2004, 08:36:35
 Job time : 129 secs

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:32:22 ; Search time 34 Seconds
(without alignments)
481.336 Million cell updates/sec

Title: US-09-211-315-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	%		DB	ID	Description
		Query Match	Length			
1	1685	100.0	317	3	US-08-996-139-13	Sequence 13, Appl
2	1685	100.0	317	3	US-08-995-659-13	Sequence 13, Appl
3	1685	100.0	317	3	US-09-215-649A-13	Sequence 13, Appl
4	1685	100.0	317	4	US-09-052-521C-4	Sequence 4, Appli
5	1685	100.0	317	4	US-09-577-780-13	Sequence 13, Appl
6	1685	100.0	317	4	US-09-577-800-13	Sequence 13, Appl
7	1685	100.0	317	4	US-09-466-496-13	Sequence 13, Appl
8	1685	100.0	317	4	US-09-871-856-13	Sequence 13, Appl
9	1685	100.0	317	4	US-09-871-291-13	Sequence 13, Appl
10	1685	100.0	317	4	US-09-396-937-2	Sequence 2, Appli
11	1685	100.0	317	4	US-09-877-650-13	Sequence 13, Appl

12	1417.5	84.1	316	2	US-08-842-842-7	Sequence 7, Appli
13	1417.5	84.1	316	3	US-08-989-362-2	Sequence 2, Appli
14	1417.5	84.1	316	4	US-09-052-521C-2	Sequence 2, Appli
15	1417.5	84.1	316	4	US-09-671-658A-2	Sequence 2, Appli
16	1417.5	84.1	316	4	US-09-396-937-4	Sequence 4, Appli
17	1417.5	84.1	316	4	US-09-396-937-6	Sequence 6, Appli
18	1326.5	78.7	294	3	US-08-996-139-11	Sequence 11, Appl
19	1326.5	78.7	294	3	US-08-995-659-11	Sequence 11, Appl
20	1326.5	78.7	294	3	US-09-215-649A-11	Sequence 11, Appl
21	1326.5	78.7	294	4	US-09-577-780-11	Sequence 11, Appl
22	1326.5	78.7	294	4	US-09-577-800-11	Sequence 11, Appl
23	1326.5	78.7	294	4	US-09-466-496-11	Sequence 11, Appl
24	1326.5	78.7	294	4	US-09-871-856-11	Sequence 11, Appl
25	1326.5	78.7	294	4	US-09-871-291-11	Sequence 11, Appl
26	1326.5	78.7	294	4	US-09-877-650-11	Sequence 11, Appl
27	771	45.8	187	4	US-09-396-937-8	Sequence 8, Appli
28	769	45.6	173	4	US-09-396-937-10	Sequence 10, Appl
29	759	45.0	173	4	US-09-396-937-12	Sequence 12, Appl
30	721.5	42.8	188	4	US-09-396-937-14	Sequence 14, Appl
31	711.5	42.2	182	4	US-09-396-937-16	Sequence 16, Appl
32	691	41.0	173	4	US-09-396-937-18	Sequence 18, Appl
33	670	39.8	173	4	US-09-396-937-20	Sequence 20, Appl
34	418	24.8	77	4	US-09-632-287A-11	Sequence 11, Appl
35	363	21.5	77	4	US-09-632-287A-10	Sequence 10, Appl
36	251.5	14.9	279	4	US-09-072-993C-3	Sequence 3, Appli
37	251.5	14.9	281	1	US-08-670-354-2	Sequence 2, Appli
38	251.5	14.9	281	3	US-08-584-031-1	Sequence 1, Appli
39	251.5	14.9	281	3	US-08-780-496-1	Sequence 1, Appli
40	251.5	14.9	281	3	US-08-883-086-10	Sequence 10, Appl
41	251.5	14.9	281	3	US-09-320-424-2	Sequence 2, Appli
42	251.5	14.9	281	4	US-09-333-593A-6	Sequence 6, Appli
43	251.5	14.9	281	4	US-09-157-864-11	Sequence 11, Appl
44	251.5	14.9	281	4	US-09-825-563-2	Sequence 2, Appli
45	251.5	14.9	281	4	US-10-039-785-66	Sequence 66, Appl

ALIGNMENTS

```

RESULT 1
US-08-996-139-13
; Sequence 13, Application US/08996139
; Patent No. 6017729
; GENERAL INFORMATION:
;   APPLICANT: Anderson, Dirk M.
;   APPLICANT: Galibert, Laurent
;   APPLICANT: Maraskovsky, Eugene
;   TITLE OF INVENTION: Receptor Activator of NF-kappaB
;   NUMBER OF SEQUENCES: 19
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Immunex Corporation, Law Department
;     STREET: 51 University Street
;     CITY: Seattle
;     STATE: WA
;     COUNTRY: USA
;     ZIP: 98101
;   COMPUTER READABLE FORM:

```



```

; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Power Macintosh
; OPERATING SYSTEM: Apple Operating System 7.5.5
; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/996,139
; FILING DATE: 22 DECEMBER 1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 60/064,671
; FILING DATE: 14 OCTOBER 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/813,509
; FILING DATE: 07 MARCH 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/772,330
; FILING DATE: 23 DECEMBER 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perkins, Patricia Anne
; REGISTRATION NUMBER: 34,693
; REFERENCE/DOCKET NUMBER: 2851-A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206)587-0430
; TELEFAX: (206)233-0644
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 317 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-996-139-13

```

```

Query Match          100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHHRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHHRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317

```

|||||
Db 301 PDQDATYFGAFKVRDID 317

RESULT 2

US-08-995-659-13

; Sequence 13, Application US/08995659

; Patent No. 6242213

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; APPLICANT: Galibert, Laurent

; APPLICANT: Maraskovsky, Eugene

; TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/995,659

; FILING DATE: 22 DECEMBER 1997

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 60/064,671

; FILING DATE: 14 OCTOBER 1997

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/813,509

; FILING DATE: 07 MARCH 1997

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/772,330

; FILING DATE: 23 DECEMBER 1996

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Perkins, Patricia Anne

; REGISTRATION NUMBER: 34,693

; REFERENCE/DOCKET NUMBER: 2852-A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (206)587-0430

; TELEFAX: (206)233-0644

; INFORMATION FOR SEQ ID NO: 13:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 317 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-995-659-13

Query Match 100.0%; Score 1685; DB 3; Length 317;
 Best Local Similarity 100.0%; Pred. No. 2.6e-163;
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
      |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
      |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTinATDIPSGSH 180
      |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTinATDIPSGSH 180

Qy    181 KVSLSWYHdRGWAKISNMtFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
      |||
Db    181 KVSLSWYHdRGWAKISNMtFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTkTSIKIPSSHTLMKGGSTKYWSGNSEfHFYSINVGgFFKLRSgEEISIEVSNPSLLD 300
      |||
Db    241 YVTkTSIKIPSSHTLMKGGSTKYWSGNSEfHFYSINVGgFFKLRSgEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
      |||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 3

US-09-215-649A-13

; Sequence 13, Application US/09215649A

; Patent No. 6271349

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/215,649A

; FILING DATE: 17-Dec-1998

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/996,139

```

;          FILING DATE: <Unknown>
;          APPLICATION NUMBER: USSN 08/813,509
;          FILING DATE: 07 MARCH 1997
;          APPLICATION NUMBER: USSN 08/772,330
;          FILING DATE: 23 DECEMBER 1996
;    ATTORNEY/AGENT INFORMATION:
;          NAME: Perkins, Patricia Anne
;          REGISTRATION NUMBER: 34,693
;          REFERENCE/DOCKET NUMBER: 2851-A
;    TELECOMMUNICATION INFORMATION:
;          TELEPHONE: (206)587-0430
;          TELEFAX: (206)233-0644
;    INFORMATION FOR SEQ ID NO: 13:
;          SEQUENCE CHARACTERISTICS:
;            LENGTH: 317 amino acids
;            TYPE: amino acid
;            TOPOLOGY: linear
;          MOLECULE TYPE: protein
;          SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-215-649A-13

```

```

Query Match          100.0%;  Score 1685;  DB 3;  Length 317;
Best Local Similarity 100.0%;  Pred. No. 2.6e-163;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 4

US-09-052-521C-4

; Sequence 4, Application US/09052521C

; Patent No. 6316408

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors

```
; FILE REFERENCE: A-451Brv
; CURRENT APPLICATION NUMBER: US/09/052,521C
; CURRENT FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Human
US-09-052-521C-4
```

```
Query Match          100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
      |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
      |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
      |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240
      |||
Db    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
      |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
      |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 5

US-09-577-780-13

; Sequence 13, Application US/09577780

; Patent No. 6419929

GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

```

;          CITY: Seattle
;          STATE: WA
;          COUNTRY: USA
;          ZIP: 98101
;
;  COMPUTER READABLE FORM:
;          MEDIUM TYPE: Floppy disk
;          COMPUTER: Apple Power Macintosh
;          OPERATING SYSTEM: Apple Operating System 7.5.5
;          SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
;
;  CURRENT APPLICATION DATA:
;          APPLICATION NUMBER: US/09/577,780
;          FILING DATE: 24-May-2000
;          CLASSIFICATION: <Unknown>
;
;  PRIOR APPLICATION DATA:
;          APPLICATION NUMBER: 08/995,659
;          FILING DATE: <Unknown>
;          APPLICATION NUMBER: USSN 08/813,509
;          FILING DATE: 07 MARCH 1997
;          APPLICATION NUMBER: USSN 08/772,330
;          FILING DATE: 23 DECEMBER 1996
;
;  ATTORNEY/AGENT INFORMATION:
;          NAME: Perkins, Patricia Anne
;          REGISTRATION NUMBER: 34,693
;          REFERENCE/DOCKET NUMBER: 2852-A
;
;  TELECOMMUNICATION INFORMATION:
;          TELEPHONE: (206)587-0430
;          TELEFAX: (206)233-0644
;
;  INFORMATION FOR SEQ ID NO: 13:
;          SEQUENCE CHARACTERISTICS:
;              LENGTH: 317 amino acids
;              TYPE: amino acid
;              TOPOLOGY: linear
;          MOLECULE TYPE: protein
;          SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-577-780-13

```

```

Query Match          100.0%;  Score 1685;  DB 4;  Length 317;
Best Local Similarity 100.0%;  Pred. No. 2.6e-163;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

```

```

                ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFKLRSGEESIEVSNPSLLD 300

Qy          301 PDQDATYFGAFKVRDID 317
                ||||||||||||||||
Db          301 PDQDATYFGAFKVRDID 317

```

RESULT 6

US-09-577-800-13

; Sequence 13, Application US/09577800

; Patent No. 6479635

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; APPLICANT: Galibert, Laurent

; APPLICANT: Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/577,800

; FILING DATE: 24-MAY-2000

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/996,139

; FILING DATE: 22 DECEMBER 1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 60/064,671

; FILING DATE: 14 OCTOBER 1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/813,509

; FILING DATE: 07 MARCH 1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/772,330

; FILING DATE: 23 DECEMBER 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Perkins, Patricia Anne

; REGISTRATION NUMBER: 34,693

; REFERENCE/DOCKET NUMBER: 2851-A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (206)587-0430

; TELEFAX: (206)233-0644

; INFORMATION FOR SEQ ID NO: 13:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 317 amino acids

; TYPE: amino acid

; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-577-800-13

Query Match 100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 7

US-09-466-496-13

; Sequence 13, Application US/09466496

; Patent No. 6528482

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/466,496


```

;          FILING DATE: 17-Dec-1999
;          CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
;          APPLICATION NUMBER: US/08/996,139
;          FILING DATE: 22 DECEMBER 1997
;          APPLICATION NUMBER: USSN 60/064,671
;          FILING DATE: 14 OCTOBER 1997
;          APPLICATION NUMBER: USSN 08/813,509
;          FILING DATE: 07 MARCH 1997
;          APPLICATION NUMBER: USSN 08/772,330
;          FILING DATE: 23 DECEMBER 1996
; ATTORNEY/AGENT INFORMATION:
;          NAME: Perkins, Patricia Anne
;          REGISTRATION NUMBER: 34,693
;          REFERENCE/DOCKET NUMBER: 2851-A
; TELECOMMUNICATION INFORMATION:
;          TELEPHONE: (206)587-0430
;          TELEFAX: (206)233-0644
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 317 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-466-496-13

```

```

Query Match          100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        ||||||||||||||||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 8

Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 9

US-09-871-291-13

; Sequence 13, Application US/09871291

; Patent No. 6562948

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/871,291

; FILING DATE: 30-May-2001

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/996,139

; FILING DATE: <Unknown>

; APPLICATION NUMBER: USSN 08/813,509

; FILING DATE: 07 MARCH 1997

; APPLICATION NUMBER: USSN 08/772,330

; FILING DATE: 23 DECEMBER 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Perkins, Patricia Anne

; REGISTRATION NUMBER: 34,693

; REFERENCE/DOCKET NUMBER: 2851-A

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206)587-0430
; TELEFAX: (206)233-0644
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 317 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-871-291-13
```

```
Query Match          100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
|
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
|
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
|
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
|
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
|
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
|
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 10

US-09-396-937-2

```
; Sequence 2, Application US/09396937
; Patent No. 6645500
; GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/09/396,937
; CURRENT FILING DATE: 1999-09-15
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
```

; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-396-937-2

Query Match 100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
          ||||||||||||||||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 11

US-09-877-650-13

; Sequence 13, Application US/09877650

; Patent No. 6649164

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

```

;           APPLICATION NUMBER: US/09/877,650
;           FILING DATE: 08-Jun-2001
;           CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
;           APPLICATION NUMBER: 08/995,659
;           FILING DATE: 1997-12-22
;           APPLICATION NUMBER: USSN 08/813,509
;           FILING DATE: 07 MARCH 1997
;           APPLICATION NUMBER: USSN 08/772,330
;           FILING DATE: 23 DECEMBER 1996
; ATTORNEY/AGENT INFORMATION:
;           NAME: Perkins, Patricia Anne
;           REGISTRATION NUMBER: 34,693
;           REFERENCE/DOCKET NUMBER: 2852-A
; TELECOMMUNICATION INFORMATION:
;           TELEPHONE: (206)587-0430
;           TELEFAX: (206)233-0644
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
;           LENGTH: 317 amino acids
;           TYPE: amino acid
;           TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-877-650-13

```

```

Query Match          100.0%; Score 1685; DB 4; Length 317;
Best Local Similarity 100.0%; Pred. No. 2.6e-163;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPPFAHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPPFAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 12
 US-08-842-842-7

```

; Sequence 7, Application US/08842842
; Patent No. 5843678
; GENERAL INFORMATION:
;   APPLICANT: Boyle, William J.
;   TITLE OF INVENTION: OSTEOPROTEGERIN BINDING PROTEINS
;   NUMBER OF SEQUENCES: 7
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Amgen Inc.
;     STREET: 1840 Dehavilland Drive
;     CITY: Thousand Oaks
;     STATE: California
;     COUNTRY: USA
;     ZIP: 91230-1789
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/842,842
;     FILING DATE:
;     CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Winter, Robert B.
;     REFERENCE/DOCKET NUMBER: A-451
;   INFORMATION FOR SEQ ID NO: 7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 316 amino acids
;       TYPE: amino acid
;       TOPOLOGY: linear
;     MOLECULE TYPE: protein
US-08-842-842-7

```

```

Query Match          84.1%; Score 1417.5; DB 2; Length 316;
Best Local Similarity 84.3%; Pred. No. 4.6e-136;
Matches 268; Conservative 16; Mismatches 31; Indels 3; Gaps 2;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLH-APPPAPHPQPPAASRSMFVALLGLGLGQ 59
        ||||| |||| |||| ||| ||||| || ||| |||||:|||||
Db      1 MRRASRDYGKYLRSEEMGGSGPGVPHEGPLHPAPSAPAPAPPPAASRSMFLALLGLGLGQ 60

Qy     60 VVCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRR 119
        |||:||| ||||| ||||| ||| ||||| ||| ||:||||:| :|||:
Db     61 VVCSIALFLYFRAQMDPNRISEDSTHCFYRILRLHENAGLQDSTLESED--LPDSCRRM 118

Qy    120 KQAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGS 179
        ||||| ||||| ||||| ||| ||:||||:|:| ||||| |||||
Db    119 KQAFQGAVQKELQHIVGPRFSGAPAMMEGSWLDVAQGRKPEAQPFAPHLTINAASIPSGS 178

Qy    180 HKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLM 239
        |||:||||| ||||| ||||| ||||| ||||| ||||| :|:||||
Db    179 HKVTLSSWYHDRGWAKISNMTLSNGKLVRNQDGFYYLYANICFRHHETSGSVPTDYLQLM 238

Qy    240 VYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGFFFKLRSGEEISIEVSNPSLL 299
        ||| ||||| ||||| ||||| ||||| ||||| |||||:||||:||||
Db    239 VYVVKTSIKIPSSHNLMKGGSTKNWSGNSEFHFYSINVGFFFKLRAGEEISIQVSNPSLL 298

```

Qy 300 DPDQDATYFGAFKVRDID 317
|||||||:|
Db 299 DPDQDATYFGAFKVQDID 316

RESULT 13
US-08-989-362-2
; Sequence 2, Application US/08989362
; Patent No. 6242586
; GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Mattson, Jeanine D.
; TITLE OF INVENTION: Mammalian Cell Surface Antigens; Related
; TITLE OF INVENTION: Reagents
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/989,362
; FILING DATE: 12-DEC-1997
; CLASSIFICATION: 56
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/032,846
; FILING DATE: 13-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0686
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650)852-9196
; TELEFAX: (650)496-1204
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 316 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-989-362-2

Query Match 84.1%; Score 1417.5; DB 3; Length 316;
Best Local Similarity 84.3%; Pred. No. 4.6e-136;
Matches 268; Conservative 16; Mismatches 31; Indels 3; Gaps 2;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLH-APPPAPHQPPAASRSMFVALLGLGLGQ 59
||||||| |||| |||| ||| ||||| || ||| |||||:|||||||
Db 1 MRRASRDYGKYLRSSSEEMGSGPGVPHEGPLHPAPSAPAPAPPPAASRSMFLALLGLGLGQ 60


```

; Sequence 2, Application US/09671658A
; Patent No. 6525180
; GENERAL INFORMATION:
; APPLICANT: Gorman, Daniel M.
; Mattson, Jeanine D.
; TITLE OF INVENTION: Mammalian Cell Surface Antigens; Related
; Reagents
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/671,658A
; FILING DATE: 27-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/989,362
; FILING DATE: 12-DEC-1997
; APPLICATION NUMBER: US 60/032,846
; FILING DATE: 13-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0686
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650)852-9196
; TELEFAX: (650)496-1204
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 316 amino acids
; TYPE: amino acid

```

```

;          TOPOLOGY: linear
;          MOLECULE TYPE: protein
;          SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-671-658A-2

```

Query Match 84.1%; Score 1417.5; DB 4; Length 316;
Best Local Similarity 84.3%; Pred. No. 4.6e-136;
Matches 268; Conservative 16; Mismatches 31; Indels 3; Gaps 2;

Qy	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLH-APPPAPHPQPPAASRSMFVALLGLGLGQ	59
		:	
Db	1	MRRASRDYGKYLRSSSEEMGSGPGVPHEGPLHPAPSAPAPAPPPAASRSMFLALLGLGLGQ	60
Qy	60	VVCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRI	119
		: : : : :	
Db	61	VVCSIALFLYFRAQMDPNRISEDSTHCFYRILRLHENAGLQDSTLESED--LPDSCRRM	118
Qy	120	KQAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGS	179
		: : :	
Db	119	KQAFQGAVQKELQHIVGPPQRFSGAPAMMEGSWLDVAQRGKPEAQPFAHLTINAASIPSGS	178
Qy	180	HKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLM	239
		: : :	
Db	179	HKVTLSSWYHDRGWAKISNMTLSNGKLVRVNQDGFYYLYANICFRHHETSGSVPTDYLQLM	238
Qy	240	VYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESISIEVSNPSLL	299
		:	
Db	239	VYVVKTSIKIPSSHNLMKGGSTKNWSGNSEFHFYSINVGGFFKLRSAGEESISIQVSNPSLL	298
Qy	300	DPDQDATYFGAFKVRDID	317
Db	299	DPDQDATYFGAFKVQDID	316

Search completed: September 15, 2004, 08:34:22
Job time : 36 secs

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:32:22 ; Search time 40 Seconds
 (without alignments)
 762.318 Million cell updates/sec

Title: US-09-211-315-39
 Perfect score: 1685
 Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : PIR_78:*
 1: pirl:*
 2: pir2:*
 3: pir3:*
 4: pir4:*

Pred. No. is the number of results predicted by chance to have a
 score greater than or equal to the score of the result being printed,
 and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	189	11.2	281	2	I38707	Fas ligand - human
2	184.5	10.9	279	2	A53062	Fas ligand - mouse
3	176.5	10.5	261	2	S53090	CD40 ligand - bovi
4	175.5	10.4	278	2	A49266	fas ligand - rat
5	158.5	9.4	261	2	I53476	CD40 ligand - huma
6	141.5	8.4	235	1	QWMSN	tumor necrosis fac
7	141	8.4	234	1	A25451	tumor necrosis fac
8	137	8.1	234	1	JH0529	tumor necrosis fac
9	133	7.9	233	1	QWHUN	tumor necrosis fac
10	132.5	7.9	235	2	I54490	tumor necrosis fac
11	131.5	7.8	235	2	JU0029	tumor necrosis fac
12	130.5	7.7	306	2	I49139	lymphotoxin-beta -
13	130	7.7	233	1	S22052	tumor necrosis fac

14	128	7.6	234	1	JQ1344	tumor necrosis fac
15	126.5	7.5	233	1	S24642	tumor necrosis fac
16	126	7.5	232	1	S12606	tumor necrosis fac
17	125.5	7.4	185	2	S52715	tumor necrosis fac
18	122	7.2	193	2	S06192	tumor necrosis fac
19	120	7.1	260	2	S21738	CD40 ligand - mous
20	117	6.9	233	2	S11688	tumor necrosis fac
21	117	6.9	244	2	A46066	lymphotoxin beta -
22	97.5	5.8	1464	1	CGHU1S	collagen alpha 1(I
23	94.5	5.6	664	2	C84747	probable protein k
24	92.5	5.5	205	1	QWHUX	lymphotoxin alpha
25	92.5	5.5	450	2	S38114	hypothetical prote
26	91.5	5.4	3848	2	T17414	TipC protein - sli
27	91	5.4	493	2	AC0937	probable GntR-fami
28	90.5	5.4	1694	2	S50065	sialoadhesin - mou
29	90	5.3	730	2	JC1456	gelatinase B (EC 3
30	89.5	5.3	331	2	AF3526	homoproteocatechuat
31	89.5	5.3	379	2	A47659	farnesyl-protein t
32	89	5.3	202	1	B27303	tumor necrosis fac
33	89	5.3	440	2	I49681	glyceraldehyde-3-p
34	89	5.3	479	2	A25052	fibrinogen beta ch
35	89	5.3	639	2	C83624	probable two-compo
36	88.5	5.3	565	2	C89893	hypothetical prote
37	88.5	5.3	578	2	S51379	probable phosphoes
38	88.5	5.3	684	2	T01267	leucine-rich repea
39	88.5	5.3	883	2	A49733	[heparan sulfate]-
40	87.5	5.2	610	2	T06690	galactonolactone d
41	87.5	5.2	1466	1	CGHU7L	collagen alpha 1(I
42	87	5.2	639	2	A32935	protein P1 - Entam
43	87	5.2	1114	2	JH0284	125K surface antig
44	87	5.2	1315	2	G96722	hypothetical prote
45	86.5	5.1	279	2	F72339	hypothetical prote

ALIGNMENTS

RESULT 1

I38707

Fas ligand - human

C;Species: Homo sapiens (man)

C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 21-Jul-2000

C;Accession: I38707; JC2340; S57565; I38554

R;Takahashi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Nagata, S.

Int. Immunol. 6, 1567-1574, 1994

A;Title: Human Fas ligand: gene structure, chromosomal location and species specificity.

A;Reference number: I38707; MUID:95127560; PMID:7826947

A;Accession: I38707

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: mRNA

A;Residues: 1-281 <RES>

A;Cross-references: EMBL:U11821; NID:g595430; PIDN:AAC50124.1; PID:g595431

R;Mita, E.; Hayashi, N.; Iio, S.; Takehara, T.; Hijioka, T.; Kasahara, A.; Fusamoto, H.; Kamada, T.

Biochem. Biophys. Res. Commun. 204, 468-474, 1994

A;Title: Role of Fas ligand in apoptosis induced by hepatitis C virus infection.

A;Reference number: JC2340; MUID:95071350; PMID:7980502
 A;Accession: JC2340
 A;Molecule type: DNA
 A;Residues: 1-281 <MIT>
 A;Cross-references: GB:D38122; DDBJ:D29820; NID:g601892; PIDN:BAA07320.1; PID:g1369902
 R;Schatzlein, C.E.
 submitted to the EMBL Data Library, June 1995
 A;Reference number: S57565
 A;Accession: S57565
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-281 <SCH>
 A;Cross-references: EMBL:X89102; NID:g887455; PID:g887456
 R;Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Goodwin, R.G.; Smith, C.A.; Ramsdell, F.; Lynch, D.H.
 J. Exp. Med. 181, 71-77, 1995
 A;Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.
 A;Reference number: I38554; MUID:95105731; PMID:7528780
 A;Accession: I38554
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-281 <RE2>
 A;Cross-references: EMBL:U08137; NID:g624627; PIDN:AAC50071.1; PID:g624628
 C;Genetics:
 A;Gene: FasL
 A;Introns: 151/1; 116/3
 C;Keywords: glycoprotein; transmembrane protein
 F;80-102/Domain: transmembrane #status predicted <TMM>
 F;76,184,250,260/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 11.2%; Score 189; DB 2; Length 281;
 Best Local Similarity 21.7%; Pred. No. 1.9e-08;
 Matches 69; Conservative 43; Mismatches 98; Indels 108; Gaps 11;

Qy	22	PGAPHEGPLHAPPPAP----	HQPPAASRS-----	MFVALLGLGLGQVVCS	63
				:	
Db	46	PPPPPPPLPPPPPPPLPPLPLPPLKKRGNHSTGLCLLMFFMVLVALVGLGLG----			100
Qy	64	VALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAF			123
		:	: : :		
Db	101	--MFQLFHLQ-----	KELAELESTSQMHTA-----		124
Qy	124	QGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLT--	INATDIPSGSHK		181
		: : :	: :		
Db	125	--SSLEKQIGH-----	PSPPEKKELRKVAHLTGKSNRSRSM-----		159
Qy	182	VSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLMVY			241
		: : : : : :	:		
Db	160	---LEWEDTYGIVLLSGVKYKGGGLVINETGLYFVYSKVYFRGQSCNN-----	LPLSHK		210
Qy	242	VTKTSIKIPSSHTLMKGGSTKY-----	WSGNSEHFYSINVG GFFKLRS GEEISIEVSN		295
		: :	: : : :		
Db	211	VYMRNSKYPQDLVMEGKMMSYCTTGQMWARSS-----	YLGAVENLTSADHLYVNVSE		263
Qy	296	PSLLDPDQDATYFGAFKV			313

||:: :: |::| ::|
Db 264 LSLVNFEEESQTFGLYKL 281

RESULT 2

A53062

Fas ligand - mouse

C;Species: Mus musculus (house mouse)

C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 05-Nov-1999

C;Accession: A53062

R;Takahashi, T.; Tanaka, M.; Brannan, C.I.; Jenkins, N.A.; Copeland, N.G.; Suda, T.; Nagata, S.

Cell 76, 969-976, 1994

A;Title: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

A;Reference number: A53062; MUID:94185175; PMID:7511063

A;Accession: A53062

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-279 <TAK>

A;Cross-references: GB:U06948; NID:g473564; PIDN:AAA17800.1; PID:g473565

Query Match 10.9%; Score 184.5; DB 2; Length 279;
Best Local Similarity 21.7%; Pred. No. 4.6e-08;
Matches 70; Conservative 45; Mismatches 106; Indels 101; Gaps 11;

Qy 13 RGSEEMGGGPGAPHEGPLHAPPPAPHQP-----PAASRSMFVALLGLGL 57
|| :: | | | | | | | | : |||::||

Db 38 RGPDQRRPPPPPPVSPPLPPPSQPLPLPLPLTPLKKKDHTNLWLFPVVFVFMVLVALVGMGL 97

Qy 58 GQVVCVSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCR 117
| :|:: |

Db 98 G-----MYQLFHL----- 105

Qy 118 RIKQAFQGAVQKELQHI--VGSQHRA---EKAMVDGSWLDLAKRSKLEAQPFAHLTINA 172
||| : :| :: || : : | | : ||| |

Db 106 -----QKELAELEFRTNQSLKVSSFQKQIANPS----TPSEKKEPRSVAHLTGN- 150

Qy 173 TDIPSGSHKVSL-SWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDL 231
| | : | | | | : : | |::| : | |::| : : | | :

Db 151 -----PHSRSIPLEWEDTYGTALISGVKYKKGGLVINETGLYFVYSKVYFRGQSCN--- 201

Qy 232 ATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGFFKLRSGEEISI 291
: | ||: : | | ||: | : : :| :| | | : : :

Db 202 -NQPLNHKVYMRNS--KYPEDLVLMEEKRLNYCT-TGQIWAHSSYLGAVERNLTADHLYV 257

Qy 292 EVSNPSLLDPDQDATYFGAFKV 313
:| ||:: :: |::| ::|

Db 258 NISQLSLINFEESKTFGLYKL 279

RESULT 3

S53090

CD40 ligand - bovine

C;Species: Bos primigenius taurus (cattle)

C;Date: 08-Jul-1995 #sequence_revision 21-Jul-1995 #text_change 05-Nov-1999

C;Accession: S53090

Qy 21 GPGAPHEGPLHAPPPAPHPQPPAASRSM-----FVALLGLGL 57
 ||| | |||:| |: : |||:|:|
 Db 39 GPGQRRPPP--PPPPPSPLPPPSQPPPLPPLSPLKKKDNIELWLPVIFFMVLVALVGMGL 96

Qy 58 GQVVCVSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCR 117
 | : | | : : | | : | : : | | : : :
 Db 97 G-----MYQLFHLQKELAELEFNTNHSR-RVSSFQKQIANPSTPSETKKPRSV----- 143

Qy 118 RIKQAFQGAQKELQHIVGSQHIRAEKAMVDGSLDLAKRSKLEAQPFALHTINATDIPS 177
 |||| |
 Db 144 -----AHLTG NPR----- 151

Qy 178 GSHKVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQ 237
 | : | | | | : : | | : : | | : : | | : : |
 Db 152 -SRSIPL-EWEDTYGTALISGVKYKKGGLVINEAGLYFVYSKVYFRGQSCN----SQPLS 205

Qy 238 LMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFKLRSGEIEISIEVSNPS 297
 ||: : | | ||: | : : : | : | | : : : | |
 Db 206 HKVYM--RNFKYPGDLVLMEEKKLNCT-TGQIWAHSSYLGAFFNLTVADHLYVNISQLS 262

Qy 298 LLDPDQDATYFGAFKV 313
 |:: : |::| :|:
 Db 263 LINFEESKTFFGLYKL 278

RESULT 5

I53476

CD40 ligand - human

N;Alternate names: glycoprotein 39; hCD40-L protein; T-cell antigen gp39; TRAP protein

C;Species: Homo sapiens (man)

C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 20-Apr-2001

C;Accession: S28017; JH0793; S26694; S28852; I53476; S25684; S30593

R;Hollenbaugh, D.; Grosmaire, L.S.; Kullas, C.D.; Chalupny, N.J.; Braesch-Andersen, S.; Noelle, R.J.; Stamenkovic, I.; Ledbetter, J.A.; Aruffo, A. EMBO J. 11, 4313-4321, 1992

A;Title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

A;Reference number: S28017; MUID:93049181; PMID:1385114

A;Accession: S28017

A;Molecule type: mRNA

A;Residues: 1-261 <HOL>

A;Cross-references: EMBL:Z15017; NID:g38483; PIDN:CAA78737.1; PID:g38484

R;Spriggs, M.K.; Armitage, R.J.; Strockbine, L.; Clifford, K.N.; Macduff, B.M.; Sato, T.A.; Maliszewski, C.R.; Fanslow, W.C. J. Exp. Med. 176, 1543-1550, 1992

A;Title: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.

A;Reference number: JH0793; MUID:93094757; PMID:1281209

A;Accession: JH0793

A;Molecule type: mRNA

A;Residues: 1-261 <SPR>

A;Cross-references: GB:X67878; NID:g38411; PIDN:CAA48077.1; PID:g38412

A;Experimental source: peripheral blood T-cell

R;Graf, D.; Korthaeuer, U.; Mages, H.W.; Senger, G.; Kroczeck, R.A.

Eur. J. Immunol. 22, 3191-3194, 1992

A;Title: Cloning of TRAP, a ligand for CD40 on human T cells.
A;Reference number: S26694; MUID:93076854; PMID:1280226
A;Accession: S26694
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-261 <GRA>
A;Cross-references: EMBL:X68550; NID:g37269; PIDN:CAA48554.1; PID:g37270
R;Gauchat, J.F.; Aubry, J.P.; Mazzei, G.; Life, P.; Jomotte, T.; Elson, G.; Bonnefoy, J.Y.
FEBS Lett. 315, 259-266, 1993
A;Title: Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production.
A;Reference number: S28852; MUID:93138085; PMID:7678552
A;Accession: S28852
A;Molecule type: mRNA
A;Residues: 1-261 <GAU>
A;Cross-references: EMBL:L07414; NID:g180123; PIDN:AAA35662.1; PID:g180124
A;Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 6-Gln
C;Genetics:
A;Gene: GDB:CD40LG; HIGM1; IMD3
A;Cross-references: GDB:120632; OMIM:308230
A;Map position: Xq26-Xq26
C;Keywords: glycoprotein; transmembrane protein
F;13-44/Domain: transmembrane #status predicted <TMM>
F;45-261/Domain: extracellular #status predicted <EXT>
F;6,240/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 9.4%; Score 158.5; DB 2; Length 261;
Best Local Similarity 24.5%; Pred. No. 6.8e-06;
Matches 68; Conservative 53; Mismatches 113; Indels 43; Gaps 15;

```

Qy      45 SRSMFVALLGLGL-GQVVCVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDT- 102
      |  :| : || : | |:: |      |  ::| :| ::      |||: | |
Db      20 SMKIFMYLLTVFLITQMIGSALFAVYLHRRLD--KIEDE-----RNLHEDFVFMKTI 69

Qy     103 -TLESQDTKLIPDSCRRIKQAFQGA VQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLE 161
      : : |  :| || |:: | |::      : | :  : | : : | :
Db      70 QRCNTGERSLSLLNCEEIKSQFEGFV-KDIM-----LNKEETKKENSF-EMQKGDQ-N 119

Qy     162 AQPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN--MTFSNGK-LIVNQDGFYYLYA 218
      | ||:  | :      | | : | ::| : ||  :| ||| | | : | ||: ||
Db     120 PQIAAHVISEAS-----SKTTSVLQW-AEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYA 173

Qy     219 NICFRHHETSGDLATEYLQLMVYVTKTSIKIPS--SHTLMKGGSTKYWSGNSEFHFYSIN 276
      : | : :  |  ::      :| : | |  |:: :| |  ||:
Db     174 QVTFCNREASSQAP-----FIASLCLKSPGRFERILLRAANTH--SSAKPCGQQSIH 224

Qy     277 VGGFFKLRSGEIEISIEVSNPSLLDPDQDATYFGAFKV 313
      :|| |:: |  : : |::|| :      | ||  | :
Db     225 LGGVFELQPGASVFVNVTDP SQVSHGTGFTSFGLLKL 261

```

RESULT 6
QWMSN
tumor necrosis factor alpha precursor - mouse
N;Alternate names: cachectin; TNF alpha

C;Species: Mus musculus (house mouse)
 C;Date: 31-Mar-1988 #sequence_revision 31-Mar-1988 #text_change 04-Feb-2000
 C;Accession: A22908; S03791; A27303; A25164; A23127; A34251; I59058; A36696
 R;Shirai, T.; Shimizu, N.; Shiojiri, S.; Horiguchi, S.; Ito, H.
 DNA 7, 193-201, 1988
 A;Title: Cloning and expression in Escherichia coli of the gene for mouse tumor necrosis factor.
 A;Reference number: A22908; MUID:88224564; PMID:2836146
 A;Accession: A22908
 A;Molecule type: DNA
 A;Residues: 1-235 <SHI>
 A;Cross-references: GB:M20155
 R;Shakhov, A.N.; Nedospasov, S.A.
 Bioorg. Khim. 13, 701-705, 1987
 A;Title: Molecular cloning of the genes coding for tumor necrosis factors: complete nucleotide sequence of the genomic copy of TNF-alpha in mice.
 A;Reference number: S03791; MUID:87298639; PMID:3040015
 A;Accession: S03791
 A;Molecule type: DNA
 A;Residues: 1-235 <SHA>
 A;Cross-references: GB:M38296; NID:g202086; PIDN:AAA40459.1; PID:g202087
 A;Note: article in Russian with English abstract
 R;Semon, D.; Kawashima, E.; Jongeneel, C.V.; Shakhov, A.N.; Nedospasov, S.A.
 Nucleic Acids Res. 15, 9083-9084, 1987
 A;Title: Nucleotide sequence of the murine TNF locus, including the TNF-alpha- (tumor necrosis factor) and TNF-beta-(lymphotoxin) genes.
 A;Reference number: A93679; MUID:88067722; PMID:3684584
 A;Accession: A27303
 A;Molecule type: DNA
 A;Residues: 1-235 <SEM>
 A;Cross-references: GB:Y00467; NID:g54830; PIDN:CAA68530.1; PID:g54832
 R;Pennica, D.; Hayflick, J.S.; Bringman, T.S.; Palladino, M.A.; Goeddel, D.V.
 Proc. Natl. Acad. Sci. U.S.A. 82, 6060-6064, 1985
 A;Title: Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.
 A;Reference number: A25164; MUID:85298296; PMID:3898078
 A;Accession: A25164
 A;Molecule type: mRNA
 A;Residues: 1-235 <PEN>
 A;Cross-references: GB:M11731; NID:g202084; PIDN:AAA40458.1; PID:g202085
 R;Fransen, L.; Muller, R.; Marmenout, A.; Tavernier, J.; van der Heyden, J.; Kawashima, E.; Chollet, A.; Tizard, R.; van Heuverswyn, H.; van Vliet, A.; Ruyschaert, M.R.; Fiers, W.
 Nucleic Acids Res. 13, 4417-4429, 1985
 A;Title: Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression.
 A;Reference number: A23127; MUID:85242112; PMID:2989794
 A;Accession: A23127
 A;Molecule type: mRNA
 A;Residues: 1-235 <FRA>
 A;Cross-references: GB:X02611; NID:g54844; PIDN:CAA26457.1; PID:g54845
 R;Cseh, K.; Beutler, B.
 J. Biol. Chem. 264, 16256-16260, 1989
 A;Title: Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein.
 A;Reference number: A34251; MUID:89380231; PMID:2777790
 A;Accession: A34251

A;Molecule type: protein
A;Residues: 70-87 <CSE>
R;Caput, D.; Beutler, B.; Hartog, K.; Thayer, R.; Brown-Shimer, S.L.; Cerami, A.
Proc. Natl. Acad. Sci. U.S.A. 83, 1670-1674, 1986
A;Title: Identification of a common nucleotide sequence in the 3'-untranslated
region of mRNA molecules specifying inflammatory mediators.
A;Reference number: I59058; MUID:86149365; PMID:2419912
A;Accession: I59058
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-230,'R',232-235 <RES>
A;Cross-references: GB:M13049; NID:g202082; PIDN:AAA40457.1; PID:g202083
R;Sherry, B.; Jue, D.M.; Zentella, A.; Cerami, A.
Biochem. Biophys. Res. Commun. 173, 1072-1078, 1990
A;Title: Characterization of high molecular weight glycosylated forms of murine
tumor necrosis factor.
A;Reference number: A36696; MUID:91097531; PMID:2268312
A;Accession: A36696
A;Molecule type: protein
A;Residues: 80-85,'X',87-99 <SHE>
C;Genetics:
A;Introns: 62/3; 81/1; 97/1
A;Note: the first intron occurs in the 5'-untranslated region
C;Superfamily: tumor necrosis factor
C;Keywords: cytokine; cytotoxin; glycoprotein; lipoprotein; lymphokine;
macrophage; membrane protein; myristylation
F;80-235/Product: tumor necrosis factor #status experimental <MAT>
F;20/Binding site: myristate (Lys) (covalent) #status predicted
F;84/Binding site: carbohydrate (Ser) (covalent) #status predicted
F;86/Binding site: carbohydrate (Asn) (covalent) #status predicted
F;148-179/Disulfide bonds: #status predicted

Query Match 8.4%; Score 141.5; DB 1; Length 235;
Best Local Similarity 25.9%; Pred. No. 0.00017;
Matches 42; Conservative 28; Mismatches 57; Indels 35; Gaps 7;

```

Qy      163 QPFAHLTINATDIPSGSHKVSLS-SWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANI 220
          :| ||: | | :| | | | :| | : :| | || | :| :
Db      90 KPAHVVAN-----HQVEEQLEWLSQRANALLANGMDLKDNLVVPADGLYLVSQV 141

Qy      221 CFRHHETSGDLATEYLQLMVYVTK-----TSIKIPSSHTLMKGGSTKYWSGNS 268
          |: | | :| | | :| : :| | :| | |
Db      142 LFK-----GQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPW---- 192

Qy      269 EFHFYSINVGGFFKLRSGEESIEVSNPSLLD-PDQDATYFG 309
          : | :| | | :| | :| | | : | | :
Db      193 ---YEPIYLGGVFQLEKGDQLSAEVNLPKYLDFAESGQVYFG 231

```

RESULT 7

A25451

tumor necrosis factor alpha precursor - rabbit

N;Alternate names: cachectin; TNF alpha

C;Species: Oryctolagus cuniculus (domestic rabbit)

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 04-Feb-2000

C;Accession: A25454; A25451; JS0727

R;Ito, H.; Yamamoto, S.; Kuroda, S.; Sakamoto, H.; Kajihara, J.; Kiyota, T.; Hayashi, H.; Kato, M.; Seko, M.
DNA 5, 149-156, 1986
A;Title: Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor.
A;Reference number: A25454; MUID:86219711; PMID:3519137
A;Accession: A25454
A;Molecule type: mRNA
A;Residues: 1-234 <ITO>
A;Cross-references: GB:M12845; NID:g165759; PIDN:AAA31486.1; PID:g165760
R;Ito, H.; Shirai, T.; Yamamoto, S.; Akira, M.; Kawahara, S.; Todd, C.W.; Wallace, R.B.
DNA 5, 157-165, 1986
A;Title: Molecular cloning of the gene encoding rabbit tumor necrosis factor.
A;Reference number: A25451; MUID:86219712; PMID:3519138
A;Accession: A25451
A;Molecule type: DNA
A;Residues: 1-234 <IT2>
A;Note: this sequence differs from that shown in having a Gln inserted between residues 62 and 63
R;Shakhov, A.N.; Kuprash, D.V.; Azizov, M.M.; Jongeneel, C.V.; Nedospasov, S.A.
Gene 95, 215-221, 1990
A;Title: Structural analysis of the rabbit TNF locus, containing the genes encoding TNF-beta (lymphotoxin) and TNF-alpha (tumor necrosis factor).
A;Reference number: JH0309; MUID:91065534; PMID:2249779
A;Accession: JS0727
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-62,'Q',63-234 <SHA>
A;Cross-references: GB:M60340; GB:M35326; NID:g165754; PIDN:AAA31484.1; PID:g165756
C;Genetics:
A;Introns: 62/3; 80/1; 96/1
C;Superfamily: tumor necrosis factor
C;Keywords: cytokine; cytotoxin; glycoprotein; lipoprotein; lymphokine; macrophage; membrane protein; myristylation
F;1-81/Domain: propeptide #status predicted <PRO>
F;82-234/Product: tumor necrosis factor #status predicted <MAT>
F;19,20/Binding site: myristate (Lys) (covalent) #status predicted
F;83/Binding site: carbohydrate (Ser) (covalent) #status predicted
F;147-178/Disulfide bonds: #status predicted

Query Match 8.4%; Score 141; DB 1; Length 234;
Best Local Similarity 21.6%; Pred. No. 0.00018;
Matches 65; Conservative 35; Mismatches 99; Indels 102; Gaps 13;

Qy	27	EGPLHAPPPAPHPQPPAASR----	SMFVALLGLGLGQVVCSVALFFYFRAQMDPNRISED	82	
			: : : : :		
Db	14	EGPL----PKKAGGPQGSKRCLCLSLFSFLLVAGATTLCF----	LLHFRVIGPQEEESPN	65	
Qy	83	GTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAFQGA	VQKELQHIVGSQHIRA	142	
		:			
Db	66	NLHLV-----NPVAQMVTLSR-----	A	82	
Qy	143	EKAMVDGSWL DLAKRSKLEAQPF	AHLTINATDIPSGSHKVSLS	SSWYHDRGWAKISN-MTF	201
		: :	:	: :	
Db	83	SRALSD-----	KPLAHVVAN----	PQVEGQL---QWLSQRANALLANGMKL	121

Qy 202 SNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKG--- 258
 :: :|:| || | :|: : | || | : | | : : : | : | :
 Db 122 TDNQLVVPADGLYLIYSQVLF-----SGQGCRSYVLLTHTVSRFAVSYPNKVNLLSAIKS 176

Qy 259 -----GSTKYWSGNSEFHFYSINVGGFKLRSGEEISIEVSNPSLLD-PDQDATYF 308
 | : | :| | :| | : :| ||: | || : ||
 Db 177 PCHRETPEEAEPMAW-----YEPIYLGGVFQLEKGDRLSTEVNQPEYLDLAESGQVYF 229

Qy 309 G 309
 |
 Db 230 G 230

RESULT 8

JH0529

tumor necrosis factor alpha precursor - sheep

N;Alternate names: cachectin; TNF alpha

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 04-Feb-2000

C;Accession: JH0529; S48118; S13114; S20661

R;Green, I.R.; Sargan, D.R.

Gene 109, 203-210, 1991

A;Title: Sequence of the cDNA encoding ovine tumor necrosis factor-alpha: problems with cloning by inverse PCR.

A;Reference number: JH0529; MUID:92112044; PMID:1765267

A;Accession: JH0529

A;Molecule type: mRNA

A;Residues: 1-234 <GRE>

A;Cross-references: EMBL:X55152; NID:g1405; PIDN:CAA38952.1; PID:g1406

A;Experimental source: alveolar macrophage

R;Nash, A.D.; Barcham, G.J.; Brandon, M.R.; Andrews, A.E.

Immunol. Cell Biol. 69, 273-283, 1991

A;Title: Molecular cloning, expression and characterization of ovine TNF-alpha.

A;Reference number: S48118; MUID:92155784; PMID:1786996

A;Accession: S48118

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-234 <NAS>

A;Cross-references: EMBL:X56756; NID:g297806; PIDN:CAA40076.1; PID:g297807

R;Young, A.J.; Hay, J.B.; Chan, J.Y.C.

Nucleic Acids Res. 18, 6723, 1990

A;Title: Primary structure of ovine tumor necrosis factor alpha cDNA.

A;Reference number: S13114; MUID:91067496; PMID:2251151

A;Accession: S13114

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-62,64-234 <YOU>

A;Cross-references: EMBL:X55966; NID:g1403; PIDN:CAA39437.1; PID:g1404

A;Note: comparison with the introns of homologous sequences suggest that this is probably an alternative splicing

C;Superfamily: tumor necrosis factor

C;Keywords: alternative splicing; cytokine; cytotoxin; glycoprotein; lipoprotein; lymphokine; macrophage; myristylation; transmembrane protein

F;1-77/Domain: propeptide #status predicted <PRO>

F;78-234/Product: tumor necrosis factor alpha #status predicted <TUM>

F;20/Binding site: myristate (Lys) (covalent) #status predicted

R;Pennica, D.; Nedwin, G.E.; Hayflick, J.S.; Seeburg, P.H.; Derynck, R.; Palladino, M.A.; Kohr, W.J.; Aggarwal, B.B.; Goeddel, D.V.
Nature 312, 724-729, 1984

A;Title: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
A;Reference number: A93351; MUID:85086244; PMID:6392892
A;Accession: A93351
A;Molecule type: mRNA
A;Residues: 1-233 <PEN>
A;Cross-references: GB:X02910; GB:X02159; NID:g37209; PIDN:CAA26669.1; PID:g37210
A;Note: this protein was isolated from the monocyte-like cell line HL-60 from a promyelocytic leukemia

R;Wang, A.M.; Creasey, A.A.; Ladner, M.B.; Lin, L.S.; Strickler, J.; Van Arsdell, J.N.; Yamamoto, R.; Mark, D.F.
Science 228, 149-154, 1985

A;Title: Molecular cloning of the complementary DNA for human tumor necrosis factor.
A;Reference number: A44189; MUID:85142190; PMID:3856324
A;Accession: A44189
A;Molecule type: mRNA
A;Residues: 1-62,'S',64-233 <WAN>
A;Cross-references: GB:M10988; NID:g339737; PIDN:AAA61198.1; PID:g339738

R;Fukuda, S.; Ando, S.; Sanou, O.; Taniai, M.; Fujii, M.; Masaki, N.; Nakamura, K.I.; Ando, O.; Torigoe, K.; Sugimoto, T.; Kurimoto, M.
Lymphokine Res. 7, 175-185, 1988

A;Title: Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ.
A;Reference number: A61478; MUID:88301617; PMID:2841543
A;Accession: B61478
A;Molecule type: protein
A;Residues: 83-102;109-119;121-128,'X',130-131;142-144,'X',146,'XXX',150-152;159-174;180,'X',182-204 <FUK>

R;Marmenout, A.; Fransen, L.; Tavernier, J.; Van Der Heyden, J.; Tizard, R.; Kawashima, E.; Shaw, A.; Johnson, M.
Eur. J. Biochem. 152, 515-522, 1985

A;Title: Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor.
A;Reference number: I53311; MUID:86030296; PMID:3932069
A;Accession: I53311
A;Status: translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-233 <MAR>
A;Cross-references: GB:M26331; NID:g339763; PIDN:AAA36758.1; PID:g339764
A;Experimental source: U-937 cells

R;Takakura-Yamamoto, R.; Yamamoto, S.; Fukuda, S.; Kurimoto, M.
Eur. J. Biochem. 235, 431-437, 1996

A;Title: O-Glycosylated species of natural human tumor-necrosis factor-alpha.
A;Reference number: S62610; MUID:96202967; PMID:8631363
A;Accession: S62610
A;Molecule type: protein
A;Residues: 77-99 <TAK>

R;D'Alfonso, S.; Richiardi, P.M.
Immunogenetics 39, 150-154, 1994

A;Title: A polymorphic variation in a putative regulation box of the TNFA promoter region.
A;Reference number: I54522; MUID:94102809; PMID:7903959

A;Accession: I54522
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 1-8 <DAL>
 A;Cross-references: GB:S68530; NID:g544751
 R;Stevenson, F.T.; Bursten, S.L.; Locksley, R.M.; Lovett, D.H.
 J. Exp. Med. 176, 1053-1062, 1992
 A;Title: Myristyl acylation of the tumor necrosis factor alpha precursor on
 specific lysine residues.
 A;Reference number: A59163; MUID:93018820; PMID:1402651
 A;Contents: annotation; identification of myristylated lysines
 R;Aggarwal, B.B.; Kohr, W.J.; Hass, P.E.; Moffat, B.; Spencer, S.A.; Henzel,
 W.J.; Bringman, T.S.; Nedwin, G.E.; Goeddel, D.V.; Harkins, R.N.
 J. Biol. Chem. 260, 2345-2354, 1985
 A;Title: Human tumor necrosis factor. Production, purification, and
 characterization.
 A;Reference number: A92511; MUID:85130974; PMID:3871770
 A;Contents: annotation; disulfide bond
 C;Comment: Secreted from mitogen-activated macrophages within 4-24 hours after
 induction, TNF-alpha can cause cytolysis of certain tumor cell lines and have an
 antiproliferative effect on others without detriment to normal cells. It can
 also act synergistically with interferon gamma to kill certain transformed cell
 lines.
 C;Comment: TNF-alpha and -beta (lymphotoxin) are the products of different genes
 closely linked on chromosome 6. They are induced by similar mitogenic stimuli
 and have similar biological activities but are produced by different cell types
 and have different induction kinetics.
 C;Genetics:
 A;Gene: GDB:TNF; TNFA
 A;Cross-references: GDB:120441; OMIM:191160
 A;Map position: 6p21.3-6p21.3
 A;Introns: 62/3; 78/1; 94/1
 C;Complex: homotrimer
 C;Superfamily: tumor necrosis factor
 C;Keywords: cytokine; cytotoxin; glycoprotein; homotrimer; lipoprotein;
 lymphokine; macrophage; membrane protein; myristylation
 F;1-76/Domain: propeptide #status predicted <PRO>
 F;77-233/Product: tumor necrosis factor #status experimental <MAT>
 F;19,20/Binding site: myristate (Lys) (covalent) #status experimental
 F;81/Binding site: carbohydrate (Ser) (covalent) (partial) #status experimental
 F;145-177/Disulfide bonds: #status experimental

Query Match 7.9%; Score 133; DB 1; Length 233;
 Best Local Similarity 25.5%; Pred. No. 0.00086;
 Matches 40; Conservative 31; Mismatches 62; Indels 24; Gaps 8;

```

Qy      163 QPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANIC 221
          :| ||: |   |   ::   | : | | ::| :   : :|| :| | :| :
Db      87 KPAHVVAN----PQAEQQL---QWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVL 139

Qy      222 FRHH--ETSGDLATEYLQLMV--YVTK----TSIKIPSSHTLMKGGSTKYWSGNSEFHFY 273
          |:   :: | | : : | ||   :|| |   :| | |   :
Db      140 FKGQGPCSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPW-----YE 192

Qy      274 SINVGGFVKLRSGEEISIEVSNPSLLD-PDQDATYFG 309
          | :|| | :| | : :| | : | | :   |||
Db      193 PIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFG 229
  
```

RESULT 10

I54490

tumor necrosis factor alpha precursor - white-footed mouse

C;Species: Peromyscus leucopus (white-footed mouse)

C;Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 04-Feb-2000

C;Accession: I54490

R;Crew, M.D.; Filipowsky, M.E.

Immunogenetics 35, 351-353, 1992

A;Title: Sequence of the tumor necrosis factor/cachectin (TNF) gene from Peromyscus leucopus (family Cricetidae).

A;Reference number: I54490; MUID:92218012; PMID:1348497

A;Accession: I54490

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-235 <RES>

A;Cross-references: GB:M59233; NID:g202506; PIDN:AAA40596.1; PID:g202507

C;Genetics:

A;Gene: PlTNF

A;Introns: 62/3; 81/1; 97/1

C;Superfamily: tumor necrosis factor

C;Keywords: glycoprotein; lipoprotein; myristylation

F;19,20/Binding site: myristate (Lys) (covalent) #status predicted

F;84/Binding site: carbohydrate (Ser) (covalent) #status predicted

Query Match 7.9%; Score 132.5; DB 2; Length 235;
Best Local Similarity 25.3%; Pred. No. 0.00096;
Matches 42; Conservative 27; Mismatches 54; Indels 43; Gaps 7;

```

Qy      163 QPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISNMTFSG-----KLIVNQDGFYYL 216
          :| ||: |           ||:           : ||           :||           :||: || |:
Db      90 KPAHVVAN-----HQVDEQLEWLSRG----ANALLANGMDLKDNLVIPADGLYL 137

Qy      217 YANICFRHHETSGDLATEYLQLMVYVTK-----TSIKIPSSHTLMKGGSTKYW 264
          |: : |: |       : |: |       |::           :|| |       :| | |
Db      138 YSQVLFK-----GQGCSSYVLLTHTVSRFAVSIEDKVNLLSAIKSPCPKETPEGSELKPW 192

Qy      265 SGNSEFHFYSINVGGFFKLRSGEIEISIEVSNPSLLD-PDQDATYFG 309
          : | :|| |:| | : :| ||: | || :   |||
Db      193 -----YEPIYLGGVFQLEKGDRLSAEVNLPKYLDFAESGQVYFG 231

```

RESULT 11

JU0029

tumor necrosis factor alpha precursor - rat

N;Alternate names: cachectin; TNF alpha

C;Species: Rattus norvegicus (Norway rat)

C;Date: 07-Jun-1990 #sequence_revision 07-Jun-1990 #text_change 04-Feb-2000

C;Accession: JU0029; JN0868; S21674

R;Shirai, T.; Shimizu, N.; Horiguchi, S.; Ito, H.

Agric. Biol. Chem. 53, 1733-1736, 1989

A;Title: Cloning and expression in Escherichia coli of the gene for rat tumor necrosis factor.

A;Reference number: JU0029

A;Accession: JU0029

A;Molecule type: DNA

A;Residues: 1-235 <SHI>
 R;Kwon, J.; Chung, I.Y.; Benveniste, E.N.
 Gene 132, 227-236, 1993
 A;Title: Cloning and sequence analysis of the rat tumor necrosis factor-encoding genes.
 A;Reference number: JN0868; MUID:94040766; PMID:8224868
 A;Accession: JN0868
 A;Molecule type: DNA
 A;Residues: 1-235 <KWO>
 A;Cross-references: GB:L00981; NID:g205253; PIDN:AAA16275.1; PID:g205254
 R;Estler, H.C.; Grewe, M.; Gaussling, R.; Pavlovic, M.; Decker, K.
 Biol. Chem. Hoppe-Seyler 373, 271-281, 1992
 A;Title: Rat tumor necrosis factor-alpha. Transcription in rat Kupffer cells and in vitro posttranslational processing based on a PCR-derived cDNA.
 A;Reference number: S21674; MUID:92329007; PMID:1627266
 A;Accession: S21674
 A;Molecule type: mRNA
 A;Residues: 1-38,'P',40-162,'T',164-201,'S',203-235 <EST>
 A;Cross-references: GB:X66539; GB:S40199; NID:g395369; PIDN:CAA47146.1; PID:g395370
 C;Comment: Tumor necrosis factor is secreted by macrophages in response to endotoxin and produces hemorrhagic necrosis of tumors.
 C;Genetics:
 A;Gene: TNF-alpha
 A;Introns: 62/3; 81/1; 97/1
 C;Superfamily: tumor necrosis factor
 C;Keywords: cytokine; cytotoxin; glycoprotein; lipoprotein; lymphokine; macrophage; membrane protein; myristylation
 F;80-235/Product: tumor necrosis factor #status predicted <MAT>
 F;19,20/Binding site: myristate (Lys) (covalent) #status predicted
 F;84/Binding site: carbohydrate (Ser) (covalent) #status predicted
 F;86/Binding site: carbohydrate (Asn) (covalent) #status predicted
 F;148-179/Disulfide bonds: #status predicted

Query Match 7.8%; Score 131.5; DB 2; Length 235;
 Best Local Similarity 25.3%; Pred. No. 0.0012;
 Matches 41; Conservative 27; Mismatches 59; Indels 35; Gaps 7;

```

Qy      163 QPFAHLTINATDIPSGSHKVSLS-SWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANI 220
          :| ||: |          |:          | | :|| | : :|| | || | :|: :
Db      90 KPAHVVAN-----HQAEQLEWLSQRANALLANGMDLKDNLVVPADGLYLIYSQV 141

Qy      221 CFRHHETSGDLATEYLQLMVYVTK-----TSIKIPSSHTLMKGGSTKYWSGNS 268
          |:          | :|: | |:          :|| | :| | |
Db      142 LFK-----GQGCPDYVLLTHTVSRFAISYQEKVSLLSAIKSPCKDTPEGAELKPW---- 192

Qy      269 EFHFYISINVGGFFKLRSGEEISIEVSNPSLLD-PDQDATYFG 309
          : : :|| |:| |: :| ||: | || :   |||
Db      193 ---YEPMYLGGVFQLEKGDLLSAEVNLPKYLDITESGQVYFG 231

```

RESULT 12

I49139

lymphotoxin-beta - mouse

C;Species: Mus musculus (house mouse)

C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 05-Nov-1999

C;Accession: I49139; I49138; I49076

R;Lawton, P.; Nelson, J.; Tizard, R.; Browning, J.L.
J. Immunol. 154, 239-246, 1995
A;Title: Characterization of the mouse lymphotoxin-beta gene.
A;Reference number: I49138; MUID:95088371; PMID:7995944
A;Accession: I49139
A;Status: translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-306 <RES>
A;Cross-references: EMBL:U16985; NID:g577830; PIDN:AAA70089.1; PID:g577831
A;Accession: I49138
A;Status: translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-306 <RE3>
A;Cross-references: EMBL:U16984; NID:g577431; PIDN:AAB60493.1; PID:g577432
R;Pokholok, D.K.; Maroulakou, I.G.; Kuprash, D.V.; Alimzhanov, M.B.; Kozlov,
S.V.; Novobrantseva, T.I.; Turetskaya, R.L.; Green, J.E.; Nedospasov, S.A.
Proc. Natl. Acad. Sci. U.S.A. 92, 674-678, 1995
A;Title: Cloning and expression analysis of the murine lymphotoxin beta gene.
A;Reference number: A55602; MUID:95148600; PMID:7846035
A;Accession: I49076
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-306 <RE2>
A;Cross-references: EMBL:U12029; NID:g515508; PIDN:AAA67716.1; PID:g515509
C;Genetics:
A;Gene: LT-beta
A;Introns: 54/3: 160/1

Qy	105	ESQDTKLIP---DSCRRIKQAIFQGAVQKELQHIVGSGHIRAEKAMVDGSWLDLAKRSKLE	161
		: : : : : : : : : :	
Db	86	ETPDPRLHPQRSNASRNLASTSQGPV-----AQSSREASAWMTI-----	124
Qy	162	AQPFAHLTIN--ATDIPSGSHKVSLSE-----SWYHDRG--WAKISNMTF-----	201
		: : : : : :	
Db	125	LSPAADSTPDPGVQQLPKGEPETDLNPELPAAHLLIGAWMSGQGLSWEASQEEAFLRSGAQ	184
Qy	202	---SNGKLIVNQDGFFYYLIANICFR-HHETSGDLATEYLQL--MVYVTKTSIKIPSSHTL	255
		: : : : : : : :	
Db	185	FSPTHG-LALPQDGVYYLYCHVGVRGRTPPAGRSRARSLTLRSALYRAGGAYGRGPSPELL	243
Qy	256	MKGGST-----KYWSGNSEFHFY SINVG GFFKL RSGEE ISIEVS NP SLL DP DQD	304
		: : : : : : : : : : : :	
Db	244	LEGAETVTPVVDP IGYGSLW-----YT SVGF GG LAQL RSGERV VNI SHPDMVDYRRG	296
Qy	305	ATYFGAFKV	313
		:	
Db	297	KTFFGAVMV	305

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 04-Feb-2000
 C;Accession: S22052
 R;Sanjanwala, M.; Edwards, A.
 submitted to the EMBL Data Library, September 1991
 A;Description: Baboon Tumor Necrosis Factor Derived from Sequences of Genomic DNA.
 A;Reference number: S22052
 A;Accession: S22052
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-233 <SAN>
 A;Cross-references: EMBL:X62141; NID:g38159; PIDN:CAA44068.1; PID:g38160
 C;Genetics:
 A;Introns: 62/3; 78/1; 94/1
 C;Superfamily: tumor necrosis factor
 C;Keywords: glycoprotein; lipoprotein; myristylation; transmembrane protein
 F;19,20/Binding site: myristate (Lys) (covalent) #status predicted
 F;81/Binding site: carbohydrate (Ser) (covalent) #status predicted
 F;145-177/Disulfide bonds: #status predicted

Query Match 7.7%; Score 130; DB 1; Length 233;
 Best Local Similarity 25.5%; Pred. No. 0.0015;
 Matches 40; Conservative 31; Mismatches 62; Indels 24; Gaps 8;

```

Qy      163 QPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANIC 221
          :| ||: |   |   ::   | : | | :| :   : :|:| :| | :|: :
Db      87 KPAHVVAN----PQAEQQL---QWLNRRANALLANGVELRDNLVVPSEGLYLIYSQVL 139

Qy      222 FRHH--ETSGDLATEYLQLMV--YVTK----TSIKIPSSHTLMKGGSTKYWSGNSEFHFY 273
          |:   :: | | : :   | ||   :|| |   :| | |   :
Db      140 FKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPW-----YE 192

Qy      274 SINVGGFKLRSGEIEISIEVSNPSSLDD-PDQDATYFG 309
          | :|| |:| |: :| |: :| || :   |||
Db      193 PIYLGGVFQLEKGDRLSAEINLPDYLDFAESGQVYFG 229

```

RESULT 14

JQ1344

tumor necrosis factor alpha precursor - horse

N;Alternate names: cachectin; TNF alpha

C;Species: Equus caballus (domestic horse)

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 04-Feb-2000

C;Accession: JQ1344

R;Su, X.; Morris, D.D.; McGraw, R.A.

Gene 107, 319-321, 1991

A;Title: Cloning and characterization of gene TNF alpha encoding equine tumor necrosis factor alpha.

A;Reference number: JQ1344; MUID:92084125; PMID:1748301

A;Accession: JQ1344

A;Molecule type: DNA

A;Residues: 1-234 <SUX>

A;Cross-references: GB:M64087; NID:g164244; PIDN:AAA30959.1; PID:g164245

C;Comment: This protein is an important proximal mediator of endotoxemia.

C;Genetics:

A;Gene: TNF-alpha

A;Introns: 62/3; 79/1; 95/1

Qy 191 RGWAKISNMTFSNG-----KLIVNQDGFYLYANICFRHH-----ETSGDLATE 234
 | | :| :|| :|| | | :| : | |
 Db 103 RWWDSYANALMANGVKLEDNQLVVPADGLYLIYSQVLFRGQGCPSTPLFLTHTISRIAVS 162

Qy 235 YLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVS 294
 | | | : :|| | : | | : | | | : | : :| | :
 Db 163 Y-QTKVNIL-SAIKSPCHRETPEWAEAKPW-----YEPIYQGGVFQLEKGDRLSAEIN 213

Qy 295 NPSLLD-PDQDATYFG 309
 | | | : |||
 Db 214 LPDYLDYAESGQVYFG 229

Search completed: September 15, 2004, 08:33:42
 Job time : 42 secs

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:34:26 ; Search time 671 Seconds
(without alignments)
151.503 Million cell updates/sec

Title: US-09-211-315-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1335176 seqs, 320689617 residues

Total number of hits satisfying chosen parameters: 1335176

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query					
No.	Score	Match	Length	DB	ID	Description

1	1685	100.0	317	9	US-09-813-329-7	Sequence 7, Appli
2	1685	100.0	317	9	US-09-871-856-13	Sequence 13, Appl
3	1685	100.0	317	9	US-09-877-650-13	Sequence 13, Appl
4	1685	100.0	317	12	US-10-289-456-79	Sequence 79, Appl
5	1685	100.0	317	12	US-10-202-062-22	Sequence 22, Appl
6	1685	100.0	317	12	US-09-865-363-13	Sequence 13, Appl
7	1685	100.0	317	12	US-10-151-071-10	Sequence 10, Appl
8	1685	100.0	317	12	US-09-957-944-6	Sequence 6, Appli
9	1685	100.0	317	14	US-10-218-547-22	Sequence 22, Appl
10	1685	100.0	317	14	US-10-405-878-13	Sequence 13, Appl
11	1685	100.0	317	14	US-10-167-182-11	Sequence 11, Appl
12	1685	100.0	317	14	US-10-310-793-28	Sequence 28, Appl
13	1685	100.0	317	15	US-10-460-623-11	Sequence 11, Appl
14	1685	100.0	317	16	US-10-664-801-2	Sequence 2, Appli
15	1685	100.0	317	16	US-10-381-160-6	Sequence 6, Appli
16	1424.5	84.5	316	12	US-09-957-944-8	Sequence 8, Appli
17	1422	84.4	270	12	US-10-289-456-80	Sequence 80, Appl
18	1417.5	84.1	316	10	US-09-079-569-7	Sequence 7, Appli
19	1417.5	84.1	316	10	US-09-873-829-4	Sequence 4, Appli
20	1417.5	84.1	316	13	US-10-017-910-4	Sequence 4, Appli
21	1417.5	84.1	316	14	US-10-105-057-2	Sequence 2, Appli
22	1417.5	84.1	316	14	US-10-272-411-19	Sequence 19, Appl
23	1417.5	84.1	316	14	US-10-272-328A-19	Sequence 19, Appl
24	1417.5	84.1	316	14	US-10-326-052-2	Sequence 2, Appli
25	1417.5	84.1	316	14	US-10-167-182-1	Sequence 1, Appli
26	1417.5	84.1	316	15	US-10-460-623-1	Sequence 1, Appli
27	1417.5	84.1	316	16	US-10-664-801-4	Sequence 4, Appli
28	1417.5	84.1	316	16	US-10-664-801-6	Sequence 6, Appli
29	1326.5	78.7	294	9	US-09-871-856-11	Sequence 11, Appl
30	1326.5	78.7	294	9	US-09-877-650-11	Sequence 11, Appl
31	1326.5	78.7	294	12	US-09-865-363-11	Sequence 11, Appl
32	1326.5	78.7	294	14	US-10-405-878-11	Sequence 11, Appl
33	1325	78.6	250	15	US-10-338-785A-1	Sequence 1, Appli
34	1325	78.6	250	16	US-10-611-363-1	Sequence 1, Appli
35	1319	78.3	249	12	US-10-289-456-82	Sequence 82, Appl
36	1319	78.3	249	14	US-10-050-902-221	Sequence 221, App
37	1319	78.3	249	14	US-10-050-898-221	Sequence 221, App
38	1301	77.2	246	14	US-10-167-182-17	Sequence 17, Appl
39	1301	77.2	246	15	US-10-460-623-17	Sequence 17, Appl
40	1293	76.7	245	10	US-09-873-829-2	Sequence 2, Appli
41	1293	76.7	245	13	US-10-017-910-2	Sequence 2, Appli
42	1292	76.7	244	12	US-10-289-456-81	Sequence 81, Appl
43	1292	76.7	244	12	US-10-211-858-42	Sequence 42, Appl
44	1292	76.7	244	14	US-10-210-951-42	Sequence 42, Appl
45	1292	76.7	244	14	US-10-050-902-222	Sequence 222, App

ALIGNMENTS

RESULT 1
 US-09-813-329-7
 ; Sequence 7, Application US/09813329
 ; Patent No. US20020012968A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bristol-Myers Suibb Company

```
; TITLE OF INVENTION: No. US20020012968A1el Drosophila Tumor Necrosis Factor
Class Molecule ("DmTNF") and
; TITLE OF INVENTION: Variants Thereof
; FILE REFERENCE: D0016.np
; CURRENT APPLICATION NUMBER: US/09/813,329
; CURRENT FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/190,816
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-813-329-7
```

```
Query Match          100.0%; Score 1685; DB 9; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
          |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy      61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
          |||
Db      61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy      121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHTINATDIPSGSH 180
          |||
Db      121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHTINATDIPSGSH 180

Qy      181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
          |||
Db      181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy      241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
          |||
Db      241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy      301 PDQDATYFGAFKVRDID 317
          |||
Db      301 PDQDATYFGAFKVRDID 317
```

RESULT 2

US-09-871-856-13

; Sequence 13, Application US/09871856

; Patent No. US20020081720A1

GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

```

;          STREET: 51 University Street
;          CITY: Seattle
;          STATE: WA
;          COUNTRY: USA
;          ZIP: 98101
;
;  COMPUTER READABLE FORM:
;          MEDIUM TYPE: Floppy disk
;          COMPUTER: Apple Power Macintosh
;          OPERATING SYSTEM: Apple Operating System 7.5.5
;          SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
;
;  CURRENT APPLICATION DATA:
;          APPLICATION NUMBER: US/09/871,856
;          FILING DATE: 31-May-2001
;          CLASSIFICATION: <Unknown>
;
;  PRIOR APPLICATION DATA:
;          APPLICATION NUMBER: 08/996,139
;          FILING DATE: <Unknown>
;          APPLICATION NUMBER: USSN 08/813,509
;          FILING DATE: 07 MARCH 1997
;          APPLICATION NUMBER: USSN 08/772,330
;          FILING DATE: 23 DECEMBER 1996
;
;  ATTORNEY/AGENT INFORMATION:
;          NAME: Perkins, Patricia Anne
;          REGISTRATION NUMBER: 34,693
;          REFERENCE/DOCKET NUMBER: 2851-A
;
;  TELECOMMUNICATION INFORMATION:
;          TELEPHONE: (206)587-0430
;          TELEFAX: (206)233-0644
;
;  INFORMATION FOR SEQ ID NO: 13:
;          SEQUENCE CHARACTERISTICS:
;              LENGTH: 317 amino acids
;              TYPE: amino acid
;              TOPOLOGY: linear
;          MOLECULE TYPE: protein
;          SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-871-856-13

```

```

Query Match          100.0%;  Score 1685;  DB 9;  Length 317;
Best Local Similarity 100.0%;  Pred. No. 1.2e-155;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQLMV 240

```

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFKLRSGEEISIEVSNPSLLD 300
 |||
 Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFKLRSGEEISIEVSNPSLLD 300
 |||
 Qy 301 PDQDATYFGAFKVRDID 317
 |||
 Db 301 PDQDATYFGAFKVRDID 317

RESULT 3

US-09-877-650-13

; Sequence 13, Application US/09877650

; Patent No. US20020169117A1

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/877,650

; FILING DATE: 08-Jun-2001

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/995,659

; FILING DATE: 1997-12-22

; APPLICATION NUMBER: USSN 08/813,509

; FILING DATE: 07 MARCH 1997

; APPLICATION NUMBER: USSN 08/772,330

; FILING DATE: 23 DECEMBER 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Perkins, Patricia Anne

; REGISTRATION NUMBER: 34,693

; REFERENCE/DOCKET NUMBER: 2852-A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (206)587-0430

; TELEFAX: (206)233-0644

; INFORMATION FOR SEQ ID NO: 13:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 317 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; SEQUENCE DESCRIPTION: SEQ ID NO: 13:

US-09-877-650-13

Query Match 100.0%; Score 1685; DB 9; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTinATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTinATDIPSGSH 180

Qy    181 KVSLSWYHdRGWAKISNMtFSNGKLIVNqDGFYYLYANICFRHHETSGDLATEYlQLMV 240
        |||
Db    181 KVSLSWYHdRGWAKISNMtFSNGKLIVNqDGFYYLYANICFRHHETSGDLATEYlQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEfHFYSINVGgFFKLRSgEEISIEVSNpSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEfHFYSINVGgFFKLRSgEEISIEVSNpSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 4

US-10-289-456-79

; Sequence 79, Application US/10289456

; Publication No. US20040033211A1

; GENERAL INFORMATION:

; APPLICANT: Bachmann, Martin

; APPLICANT: Maurer, Patrick

; APPLICANT: Spohn, Gunther

; TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease

; FILE REFERENCE: 1700.0330001

; CURRENT APPLICATION NUMBER: US/10/289,456

; CURRENT FILING DATE: 2002-11-07

; PRIOR APPLICATION NUMBER: PCT/IB02/00166

; PRIOR FILING DATE: 2002-01-21

; PRIOR APPLICATION NUMBER: US 10/050,902

; PRIOR FILING DATE: 2002-01-18

; PRIOR APPLICATION NUMBER: US 60/396,635

; PRIOR FILING DATE: 2002-07-19

; PRIOR APPLICATION NUMBER: US 60/331,045

; PRIOR FILING DATE: 2001-11-07

; NUMBER OF SEQ ID NOS: 170

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 79

; LENGTH: 317

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-289-456-79

Query Match 100.0%; Score 1685; DB 12; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        ||||||||||||||||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 5

US-10-202-062-22

; Sequence 22, Application US/10202062

; Publication No. US20040038349A1

; GENERAL INFORMATION:

; APPLICANT: Human Genome Sciences, Inc.,

; TITLE OF INVENTION: Heteromultimeric TNF Ligand Family members

; FILE REFERENCE: PF559

; CURRENT APPLICATION NUMBER: US/10/202,062

; CURRENT FILING DATE: 2002-07-25

; PRIOR APPLICATION NUMBER: 60/307,838

; PRIOR FILING DATE: 2001-07-27

; NUMBER OF SEQ ID NOS: 42

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 22

; LENGTH: 317

; TYPE: PRT

; ORGANISM: human

US-10-202-062-22

Query Match 100.0%; Score 1685; DB 12; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
```

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
 |||
 Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGA VQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
 |||
 Db 121 QAFQGA VQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
 |||
 Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRS GEEISIEVSNPSLLD 300
 |||
 Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRS GEEISIEVSNPSLLD 300

Qy 301 PDQDATYFGAFKVRDID 317
 |||
 Db 301 PDQDATYFGAFKVRDID 317

RESULT 6

US-09-865-363-13

; Sequence 13, Application US/09865363

; Publication No. US20020086826A1

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/865,363

; FILING DATE: 25-May-2001

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/995,659

; FILING DATE: <Unknown>

; APPLICATION NUMBER: USSN 08/813,509

; FILING DATE: 07 MARCH 1997

; APPLICATION NUMBER: USSN 08/772,330

; FILING DATE: 23 DECEMBER 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Perkins, Patricia Anne

```

;      REGISTRATION NUMBER: 34,693
;      REFERENCE/DOCKET NUMBER: 2852-A
;      TELECOMMUNICATION INFORMATION:
;      TELEPHONE: (206)587-0430
;      TELEFAX: (206)233-0644
;      INFORMATION FOR SEQ ID NO: 13:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 317 amino acids
;      TYPE: amino acid
;      TOPOLOGY: linear
;      MOLECULE TYPE: protein
;      SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-865-363-13

```

```

Query Match          100.0%;  Score 1685;  DB 12;  Length 317;
Best Local Similarity 100.0%;  Pred. No. 1.2e-155;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 7

US-10-151-071-10

```

; Sequence 10, Application US/10151071
; Publication No. US20030017151A1
; GENERAL INFORMATION:
; APPLICANT: DOUGALL, William
; APPLICANT: ANDERSON, Dirk
; TITLE OF INVENTION: THERAPEUTIC USES OF RANK ANTAGONISTS
; FILE REFERENCE: 3277-A
; CURRENT APPLICATION NUMBER: US/10/151,071
; CURRENT FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/291,919
; PRIOR FILING DATE: 2001-05-17
; NUMBER OF SEQ ID NOS: 10

```


; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-151-071-10

Query Match 100.0%; Score 1685; DB 12; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
          |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
          |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180
          |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
          |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
          |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
          |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 8

US-09-957-944-6

; Sequence 6, Application US/09957944
; Publication No. US20020086312A1
; GENERAL INFORMATION:
; APPLICANT: Dougall, William C.
; TITLE OF INVENTION: SCREENING ASSAYS FOR AGONISTS AND ANTAGONISTS OF RECEPTOR
ACTIVATOR OF
; TITLE OF INVENTION: NF-kappa B
; FILE REFERENCE: 3109-A
; CURRENT APPLICATION NUMBER: US/09/957,944
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/235,157
; PRIOR FILING DATE: 2000-09-22
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-957-944-6

Query Match 100.0%; Score 1685; DB 12; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQIMV 240
        |||
Db    181 KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQIMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 9

US-10-218-547-22

; Sequence 22, Application US/10218547

; Publication No. US20030100074A1

; GENERAL INFORMATION:

; APPLICANT: Human Genome Sciences, Inc.

; TITLE OF INVENTION: Methods And Compositions For Treating Metabolic Bone Diseases Relating To

; TITLE OF INVENTION: Human Endokine Alpha

; FILE REFERENCE: PF561

; CURRENT APPLICATION NUMBER: US/10/218,547

; CURRENT FILING DATE: 2002-08-15

; PRIOR APPLICATION NUMBER: 60/312,542

; PRIOR FILING DATE: 2001-08-16

; PRIOR APPLICATION NUMBER: 60/330,761

; PRIOR FILING DATE: 2001-10-30

; NUMBER OF SEQ ID NOS: 57

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 22

; LENGTH: 317

; TYPE: PRT

; ORGANISM: human

US-10-218-547-22

Query Match 100.0%; Score 1685; DB 14; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Db	1	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV	60
Qy	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Db	61	VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK	120
Qy	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH	180
Db	121	QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH	180
Qy	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV	240
Db	181	KVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV	240
Qy	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Db	241	YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD	300
Qy	301	PDQDATYFGAFKVRDID	317
Db	301	PDQDATYFGAFKVRDID	317

RESULT 10

US-10-405-878-13

; Sequence 13, Application US/10405878

; Publication No. US20030175840A1

; GENERAL INFORMATION:

; APPLICANT: Anderson, Dirk M.

; Galibert, Laurent

; Maraskovsky, Eugene

; TITLE OF INVENTION: Receptor Activator of NF-kappaB

; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Immunex Corporation, Law Department

; STREET: 51 University Street

; CITY: Seattle

; STATE: WA

; COUNTRY: USA

; ZIP: 98101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: Apple Power Macintosh

; OPERATING SYSTEM: Apple Operating System 7.5.5

; SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/405,878

; FILING DATE: 01-Apr-2003

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/996,139

; FILING DATE: 22 DECEMBER 1997

; APPLICATION NUMBER: USSN 60/064,671

; FILING DATE: 14 OCTOBER 1997

```

;           APPLICATION NUMBER: USSN 08/813,509
;           FILING DATE: 07 MARCH 1997
;           APPLICATION NUMBER: USSN 08/772,330
;           FILING DATE: 23 DECEMBER 1996
;   ATTORNEY/AGENT INFORMATION:
;           NAME: Perkins, Patricia Anne
;           REGISTRATION NUMBER: 34,693
;           REFERENCE/DOCKET NUMBER: 2851-A
;   TELECOMMUNICATION INFORMATION:
;           TELEPHONE: (206)587-0430
;           TELEFAX: (206)233-0644
;   INFORMATION FOR SEQ ID NO: 13:
;   SEQUENCE CHARACTERISTICS:
;           LENGTH: 317 amino acids
;           TYPE: amino acid
;           TOPOLOGY: linear
;   MOLECULE TYPE: protein
;   SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-10-405-878-13

```

```

Query Match           100.0%;  Score 1685;  DB 14;  Length 317;
Best Local Similarity 100.0%;  Pred. No. 1.2e-155;
Matches 317;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        ||||||||||||||||
Db    301 PDQDATYFGAFKVRDID 317

```

RESULT 11

US-10-167-182-11

```

; Sequence 11, Application US/10167182
; Publication No. US20030176647A1
; GENERAL INFORMATION:
; APPLICANT: Yamaguchi, Kyoji
; APPLICANT: Yasuda, Hisataka
; APPLICANT: Nakagawa, No. US20030176647A1uaki

```

```

; APPLICANT: Shima, No. US20030176647Aluyuki
; APPLICANT: Kinosaki, Masahiko
; APPLICANT: Tsuda, Eisuke
; APPLICANT: Goto, Masaaki
; APPLICANT: Yano, Kazuki
; APPLICANT: Tomoyasu, Akihiro
; APPLICANT: Kobayashi, Fumie
; APPLICANT: Washida, Naohiro
; APPLICANT: Takahashi, Ken
; APPLICANT: Morinaga, Tomonori
; APPLICANT: Higashio, Kanji
; TITLE OF INVENTION: Antibodies to OCIF-binding Molecules
; FILE REFERENCE: FJN-070DV
; CURRENT APPLICATION NUMBER: US/10/167,182
; CURRENT FILING DATE: 2002-06-11
; PRIOR APPLICATION NUMBER: US 09/202,455
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: JP 97808/1997
; PRIOR FILING DATE: 1997-04-15
; PRIOR APPLICATION NUMBER: JP 151434/1997
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: JP 217897/1997
; PRIOR FILING DATE: 1997-08-12
; PRIOR APPLICATION NUMBER: JP 224803/1997
; PRIOR FILING DATE: 1997-08-21
; PRIOR APPLICATION NUMBER: JP 332241/1997
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: WO PCT/JP98/01728
; PRIOR FILING DATE: 1998-04-15
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-167-182-11

```

```

Query Match          100.0%; Score 1685; DB 14; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAPHLTINATDIPSGSH 180

Qy    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHNRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

```

```

Qy      241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
          |||
Db      241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy      301 PDQDATYFGAFKVRDID 317
          |||
Db      301 PDQDATYFGAFKVRDID 317

```

RESULT 12

US-10-310-793-28

; Sequence 28, Application US/10310793

; Publication No. US20030198640A1

; GENERAL INFORMATION:

; APPLICANT: Yu, Guo-Liang

; APPLICANT: Ni, Jian

; APPLICANT: Rosen, Craig A

; APPLICANT: Zhang, Jun

; APPLICANT: Wei, Ping

; TITLE OF INVENTION: Methods And Compositions For Treating Inflammatory Bowel Diseases

; TITLE OF INVENTION: Relating To Human Tumor Necrosis Factor-Gamma Beta

; FILE REFERENCE: PF573

; CURRENT APPLICATION NUMBER: US/10/310,793

; CURRENT FILING DATE: 2002-12-06

; PRIOR APPLICATION NUMBER: 60/336,695

; PRIOR FILING DATE: 2001-12-07

; PRIOR APPLICATION NUMBER: 10/226,294

; PRIOR FILING DATE: 2002-08-23

; PRIOR APPLICATION NUMBER: 60/314,381

; PRIOR FILING DATE: 2001-08-24

; PRIOR APPLICATION NUMBER: 09/899,059

; PRIOR FILING DATE: 2001-07-06

; PRIOR APPLICATION NUMBER: 60/278,449

; PRIOR FILING DATE: 2001-03-26

; PRIOR APPLICATION NUMBER: 60/216,879

; PRIOR FILING DATE: 2000-07-07

; PRIOR APPLICATION NUMBER: 09/559,290

; PRIOR FILING DATE: 2000-04-27

; PRIOR APPLICATION NUMBER: 60/180,908

; PRIOR FILING DATE: 2000-02-08

; PRIOR APPLICATION NUMBER: 60/134,067

; PRIOR FILING DATE: 1999-05-13

; PRIOR APPLICATION NUMBER: 60/132,227

; PRIOR FILING DATE: 1999-05-03

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 71

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 28

; LENGTH: 317

; TYPE: PRT

; ORGANISM: human

US-10-310-793-28

Query Match 100.0%; Score 1685; DB 14; Length 317;

Best Local Similarity 100.0%; Pred. No. 1.2e-155;

Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
 |||
 Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
 |||
 Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180
 |||
 Db 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLTINATDIPSGSH 180

Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
 |||
 Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
 |||
 Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy 301 PDQDATYFGAFKVRDID 317
 |||
 Db 301 PDQDATYFGAFKVRDID 317

RESULT 13

US-10-460-623-11

; Sequence 11, Application US/10460623

; Publication No. US20030208045A1

; GENERAL INFORMATION:

; APPLICANT: Yamaguchi, Kyoji

; APPLICANT: Yasuda, Hisataka

; APPLICANT: Nakagawa, No. US20030208045A1uaki

; APPLICANT: Shima, No. US20030208045A1uyuki

; APPLICANT: Kinosaki, Masahiko

; APPLICANT: Tsuda, Eisuke

; APPLICANT: Goto, Masaaki

; APPLICANT: Yano, Kazuki

; APPLICANT: Tomoyasu, Akihiro

; APPLICANT: Kobayashi, Fumie

; APPLICANT: Washida, Naohiro

; APPLICANT: Takahashi, Ken

; APPLICANT: Morinaga, Tomonori

; APPLICANT: Higashio, Kanji

; TITLE OF INVENTION: No. US20030208045A1el Protein and Method for Producing the Protein

; FILE REFERENCE: FJN-070

; CURRENT APPLICATION NUMBER: US/10/460,623

; CURRENT FILING DATE: 2003-06-13

; PRIOR APPLICATION NUMBER: JP 97808/1997

; PRIOR FILING DATE: 1997-04-15

; PRIOR APPLICATION NUMBER: JP 151434/1997

; PRIOR FILING DATE: 1997-06-09

; PRIOR APPLICATION NUMBER: JP 217897/1997

; PRIOR FILING DATE: 1997-08-12

; PRIOR APPLICATION NUMBER: JP 224803/1997

; PRIOR FILING DATE: 1997-08-21
; PRIOR APPLICATION NUMBER: JP 332241/1997
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: WO PCT/JP98/01728
; PRIOR FILING DATE: 1998-04-15
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-460-623-11

Query Match 100.0%; Score 1685; DB 15; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
|
Db 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
|
Db 61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
|
Db 121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLMV 240
|
Db 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLMV 240

Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300
|
Db 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD 300

Qy 301 PDQDATYFGAFKVRDID 317
|
Db 301 PDQDATYFGAFKVRDID 317

RESULT 14

US-10-664-801-2

; Sequence 2, Application US/10664801
; Publication No. US20040115199A1
; GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/10/664,801
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: US/09/396,937
; PRIOR FILING DATE: 1999-09-15

; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-664-801-2

Query Match 100.0%; Score 1685; DB 16; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
        |||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        |||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180
        |||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPF AHLTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240
        |||
Db    181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYLYANICFRHHETSGDLATEYQLQMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
        |||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        |||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 15

US-10-381-160-6
; Sequence 6, Application US/10381160
; Publication No. US20040131587A1
; GENERAL INFORMATION:
; APPLICANT: IMMUNEX CORPORATION
; TITLE OF INVENTION: METHOD FOR TREATMENT OF TUMORS USING COMBINATION THERAPY
; FILE REFERENCE: 2993-WO
; CURRENT APPLICATION NUMBER: US/10/381,160
; CURRENT FILING DATE: 2003-03-17
; PRIOR APPLICATION NUMBER: US 60/242,868
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-381-160-6

Query Match 100.0%; Score 1685; DB 16; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.2e-155;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
          ||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180
          ||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDLAKRSKLEAQPFAHLTINATDIPSGSH 180

Qy    181 KVSLSWYH DRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMLV 240
          ||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYH DRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMLV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300
          ||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
          |||||||
Db    301 PDQDATYFGAFKVRDID 317
```

Search completed: September 15, 2004, 09:01:41
Job time : 673 secs

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:32:23 ; Search time 116 Seconds
(without alignments)
862.235 Million cell updates/sec

Title: US-09-211-315-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_25:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	
No.	Score	Match Length DB ID Description

1	266	15.8	317	13	Q7ZYX9	Q7zyx9 brachydanio
2	265	15.7	304	13	Q7T1F2	Q7t1f2 gallus gall
3	240.5	14.3	214	13	Q9DDZ5	Q9ddz5 brachydanio
4	216.5	12.8	287	13	Q90WT9	Q90wt9 gallus gall
5	215.5	12.8	287	11	Q8K3G0	Q8k3g0 rattus norv
6	194.5	11.5	280	6	Q861W5	Q861w5 felis silve
7	187.5	11.1	279	11	Q7TMV9	Q7tmv9 mus musculu
8	184.5	10.9	252	11	Q8K3Y8	Q8k3y8 mus musculu
9	179.5	10.7	252	11	Q80YZ0	Q80yz0 mus musculu
10	177.5	10.5	252	11	Q8K3Y7	Q8k3y7 rattus norv
11	156.5	9.3	251	4	Q8NFE9	Q8nfe9 homo sapien
12	139.5	8.3	215	11	Q99ND1	Q99nd1 tamiasciuru
13	137.5	8.2	156	11	Q91ZL4	Q91zl4 sigmodon hi
14	137.5	8.2	232	11	Q80XA4	Q80xa4 peromyscus
15	133	7.9	149	6	O97543	O97543 aotus nancy
16	131.5	7.8	216	11	O70332	O70332 mesocricetu
17	130	7.7	217	11	Q9ERG6	Q9erg6 peromyscus
18	127.5	7.6	217	6	Q9BEC5	Q9bec5 tenrec ecau
19	126	7.5	149	6	O97538	O97538 aotus vocif
20	126	7.5	149	6	Q9TTG8	Q9ttg8 aotus nigri
21	126	7.5	302	11	Q7TSL5	Q7tsl5 peromyscus
22	125	7.4	216	6	Q9BEC9	Q9bec9 ochotona pr
23	120.5	7.2	217	6	Q9BEG0	Q9beg0 cyclopes di
24	120.5	7.2	217	6	Q9BEG1	Q9beg1 bradypus tr
25	118.5	7.0	138	6	Q9TTG7	Q9ttg7 aotus lemur
26	117	6.9	244	6	Q862Z7	Q862z7 pan troglod
27	116.5	6.9	169	11	Q9WV90	Q9wv90 marmota mon
28	115.5	6.9	154	6	Q8MJ19	Q8mj19 macaca mula
29	114.5	6.8	216	6	Q9BEE0	Q9bee0 macropus ru
30	113.5	6.7	216	6	Q9BEC4	Q9bec4 talpa europ
31	113.5	6.7	237	13	Q8AWC9	Q8awc9 cyprinus ca
32	113	6.7	217	6	Q9BEF4	Q9bef4 cabassous u
33	111	6.6	102	11	Q80Z03	Q80z03 castor cana
34	110.5	6.6	215	6	Q9BEE8	Q9bee8 erinaceus e
35	110	6.5	102	11	Q80Z02	Q80z02 trichys fas
36	109.5	6.5	253	13	Q7T194	Q7t194 acanthopagr
37	109	6.5	102	11	Q80Z05	Q80z05 dipodomys m
38	108	6.4	102	11	Q80Z06	Q80z06 dipus sagit
39	107.5	6.4	222	13	Q7T1U4	Q7t1u4 pagrus majo
40	107.5	6.4	409	5	Q8MY88	Q8my88 drosophila
41	107.5	6.4	409	5	Q8IGD3	Q8igd3 drosophila
42	106.5	6.3	325	5	Q9V5G2	Q9v5g2 drosophila
43	106.5	6.3	415	5	Q8MUJ1	Q8muj1 drosophila
44	106	6.3	3467	5	Q8I218	Q8i218 plasmodium
45	105.5	6.3	103	6	Q864Z0	Q864z0 physeter ca

ALIGNMENTS

RESULT 1

Q7ZYX9

ID Q7ZYX9 PRELIMINARY; PRT; 317 AA.

AC Q7ZYX9;

DT 01-JUN-2003 (TrEMBLrel. 24, Created)

DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)

OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Spleen;
 RA Sayed A.A., Horiuchi H.H., Furusawa S., Matsuda H.;
 RT "Identification and Characterization of Chicken TNF-Superfamily
 RT Ligand 8 (CD30 Ligand) and 10 (Tumor Necrosis Factor Related Apoptosis
 RT Inducing Ligand TRAIL).";
 RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AB114678; BAC79267.1; -.
 SQ SEQUENCE 304 AA; 34658 MW; DFC128B517747C96 CRC64;

Query Match 15.7%; Score 265; DB 13; Length 304;
 Best Local Similarity 27.3%; Pred. No. 1.6e-15;
 Matches 82; Conservative 56; Mismatches 126; Indels 36; Gaps 12;

Qy 38 PHQPPAASRSMFVALLGLGLGQVVCVALFFYFRAQMDP--NRISEDGTHCI--YRILRL 93
 | | : : : | : | | | : | | : : | | | : : |
 Db 3 PAGGPSAHTCGAVLVAAVLLQSVCAVYTYFTNELKQLWDYTSRSGTACLTGEELGDL 62

Qy 94 HENADFQDTTLESQDTKLIPDSCRRIKQAFQGAQVQKELQHIVGSQHIRAEKAMVDGSWLD 153
 : | | : | : | : | | : : | : : | : : : : |
 Db 63 IQNLD----VVESKDR--VADPCWQVKWHLGKLIKMMMSRI-----LQENMSAINGDRTQ 111

Qy 154 -LAKRSKLEAQP----FAHLTINATDIPSGSHKV-----SLSSWYHD-RGWAKISNM 199
 | : : | : | | | : : : | : | | : : | : : | :
 Db 112 ALSRRDEPPQGPTLRIAAHLTGSSKRSSASPHNYLSYRGIGHKIHWSERRGHSFLYNV 171

Qy 200 TFSNGKLIVNQDGFYYLYANICFRHHET----SG--DLATEYLQLMVYVTKTSIKIPSSH 253
 | : : | : | | | : : | | | : : | : | : | : |
 Db 172 ELWNGELVVPQTGFYYIYSQTYFRFRENEDEDSGLLERIKNPQQLVQYIYKLT-NYPDPI 230

Qy 254 TLMKGGSTKYWSGNSEFHFYSINVGGFKLRSGEESIEVSNPSLLDPDQDATYFGAFKV 313
 | | | | : | : | : | : | : | : | : | : | : | : | :
 Db 231 LLMKSARTSCWSKKAELYGVYQGGVFQLKREDRIFVSVSNSDIVDMDKEASFFGAFMI 290

RESULT 3

Q9DDZ5

ID Q9DDZ5 PRELIMINARY; PRT; 214 AA.

AC Q9DDZ5;

DT 01-MAR-2001 (TrEMBLrel. 16, Created)

DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)

DE TRAIL-like protein.

GN TNFSF10L.

OS Brachydanio rerio (Zebrafish) (Danio rerio).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;

OC Cyprinidae; Danio.

OX NCBI_TaxID=7955;

RN [1]

RP SEQUENCE FROM N.A.

RA Bobe J., Goetz F.W.;
 RT "Molecular cloning and expression of a TNF receptor and two TNF
 RT ligands in the fish ovary."
 RL Comp. Biochem. Physiol. B, Comp. Biochem. 129:475-481(2001).
 DR EMBL; AF250041; AAG47640.1; -.
 DR HSSP; P50591; 1D2Q.
 DR ZFIN; ZDB-GENE-010801-1; tnfsf10l.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 SQ SEQUENCE 214 AA; 24093 MW; 98C002474FF691AA CRC64;

Query Match 14.3%; Score 240.5; DB 13; Length 214;
 Best Local Similarity 28.6%; Pred. No. 1.6e-13;
 Matches 61; Conservative 50; Mismatches 83; Indels 19; Gaps 5;

Qy 118 RIKQAFQGAVQKELQHIVGSQHIRAEKAMVDGSLDLAK-RSKLEAQPFALHTINATDIP 176
 :: : : : | : | : | : : | : : : | |||:::
 Db 2 KLAEGIKAYISKVTDISIISKQTLHAARTQTHSYNTTGSKFMTTVMQRPSAHLTLSSASDN 61

 Qy 177 S-----GSHKVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICF 222
 | : : : | : | : ||| :||:| | ||| |||: : |
 Db 62 SRPQSDMHQPQFDLHQSCRHPVHTWANKSFGAHLNMTLTNGRLRVPQDGRYYLYSQVYF 121

 Qy 223 RHHETS-GDLATEYLLQLMVYV-TKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGF 280
 | : | | : : || : ||| | :|| ||| : : : : : : ||
 Db 122 RYPSPSDSDQSSVSHQLVQCIYKKTSYLNPIQ--LLKGVGTCWAPDAEYALHSVYQGGL 179

 Qy 281 FKLRSGEIEISIEVSNPSLLDPDQDATYFGAFKV 313
 | : || : | : : || : | : : : : : : ||||| : :
 Db 180 FELRAGDEVFVSVSSPTMVYGEDSSSYFGAFRL 212

RESULT 4

Q90WT9

ID Q90WT9 PRELIMINARY; PRT; 287 AA.
 AC Q90WT9;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE TNF-related apoptosis inducing ligand.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bridgham J.T., Johnson A.L.;
 RT "TNF-related apoptosis inducing ligand (TRAIL) expression in the hen

RT ovary.";
 RL Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY057941; AAL23702.1; -.
 DR HSSP; O35235; 1IQA.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 SQ SEQUENCE 287 AA; 32092 MW; DB06E1C95087B108 CRC64;

Query Match 12.8%; Score 216.5; DB 13; Length 287;
 Best Local Similarity 24.7%; Pred. No. 3.5e-11;
 Matches 61; Conservative 57; Mismatches 104; Indels 25; Gaps 6;

Qy 80 SEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAFQGAVQKELQHIVGSQH 139
 | : | : | : | : : : : : | : : : :
 Db 51 SSEEELRCLQLINQQQEGSNLEEL-----ISNQSLKLANTIKAYVATVTENVISRSV 102

Qy 140 I-RAEKAMVDGSWLDLAKRSKLEAQPFahlTINATDIP-----SGSHKVSLSW 187
 : : | : : | : | : | : : : : : | : : : : |
 Db 103 VNEAQKSYFNISEGQVA--TKTLGKPSAHLIFRPQNPAQDGSSRRFGNLSQSCRHAITRW 160

Qy 188 YHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVT-KTS 246
 : : | : : : : | | | | | : : : : : | : : : : |
 Db 161 EDSTIHSHLQNITYRDGRLRVNQAGKYYVYSQIYFRYSRDGAGARVSVPLVQCINWKTS 220

Qy 247 IKIPSSHTLMKGGSTKYWSGNSEHFYYSINVGGFKLRSGEIEISIEVSNPSLLDPDQDAT 306
 | : | : | | : : : : : | : : : : : : : : : : | : : : :
 Db 221 YSQPI--LLLKGVGTKCWAPEAEYGLHALYQGGFLFELKAGDELFSVSVSSLAIDYSDAAAS 278

Qy 307 YFGAFKV 313
 | | | | : :
 Db 279 YFGAFRL 285

RESULT 5

Q8K3G0

ID Q8K3G0 PRELIMINARY; PRT; 287 AA.
 AC Q8K3G0;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE TNF-related apoptosis inducing ligand.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.

RC STRAIN=DA;
 RA Mueller A.M., Giegerich G.;
 RT "Rattus norvegicus TNF-related apoptosis inducing ligand (TRAIL).";
 RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY115578; AAM49797.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 SQ SEQUENCE 287 AA; 32979 MW; CA4F5B5D7C833FEC CRC64;

Query Match 12.8%; Score 215.5; DB 11; Length 287;
 Best Local Similarity 24.2%; Pred. No. 4.3e-11;
 Matches 73; Conservative 59; Mismatches 113; Indels 57; Gaps 14;

Qy 42 PAASRSMFVALLGLGLGQVV---CSVAL-FFYFRAQMD--PNRISEDGTHCIYRILRLHE 95
 |: |: : :: : | ||: : ||: : || : : : |: | | : |
 Db 10 PSFSQHFTMTVICIVLLQVLLQALTVAVTYMYFNNEVKQLQDNYSKIGLACFSK-----E 64

Qy 96 NADFQDTTLESQDTKLIPDSCRRIKQAFQGAVQKELQHIVGSQHIRA-EKAMVDGSWLDL 154
 : || |:| | : : | : : | : : : | || : :
 Db 65 DGDFWDST----DEGILNRPCLOVK-----RQLYQLIEEVTLRTEFT-----IST 106

Qy 155 AKRSKLEAQPF-----AHLT-----INATDIPSGSHKVSL----SSWYHD-RGWA 194
 :| | | : || : | | : | : | : | : | :
 Db 107 VPEKQLSTPPLPRGRRPQ RVAAHITGITRRSNLALIPISKDGKTLGQKIETWESSRRGHS 166

Qy 195 KISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLAT-----EYLQLMVYVTKTSIK 248
 : :: : ||:| : : ||:| : : | | | : : | : | :
 Db 167 FLNHVHLRNGELVIQEEGLYYIYSQTYRFEKEAKEASKTVSKDGGRIKQMVQYIYKYT-S 225

Qy 249 IPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLDPDQDATYF 308
 | ||| || : : ||| || |:| : : | : |:| | : : :
 Db 226 YPDPIILMKSARNSCWSREAEGLYSIYQGGLFELKENDRIFVSVTNEHLMDLDEASFF 285

Qy 309 GA 310
 ||
 Db 286 GA 287

RESULT 6

Q861W5

ID Q861W5 PRELIMINARY; PRT; 280 AA.
 AC Q861W5;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Fas ligand.
 OS Felis silvestris catus (Cat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
 OX NCBI_TaxID=9685;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99053606; PubMed=9839871;
 RA Mizuno T., Endo Y., Momoi Y., Goto Y., Nishimura Y., Tsubota K.,
 RA Mikami T., Ohno K., Watari T., Tsujimoto H., Hasegawa A.;
 RT "Molecular cloning of feline Fas antigen and Fas ligand cDNAs.";
 RL Vet. Immunol. Immunopathol. 65:161-172(1998).
 DR EMBL; AB009280; BAC76426.1; -.
 DR GO; GO:0005576; C:extracellular; IEA.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006915; P:apoptosis; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR GO; GO:0007165; P:signal transduction; IEA.
 DR InterPro; IPR008064; Fas_ligand.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01681; FASLIGAND.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 SQ SEQUENCE 280 AA; 31361 MW; 6AA7E2DE1F1A6B5C CRC64;

Query Match 11.5%; Score 194.5; DB 6; Length 280;
 Best Local Similarity 22.8%; Pred. No. 3.3e-09;
 Matches 74; Conservative 40; Mismatches 98; Indels 113; Gaps 12;

QY	20	GGPG----APHEGPLHAPPPAPHPQPPAASRSM-----FVALLGLG	56
		: :	
Db	38	GRPGQRRPPPPPPPTLPPPPPPPLPPLPLPPLKTRRDHNTGLCLLVMMFFMVLVALVGLG	97
QY	57	LGQVVCVSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSC	116
		: : : : :	
Db	98	LG-----MFQLFHLQ-----KELAELESTSQKH-----	121
QY	117	RRIKQAFQGAQVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLT--INATD	174
		: : : : :	
Db	122	-----VASSLEKQIGQLNPPSEKR-----ELRKVAHLTGKPNRSRS	156
QY	175	IPSGSHKVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATE	234
		: : : : : : :	
Db	157	IP-----LEWEDTYGIALVSGVKYKKGLVINDTGMVFVYSKVNFRGQSCN----NQ	204
QY	235	YLQLMVYVTKTSIKIPSSHTLMKGGSTKY-----WSGNSEFHFYSINVGGFFKLRSAGEE	288
		: : : : :	
Db	205	PLNHKVYMRNS--KYPQDLVLMEGKMMNYCTTGQMWARSS-----YLGAVFNLTSAHDH	255
QY	289	ISIEVSNPSLLDPDQDATYFGAFKV	313
		: : : : : : :	
Db	256	LYVNVSELSLVSFEEKSTFFGLYKL	280

RESULT 7

Q7TMV9

ID Q7TMV9 PRELIMINARY; PRT; 279 AA.
 AC Q7TMV9;
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Tnfsf6 protein.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6NCr; TISSUE=Hematopoietic Stem Cell;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences."
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6NCr; TISSUE=Hematopoietic Stem Cell;
 RA Strausberg R.;
 RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; BC052866; AAH52866.1; -.
 SQ SEQUENCE 279 AA; 31416 MW; C2972E2728FBBB7B CRC64;

Query Match 11.1%; Score 187.5; DB 11; Length 279;
 Best Local Similarity 21.7%; Pred. No. 1.4e-08;
 Matches 70; Conservative 46; Mismatches 105; Indels 101; Gaps 11;

Qy 13 RGSEEMGGGPGAPHEGPHLAPPPAPHP-----PAASRSMFVALLGLGL 57
 || :: | | || | | | | : |||:|:
 Db 38 RGPDQRRPPPPPPVSPPLPPPSQPLPLPPLTPLKKKDHNTNLWLPVVFFMVLVALVGMGL 97
 Qy 58 GQVVCVSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCR 117
 | :|:: |
 Db 98 G-----MYQLFHL----- 105

```

Qy      118 RIKQAFQGAVQKELQHI--VGSQHIRA---EKAMVDGSWLDLAKRSKLEAQPFHAHLTINA 172
          ||| : : : || : : | | : ||| |
Db      106 -----QKELAEELREFTNQSLKVSSFQKQIANPS----TPSEKKEPRSVVAHLTGN- 150

Qy      173 TDIPSGSHKVSLS-SWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDL 231
          | | : | | || : : | | : | | : : : || :
Db      151 -----PHSRSIPLIEWEDTYGTALISGVKYKKGGLVINETGLYFVYSKVYFRGQSCN--- 201

Qy      232 ATEYLQLMVVYTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESI 291
          : | || : : | | || : : : : | : | : : :
Db      202 -NQPLNHKVYMRNS--KYPEDLVLMEEKRLNYCT-TGQIWAHSSHLGAVFNLTADHLYV 257

Qy      292 EVSNPSLLDPDQDATYFGAFKV 313
          : | || : : : | : | : | :
Db      258 NISQLSLINFEEKSTFFGLYKL 279

```

RESULT 8

Q8K3Y8

```

ID   Q8K3Y8          PRELIMINARY;          PRT;   252 AA.
AC   Q8K3Y8;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   TNF superfamily ligand TL1A.
GN   TNFSF15.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=BALB/c;
RX   MEDLINE=21909416; PubMed=11911831;
RA   Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S.,
RA   Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P.,
RA   Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J.,
RA   Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., Wei P.;
RT   "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T
RT   cell costimulator.";
RL   Immunity 16:479-492(2002).
DR   EMBL; AF520786; AAM77367.1; -.
DR   MGD; MGI:2180140; Tnfsf15.
DR   GO; GO:0016020; C:membrane; IEA.
DR   GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
DR   GO; GO:0006955; P:immune response; IEA.
DR   InterPro; IPR006053; TNF_abc.
DR   InterPro; IPR006052; TNF_family.
DR   InterPro; IPR008983; TNF_like.
DR   InterPro; IPR003636; TNF_subf.
DR   Pfam; PF00229; TNF; 1.
DR   PRINTS; PR01234; TNECROSISFCT.
DR   ProDom; PD002012; TNF_subf; 1.
DR   SMART; SM00207; TNF; 1.
DR   PROSITE; PS50049; TNF_2; 1.
SQ   SEQUENCE   252 AA;  27723 MW;  BB901C9350119E0F CRC64;

```

Query Match 10.9%; Score 184.5; DB 11; Length 252;
 Best Local Similarity 26.2%; Pred. No. 2.3e-08;
 Matches 64; Conservative 39; Mismatches 100; Indels 41; Gaps 10;

```

Qy      105 ESQDTKLIPDSCRRIKQAFQGAVQK-----ELQHIVG-SQHIRAEKAMVDGSW 151
      |   ::||| :| | : :| | :| :| |
Db      11 EGVPEVLPEGCRHRPEARAGLAARSKACIALTCCLLSFPILAGLSTLLMAGQLRVPGK- 69

Qy      152 LDLAKRSKLE-----AQPFAHLTI-NATDIPSGSHKVSLSWYHDRGWAK 195
      | | : | :| ||||| | | :::| | | | |
Db      70 -DCMLRAITEERSESPQQVYSPPRGKPRAHLTIKKQTPAPHLKNQLSALHWEHDLGMAF 128

Qy      196 ISN-MTFSNGKLIVNQDGFYYLYANICFR-HHETSGDLA-----TEYLQLMVYVTKTSIK 248
      | | : | |:: :| |::| | | | |:: : :| | :| | :
Db      129 TKNGMKYINKSLVIPESGDYFYISQITFRGTTSVCGDISRGRRPKNKPD SITV VITKVADS 188

Qy      249 IPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPSLLD-PDQDATY 307
      | | : | : | :| | :| | | : : :| | :| | :| | :
Db      189 YPEPARLLTGSKSVCEISNN--WFQSLYLGAMFSLEEGDRLMVNVSDISIVDYTKEDKTF 246

Qy      308 FGAF 311
      ||||
Db      247 FGAF 250
  
```

RESULT 9

Q80YZ0

```

ID   Q80YZ0          PRELIMINARY;          PRT;    252 AA.
AC   Q80YZ0;
DT   01-JUN-2003 (TrEMBLrel. 24, Created)
DT   01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   BM20K13.3 (Tumor necrosis factor (Ligand) superfamily, member
DE   15).
GN   TNFSF15.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Sycamore N.;
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AL691468; CAD83021.1; -.
DR   GO; GO:0016020; C:membrane; IEA.
DR   GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
DR   GO; GO:0006955; P:immune response; IEA.
DR   InterPro; IPR006053; TNF_abc.
DR   InterPro; IPR006052; TNF_family.
DR   InterPro; IPR008983; TNF_like.
DR   InterPro; IPR003636; TNF_subf.
DR   Pfam; PF00229; TNF; 1.
DR   PRINTS; PR01234; TNECROSISFCT.
DR   ProDom; PD002012; TNF_subf; 1.
DR   SMART; SM00207; TNF; 1.
DR   PROSITE; PS50049; TNF_2; 1.
  
```

SQ SEQUENCE 252 AA; 27725 MW; A63ABDCC9E969E0F CRC64;

Query Match 10.7%; Score 179.5; DB 11; Length 252;
Best Local Similarity 25.8%; Pred. No. 6.5e-08;
Matches 63; Conservative 40; Mismatches 100; Indels 41; Gaps 10;

```
Qy      105 ESQDTKLIPDSCRRIKQAFQGAVQK-----ELQHIVG-SQHIRAEKAMVDGSW 151
          |   :::|: ||   :| |   :           : | |   : | : | |
Db      11 EGVPEVLPPEGCRHRPEARAGLAARSKACLALTCCLLSFPILAGLSTLLMAGQLRVP GK- 69

Qy      152 LDLAKRSKLE-----AQPFAHLTI-NATDIPSGSHKVSLSWYHDRGWAK 195
          |   |: |           :| ||||| | |   ::| | || | |
Db      70 -DCMLRAITEERSESPSQQVYSPRGKPRAHLTIKKQTPAPHLKNQLSALHWEHDLGMAF 128

Qy      196 ISN-MTFSNGKLIVNQDGFYLYLANICFR-HHETSGDLA-----TEYLQLMVYVTKTSIK 248
          | | : | |:: : | |::| | ||   ||::   :   : : || :
Db      129 TKNGMKYINKSLVIPESGDYFIYSQITFRGTTSCGDISRGRRPKNKPD SITMVITKVADS 188

Qy      249 IPSSHTLMKGGSTKYWSGNSEFHFYSINVG GFFKLRS GEEISIEVSNPSLLD-PDQDATY 307
          |   |: | :   |: | |: :| | | |: : : ||: ||:| : | |:
Db      189 YPEPARLLTGSKSVCEISNN--WFQSLYLGATFSLEEGDRLMVNVSDISLVDYTKEDKTF 246

Qy      308 FGAF 311
          ||||
Db      247 FGAF 250
```

RESULT 10

Q8K3Y7

ID Q8K3Y7 PRELIMINARY; PRT; 252 AA.
AC Q8K3Y7;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE TNF superfamily ligand TL1A.
GN TNFSF15.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley;
RX MEDLINE=21909416; PubMed=11911831;
RA Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S.,
RA Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P.,
RA Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J.,
RA Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., Wei P.;
RT "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T
RT cell costimulator."
RL Immunity 16:479-492(2002).
DR EMBL; AF520787; AAM77368.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR InterPro; IPR006053; TNF_abc.
DR InterPro; IPR006052; TNF_family.

DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 SQ SEQUENCE 252 AA; 28029 MW; 7789E6556D46F293 CRC64;

Query Match 10.5%; Score 177.5; DB 11; Length 252;
 Best Local Similarity 25.1%; Pred. No. 9.8e-08;
 Matches 62; Conservative 43; Mismatches 99; Indels 43; Gaps 9;

Qy 105 ESQDTKLIPDSCRRRIKQAFQGA VQKELQHI-----VGSQH IRAEK 144
 | : : : | : | : | : : | : : : | : : :
 Db 11 EAVPVEM LPEGCRHRREARTGLAARSKAC LALTCCLLSFPILAGLSTLLMTGQLRIPGKD 70
 Qy 145 AMVDGSWLDLAKRSKLEAQPF-----AHLTI-NATDIPSGSHK VSLSSWYHDRGWA 194
 | : : : | : : : | : : : | : : : | : : :
 Db 71 CMFP---TVTEERSAPS AQPVYTPSRDKPKAHLTIMRQTPVPHLKNELAA LHWENN LGMA 127
 Qy 195 KISN-MTFSNGKLIVNQDGFYYLYANICFRHHETS-GDLA-----TEYLQ LVMVYVTKTSI 247
 | : : : | : : : | : : : | : : : | : : :
 Db 128 FTKNRMNYTNKFLVIPESGDYFIYSQITFRGTTSECGDISRVRRPKPKD SITVVITKVAD 187
 Qy 248 KIPSSHTLMKGGSTKYWSGNSEFHFYSINVG GFFKLRS GEEISIEVS NPSLLD-PDQDAT 306
 | : : : | : : : | : : : | : : : | : : :
 Db 188 SYPEPAHLLTG--TKSVCEISSNWFQPIYLGAMFSLEEGDR L MVNVSDISLVDYTKEDKT 245
 Qy 307 YFGAFKV 313
 : : : : :
 Db 246 FFGAFLI 252

RESULT 11

Q8NFE9

ID Q8NFE9 PRELIMINARY; PRT; 251 AA.
 AC Q8NFE9;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE TNF superfamily ligand TL1A.
 GN TNFSF15.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21909416; PubMed=11911831;
 RA Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S.,
 RA Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P.,
 RA Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J.,
 RA Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., Wei P.;
 RT "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T
 RT cell costimulator."
 RL Immunity 16:479-492(2002).

DR EMBL; AF520785; AAM77366.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
DR GO; GO:0006955; P:immune response; IEA.
DR InterPro; IPR006053; TNF_abc.
DR InterPro; IPR006052; TNF_family.
DR InterPro; IPR008983; TNF_like.
DR InterPro; IPR003636; TNF_subf.
DR Pfam; PF00229; TNF; 1.
DR PRINTS; PR01234; TNECROSISFCT.
DR ProDom; PD002012; TNF_subf; 1.
DR SMART; SM00207; TNF; 1.
DR PROSITE; PS50049; TNF_2; 1.
SQ SEQUENCE 251 AA; 28087 MW; 65ED70E367E3446D CRC64;

Qy	163	QPF A HLT-INATDIPSGSHK V SLSSWYH D RGWAKISN-MTFSNGKLI V NQDGFYYLYANI	220
		: : :: : : : : : : :	
Db	94	KPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFL L IPESGDYFIYSQV	153
Qy	221	CFRH H ETSGDLATEYLQ-----LMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFH	271
		: : : : : : : : :	
Db	154	TFRGMTSE---CSEIRQAGRPNKPDSITVVITKVTD S YPEPTQLLMGTKSVCEVGSN--W	208
Qy	272	FYSINVG G FFKLRS G EEISIEVSNP S LLD-PDQDATYFGAF	311
		: : : : : : : :	
Db	209	FOPIYLGAMF S LOEGDKLMVNVSDISLV D YTKEDKTEFFGAF	249

RESULT 12

DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 FT NON_TER 1 1
 FT NON_TER 215 215
 SQ SEQUENCE 215 AA; 23739 MW; 36441309CA5E9898 CRC64;

Query Match 8.3%; Score 139.5; DB 11; Length 215;
 Best Local Similarity 26.5%; Pred. No. 0.00021;
 Matches 40; Conservative 27; Mismatches 51; Indels 33; Gaps 5;

Qy 163 QPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANIC 221
 :| ||: | |: | | | ::| | : ::| || | :: :
 Db 79 KPSVAHVANQTE-----EQLQWLSRRANALLANGMELIDNQLVVPADGLYLIYSQVL 130
 Qy 222 FRHHETSGDLATEYLQLMVYVTK-----TSIKIPSSHTLMKGGSTKYWSGNSE 269
 |: | : |: | :: : :|| | : :| | |
 Db 131 FK-----GQGCSYVLLTHTVSRFAVSQDKVNLLSAIKSPCPKESLEGAEFKPW----- 180
 Qy 270 FHFYSINVGGFKLRSGEIEISIEVSNPSLLD 300
 : | :|| |:| : :| ||: || ||
 Db 181 --YEPIYLGGVFELQKGDRLSAEVNLP SYLD 209

RESULT 13

Q91ZL4

ID Q91ZL4 PRELIMINARY; PRT; 156 AA.
 AC Q91ZL4;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Tumor necrosis factor alpha (Fragment).
 OS Sigmodon hispidus (Hispid cotton rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Sigmodontinae;
 OC Sigmodon.
 OX NCBI_TaxID=42415;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Blanco J.C., Pletneva L.M., Prince G.A.;
 RT "Sigmodon hispidus cytokines, chemokines and interferons."
 RL Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF421388; AAL18818.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.

DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 FT NON_TER 1 1
 SQ SEQUENCE 156 AA; 17303 MW; DC565F3BC3C826E4 CRC64;

Query Match 8.2%; Score 137.5; DB 11; Length 156;
 Best Local Similarity 27.0%; Pred. No. 0.0002;
 Matches 43; Conservative 25; Mismatches 68; Indels 23; Gaps 7;

Qy 160 LEAQPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYA 218
 | :| ||: | | | | :| | | :| :| || | :| :
 Db 8 LSDKPVAVHVAN-----QQAEEQLEWLSQRANALLANGMDLRNNQLVIPADGLYLVYS 60
 Qy 219 NICFRHHETSG-DLATEYLQLMV--YVTK----TSIKIPSSHTLMKGGSTKYWSGNSEFH 271
 : | : | : | : | : | :| | :| | |
 Db 61 QVLFKGLGRSNCELLTHTVSRIAVSYEDKVNLLSAIKSPCPKETPQGAELKPW----- 113
 Qy 272 FYSINVGGFKFLRSGEIEISIEVSNPSLLD-PDQDATYFG 309
 : | :|| | : | : | || :| | : |||
 Db 114 YEPIYLGGVFQLEKGDRLSAEVNHPKYLDFAESGQVYFG 152

RESULT 14

Q80XA4

ID Q80XA4 PRELIMINARY; PRT; 232 AA.
 AC Q80XA4;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Tumor necrosis factor precursor (Fragment).
 GN TNF.
 OS Peromyscus maniculatus (Deer mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Sigmodontinae;
 OC Peromyscus.
 OX NCBI_TaxID=10042;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Green R.M., Herbst M.M., Schountz T.;
 RT "Cloning of the deer mouse tumor necrosis factor gene."
 RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY249143; AAP03078.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.

DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Signal.
 FT SIGNAL 1 20 Potential.
 FT CHAIN 80 >232 tumor necrosis factor.
 FT NON_TER 232 232
 SQ SEQUENCE 232 AA; 25704 MW; E48A9379DB4F216D CRC64;

Query Match 8.2%; Score 137.5; DB 11; Length 232;
 Best Local Similarity 25.9%; Pred. No. 0.00036;
 Matches 42; Conservative 27; Mismatches 58; Indels 35; Gaps 7;

QY 163 QPFAHLTINATDIPSGSHKVSLS-SWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANI 220
 :| ||: | |:| | | ::| | : :|: | || | :|: :
 Db 90 KPVAVHVAN-----HQVDEQLEWLSRRANALLANGMDLKDNLQIVIPADGLYLVSQV 141
 QY 221 CFRHHETSGDLATEYLQLMVYVTK-----TSIKIPSSHTLMKGGSTKYWSGNS 268
 |: | : |:| |:: :|| | :| | |
 Db 142 LFK-----GQGCSNYVLLTHTVSRFAVSIEDKVNLLSAIKSPCPKETPEGSELKPW---- 192
 QY 269 EFHFYSINVGGFFKLRSGEIEISIEVSNPSLLD-PDQDATYFG 309
 : | :|| |:| |: :| ||: | || : |||
 Db 193 ---YEPIYLGGVFQLEKGDRLSAEVNLPKYLDFAESGQVYFG 231

RESULT 15

O97543

ID O97543 PRELIMINARY; PRT; 149 AA.
 AC O97543;
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Tumor necrosis factor alpha (Fragment).
 GN TNF-ALPHA.
 OS Aotus nancymaae (Ma's night monkey).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Aotinae; Aotus.
 OX NCBI_TaxID=37293;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Echeverry S.J., Hernandez E., Moreno A., Patarroyo M.E., Murillo L.A.;
 RT "Identification, cloning and sequencing of different interleukin genes
 RT in 4 Aotus species.";
 RL Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF014513; AAD01539.1; -.
 DR HSSP; P01375; 4TSV.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.

DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 FT NON_TER 1 1
 FT NON_TER 149 149
 SQ SEQUENCE 149 AA; 16466 MW; 3C2A6140778EFA8A CRC64;

Query Match 7.9%; Score 133; DB 6; Length 149;
 Best Local Similarity 25.5%; Pred. No. 0.00048;
 Matches 40; Conservative 31; Mismatches 62; Indels 24; Gaps 8;

Qy 163 QPFAHLTINATDIPSGSHKVSLSWYHDRGWAKISN-MTFSNGKLIVNQDGFYYLYANIC 221
 :| ||: | : : | : | :| : : :| :| :| : :
 Db 4 KPVAHVVAN----PQAEGQL---QWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVL 56
 Qy 222 FRHH--ETSGDLATEYLQLMV--YVTK----TSIKIPSSHTLMKGGSTKYWSGNSEFHFY 273
 |: : : | : : | || :|| | :| | | :
 Db 57 FKGQGCPSHVLTLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPW-----YE 109
 Qy 274 SINVGFFFKLRSGEIEISIEVSNPSLLD-PDQDATYFG 309
 | :|| |:| |: :| |:: | || : |||
 Db 110 PIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFG 146

Search completed: September 15, 2004, 08:38:37
 Job time : 119 secs

OM protein - protein search, using sw model

Run on: September 15, 2004, 08:32:22 ; Search time 24 Seconds
(without alignments)
687.760 Million cell updates/sec

Title: US-09-211-315-39
Perfect score: 1685
Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAFKVRDID 317

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		%	Query				
No.	Score	Match	Length	DB	ID	Description	
1	1685	100.0	317	1	TN11_HUMAN	O14788 h tumor nec	
2	1417.5	84.1	316	1	TN11_MOUSE	O35235 m tumor nec	
3	1396.5	82.9	318	1	TN11_RAT	Q9ese2 r tumor nec	
4	251.5	14.9	281	1	TN10_HUMAN	P50591 homo sapien	
5	248	14.7	291	1	TN10_MOUSE	P50592 mus musculu	
6	200	11.9	282	1	TNF6_PIG	Q9bea8 sus scrofa	
7	189	11.2	281	1	TNF6_HUMAN	P48023 homo sapien	
8	186	11.0	280	1	TNF6_MACMU	Q9myl6 macaca mula	
9	184.5	10.9	279	1	TNF6_MOUSE	P41047 mus musculu	
10	182.5	10.8	280	1	TNF6_CERTO	Q9bdn1 cercocebus	
11	176.5	10.5	261	1	TNF5_BOVIN	P51749 bos taurus	
12	175.5	10.4	278	1	TNF6_RAT	P36940 rattus norv	
13	169.5	10.1	261	1	TNF5_CALJA	Q9bdn3 callithrix	
14	167.5	9.9	261	1	TNF5_AOTTR	Q9bdm3 aotus trivi	
15	158.5	9.4	261	1	TNF5_HUMAN	P29965 homo sapien	
16	155.5	9.2	261	1	TNF5_MACMU	Q9bdc7 macaca mula	
17	155	9.2	272	1	TNF5_CHICK	Q9i8d8 gallus gall	

18	152.5	9.1	261	1	TNF5_PIG	Q95mq5	sus	scrofa
19	152	9.0	260	1	TNF5_FELCA	O97605	felis	silve
20	146	8.7	234	1	TNFA_CAVPO	P51435	cavia	porce
21	145.5	8.6	239	1	TN14_MOUSE	Q9qyh9	mus	musculu
22	145	8.6	174	1	TN15_HUMAN	O95150	homo	sapien
23	145	8.6	260	1	TNF5_CANFA	O97626	canis	famil
24	143	8.5	240	1	TNF5_MACNE	Q9bdm7	macaca	neme
25	141.5	8.4	235	1	TNFA_MOUSE	P06804	mus	musculu
26	140.5	8.3	235	1	TNFA_RABIT	P04924	oryctolagus	
27	139	8.2	233	1	TNFA_SAIISC	Q8mkg8	saimiri	sci
28	137	8.1	234	1	TNFA_SHEEP	P23383	ovis	aries
29	136	8.1	234	1	TNFA_CAPHI	P13296	capra	hircu
30	134.5	8.0	310	1	TNFC_MARMO	Q9jml0	marmota	mon
31	134	8.0	233	1	TNFA_MACFA	P79337	macaca	fasc
32	134	8.0	240	1	TN14_HUMAN	O43557	homo	sapien
33	133	7.9	232	1	TNFA_PANTR	Q8hzd9	pan	troglo
34	133	7.9	233	1	TNFA_CANFA	P51742	canis	famil
35	133	7.9	233	1	TNFA_HUMAN	P01375	homo	sapien
36	133	7.9	233	1	TNFA_MACMU	P48094	macaca	mula
37	132.5	7.9	235	1	TNFA_PERLE	P36939	peromyscus	
38	131.5	7.8	235	1	TNFA_RAT	P16599	rattus	norv
39	130.5	7.7	306	1	TNFC_MOUSE	P41155	mus	musculu
40	130	7.7	233	1	TNFA_PAPSP	P33620	papio	sp. (
41	129.5	7.7	233	1	TNFA_MARMO	O35734	marmota	mon
42	129	7.7	233	1	TNFA_PAPAN	P59695	papio	anubi
43	129	7.7	233	1	TNFA_PAPHU	O77510	papio	hamad
44	128	7.6	234	1	TNFA_HORSE	P29553	equus	cabal
45	126.5	7.5	233	1	TNFA_BOVIN	Q06599	bos	taurus

ALIGNMENTS

RESULT 1

TN11_HUMAN

ID TN11_HUMAN STANDARD; PRT; 317 AA.
AC O14788; O14723; Q96Q17; Q9P2Q3;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast
DE differentiation factor) (ODF).
GN TNFSF11 OR RANKL OR TRANCE OR OPGL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Bone marrow, and Peripheral blood;
RX MEDLINE=98032977; PubMed=9367155;
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C.,
RA Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D.,
RA Galibert L.;
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth

RT and dendritic-cell function.";
 RL Nature 390:175-179(1997).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Lymph node;
 RX MEDLINE=98227661; PubMed=9568710;
 RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,
 RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H.,
 RA Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X.,
 RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,
 RA Boyle W.J.;
 RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast
 RT differentiation and activation.";
 RL Cell 93:165-176(1998).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
 RA Ikeda T., Kuroyama H., Hirokawa K.;
 RT "Determination of human RANKL isoforms.";
 RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
 RN [4]
 RP SEQUENCE OF 73-317 FROM N.A.
 RC TISSUE=Thymocytes;
 RX MEDLINE=97460112; PubMed=9312132;
 RA Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,
 RA Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,
 RA Choi Y.;
 RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family
 RT that activates c-Jun N-terminal kinase in T cells.";
 RL J. Biol. Chem. 272:25190-25194(1997).
 RN [5]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Tongue;
 RX MEDLINE=20175237; PubMed=10708588;
 RA Nagai M., Kyakumoto S., Sato N.;
 RT "Cancer cells responsible for humoral hypercalcemia express mRNA
 RT encoding a secreted form of ODF/TRANCE that induces osteoclast
 RT formation.";
 RL Biochem. Biophys. Res. Commun. 269:532-536(2000).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcemia of malignancy.
 CC -!- SUBUNIT: Homotrimer (By similarity).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);
 CC Secreted (isoform 2). A soluble form of isoform 1 arises by
 CC proteolytic processing (By similarity).
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1;
 CC IsoId=O14788-1; Sequence=Displayed;
 CC Name=2; Synonyms=SODF;
 CC IsoId=O14788-2; Sequence=VSP_006447;
 CC Name=3;

CC IsoId=O14788-3; Sequence=VSP_006446;
 CC -!- TISSUE SPECIFICITY: HIGHEST IN THE PERIPHERAL LYMPH NODES BUT WEAK
 CC IN SPLEEN, PERIPHERAL BLOOD LEUKOCYTES, BONE MARROW, HEART,
 CC PLACENTA, SKELETAL MUSCLE, STOMACH AND THYROID.
 CC -!- INDUCTION: UPREGULATED BY T CELL RECEPTOR STIMULATION.
 CC -!- PTM: The soluble form of isoform 1 derives from the membrane form
 CC by proteolytic processing (By similarity). The cleavage may be
 CC catalyzed by ADAM17.
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF019047; AAB86811.1; -.
 DR EMBL; AF053712; AAC39731.1; -.
 DR EMBL; AB064269; BAB79694.1; -.
 DR EMBL; AB061227; BAB71768.1; -.
 DR EMBL; AB064270; BAB79695.1; -.
 DR EMBL; AF013171; AAC51762.1; -.
 DR EMBL; AB037599; BAA90488.1; -.
 DR HSSP; P50591; 1DOG.
 DR Genew; HGNC:11926; TNFSF11.
 DR MIM; 602642; -.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0005887; C:integral to plasma membrane; NAS.
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR GO; GO:0030316; P:osteoclast differentiation; NAS.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Differentiation; Receptor; Glycoprotein; Transmembrane;
 KW Signal-anchor; Alternative splicing.
 FT CHAIN 1 317 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, MEMBRANE FORM.
 FT CHAIN 140 317 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, SOLUBLE FORM (BY SIMILARITY).
 FT DOMAIN 1 47 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 48 68 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 69 317 EXTRACELLULAR (POTENTIAL).
 FT SITE 139 140 CLEAVAGE (BY SIMILARITY).
 FT CARBOHYD 171 171 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 198 198 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT VARSPLIC 1 47 Missing (in isoform 3).
 FT /FTid=VSP_006446.
 FT VARSPLIC 1 73 Missing (in isoform 2).

FT /FTId=VSP_006447.
FT CONFLICT 194 194 A -> G (IN REF. 4).
SQ SEQUENCE 317 AA; 35478 MW; 766176446348097F CRC64;

Query Match 100.0%; Score 1685; DB 1; Length 317;
Best Local Similarity 100.0%; Pred. No. 3.6e-138;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPAPHPQPPAASRSMFVALLGLGLGQV 60

Qy     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 VCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIK 120

Qy    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTINATDIPSGSH 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 QAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFahlTINATDIPSGSH 180

Qy    181 KVSLSWYHDRGWAKISNMTFsNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 KVSLSWYHDRGWAKISNMTFsNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMV 240

Qy    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHfYSINVGGFFKLRSgEEISIEVSNPSLLD 300
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHfYSINVGGFFKLRSgEEISIEVSNPSLLD 300

Qy    301 PDQDATYFGAFKVRDID 317
        ||||||||||||||||
Db    301 PDQDATYFGAFKVRDID 317
```

RESULT 2

TN11_MOUSE

ID TN11_MOUSE STANDARD; PRT; 316 AA.
AC O35235; O35306; Q9JJK8; Q9JJK9; Q9R1Y0;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast
DE differentiation factor) (ODF) (Osteoclastogenesis-inhibitory factor)
DE (OCIF).
GN TNFSF11 OR RANKL OR TRANCE OR OPGL.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Hybridoma;
RX MEDLINE=97460112; PubMed=9312132;
RA Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,
RA Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,
RA Choi Y.;

RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family
RT that activates c-Jun N-terminal kinase in T cells.";
RL J. Biol. Chem. 272:25190-25194(1997).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Thymic lymphoma;
RX MEDLINE=98032977; PubMed=9367155;
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C.,
RA Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D.,
RA Galibert L.;
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth
RT and dendritic-cell function.";
RL Nature 390:175-179(1997).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Bone marrow;
RX MEDLINE=98227661; PubMed=9568710;
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H.,
RA Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X.,
RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,
RA Boyle W.J.;
RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast
RT differentiation and activation.";
RL Cell 93:165-176(1998).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Bone marrow stroma;
RX MEDLINE=98188248; PubMed=9520411;
RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M.,
RA Mochizuki S.-I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E.,
RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;
RT "Osteoclast differentiation factor is a ligand for
RT osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
RT to TRANCE/RANKL.";
RL Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).
RN [5]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC STRAIN=129;
RX MEDLINE=99214075; PubMed=10196481;
RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,
RA Ueda M., Higashio K.;
RT "Cloning and characterization of the gene encoding mouse osteoclast
RT differentiation factor.";
RL Gene 230:121-127(1999).
RN [6]
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RX MEDLINE=21150053; PubMed=11250921;
RA Ikeda T., Kasai M., Utsuyama M., Hirokawa K.;
RT "Determination of three isoforms of the receptor activator of nuclear
RT factor-kappaB ligand and their differential expression in bone and
RT thymus.";
RL Endocrinology 142:1419-1426(2001).
RN [7]
RP SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION.
RX MEDLINE=99240759; PubMed=10224132;
RA Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H.,

RA Schloendorff J., Tempst P., Choi Y., Blobel C.P.;
 RT "Evidence for a role of a tumor necrosis factor-alpha
 RT (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a
 RT TNF family member involved in osteoclastogenesis and dendritic cell
 RT survival.";
 RL J. Biol. Chem. 274:13613-13618(1999).
 RN [8]
 RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 158-316.
 RX MEDLINE=21464816; PubMed=11581298;
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;
 RT "Crystal structure of the TRANCE/RANKL cytokine reveals determinants
 RT of receptor-ligand specificity.";
 RL J. Clin. Invest. 108:971-979(2001).
 RN [9]
 RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.
 RX MEDLINE=21839021; PubMed=11733492;
 RA Ito S., Wakabayashi K., Ubukata O., Hayashi S., Okada F., Hata T.;
 RT "Crystal structure of the extracellular domain of mouse RANK ligand at
 RT 2.2-A resolution.";
 RL J. Biol. Chem. 277:6631-6636(2002).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcemia of malignancy.
 CC -!- SUBUNIT: Homotrimer.
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein and secreted
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1;
 CC IsoId=O35235-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=O35235-2; Sequence=VSP_006449;
 CC Name=3;
 CC IsoId=O35235-3; Sequence=VSP_006448;
 CC -!- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN THYMUS AND LYMPH NODES BUT
 CC NOT IN NONLYMPHOID TISSUES AND IS ABUNDANTLY EXPRESSED IN T CELLS
 CC BUT NOT IN B CELLS. A HIGH LEVEL EXPRESSION IS ALSO SEEN IN THE
 CC TRABECULAR BONE AND LUNG.
 CC -!- PTM: N-glycosylated.
 CC -!- PTM: The soluble form of isoform 1 derives from the membrane form
 CC by proteolytic processing. The cleavage may be catalyzed by
 CC ADAM17. A further shorter soluble form was observed.
 CC -!- DISEASE: Deficiency in TNFSF11 results in failure to form lobulo-
 CC alveolar mammary structures during pregnancy, resulting in death
 CC of newborns. Trance-deficient mice show severe osteopetrosis, with
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit
 CC profound growth retardation at several skeletal sites, including
 CC the limbs, skull, and vertebrae and have marked chondrodysplasia,
 CC with thick, irregular growth plates and a relative increase in
 CC hypertrophic chondrocytes.
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----

DR EMBL; AF013170; AAC71061.1; -.
 DR EMBL; AF019048; AAB86812.1; -.
 DR EMBL; AF053713; AAC40113.1; -.
 DR EMBL; AB008426; BAA25425.1; -.
 DR EMBL; AB022039; BAA36970.1; -.
 DR EMBL; AB022036; BAA36970.1; JOINED.
 DR EMBL; AB022037; BAA36970.1; JOINED.
 DR EMBL; AB022038; BAA36970.1; JOINED.
 DR EMBL; AB032771; BAA97257.1; -.
 DR EMBL; AB032772; BAA97258.1; -.
 DR EMBL; AB036798; BAA97259.1; -.
 DR PDB; 1J TZ; 28-JAN-03.
 DR PDB; 1IQA; 14-JAN-03.
 DR MGD; MGI:1100089; Tnfsf11.
 DR GO; GO:0009887; P:organogenesis; IMP.
 DR GO; GO:0001503; P:ossification; IMP.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Differentiation; Receptor; Glycoprotein; Transmembrane;
 KW Signal-anchor; 3D-structure; Alternative splicing.
 FT CHAIN 1 316 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, MEMBRANE FORM.
 FT CHAIN 139 316 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, SOLUBLE FORM.
 FT DOMAIN 1 48 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 49 69 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 70 316 EXTRACELLULAR (POTENTIAL).
 FT SITE 138 139 CLEAVAGE.
 FT CARBOHYD 197 197 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 262 262 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT VARSPLIC 1 117 Missing (in isoform 3).
 FT /FTId=VSP_006448.
 FT VARSPLIC 14 44 SSEEMGSGPGVPHEGPLHPAPSAPAPAPPPA -> TP (in
 FT isoform 2).
 FT /FTId=VSP_006449.
 FT CONFLICT 99 99 G -> D (IN REF. 2).
 FT CONFLICT 141 143 MISSING (IN REF. 5).
 FT STRAND 164 169
 FT TURN 171 172
 FT STRAND 181 182
 FT STRAND 186 187
 FT TURN 191 192

Query Match 84.1%; Score 1417.5; DB 1; Length 316;
Best Local Similarity 84.3%; Pred. No. 4.7e-115;
Matches 268; Conservative 16; Mismatches 31; Indels 3; Gaps 2;

RESULT 3

```

ID      TN11_RAT          STANDARD;          PRT;          318 AA.
AC      Q9ESE2; Q91ZI9;
DT      28-FEB-2003 (Rel. 41, Created)
DT      28-FEB-2003 (Rel. 41, Last sequence update)
DT      28-FEB-2003 (Rel. 41, Last annotation update)
DE      Tumor necrosis factor ligand superfamily member 11 (Receptor activator
DE      of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-
DE      induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast
DE      differentiation factor) (ODF).
GN      TNFSF11 OR RANKL OR TRANCE OR OPGL.
OS      Rattus norvegicus (Rat).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX      NCBI_TaxID=10116;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      TISSUE=Tibial bone;
RX      MEDLINE=20540945; PubMed=11092398;

```

RA Xu J.K., Tan J.K., Huang L., Gao X.H., Laird R., Liu D., Wysocki S.,
 RA Zheng M.H.;
 RT "Cloning, sequence and functional characterization of the rat
 RT homologue of receptor activator of NF-kB ligand.";
 RL J. Bone Miner. Res. 15:2178-2186(2000).
 RN [2]
 RP SEQUENCE OF 266-318 FROM N.A.
 RC STRAIN=Fischer 344;
 RX MEDLINE=21662371; PubMed=11804028;
 RA Odgren P.R., Kim N., van Wesenbeeck L., MacKay C., Mason-Savas A.,
 RA Safadi F.F., Popoff S.N., Lengner C., van-Hul W., Choi Y.,
 RA Marks S.C. Jr.;
 RT "Evidence that the rat osteopetrotic mutation toothless (tl) is not in
 RT the TNFSF11 (TRANCE, RANKL, ODF, OPGL) gene.";
 RL Int. J. Dev. Biol. 45:853-859(2001).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcemia of malignancy.
 CC -!- SUBUNIT: Homotrimer (By similarity).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein and secreted (By
 CC similarity).
 CC -!- TISSUE SPECIFICITY: Highly expressed in thymus and bone tissues.
 CC -!- PTM: The soluble form derives from the membrane form by
 CC proteolytic processing (By similarity).
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF187319; AAG17031.1; -.
 DR EMBL; AF425669; AAL23963.1; -.
 DR HSSP; P50591; 1DOG.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Differentiation; Receptor; Glycoprotein; Transmembrane;
 KW Signal-anchor.
 FT CHAIN 1 318 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, MEMBRANE FORM.
 FT CHAIN 141 318 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 11, SOLUBLE FORM.
 FT DOMAIN 1 47 CYTOPLASMIC (POTENTIAL).

RA Goodwin R.G.;
 RT "Identification and characterization of a new member of the TNF
 RT family that induces apoptosis.";
 RL Immunity 3:673-682(1995).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Placenta;
 RX MEDLINE=96278649; PubMed=8663110;
 RA Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A.,
 RA Ashkenazi A.;
 RT "Induction of apoptosis by Apo-2 ligand, a new member of the tumor
 RT necrosis factor cytokine family.";
 RL J. Biol. Chem. 271:12687-12690(1996).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Lymph;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [4]
 RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 114-281.
 RX MEDLINE=20017054; PubMed=10549288;
 RA Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M.,
 RA Kelley R.F., Ashkenazi A., de Vos A.M.;
 RT "Triggering cell death: the crystal structure of Apo2L/TRAIL in a
 RT complex with death receptor 5.";
 RL Mol. Cell 4:563-571(1999).
 RN [5]
 RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 119-281.
 RX PubMed=10542098;
 RA Mongkolsapaya J., Grimes J.M., Chen N., Xu X.-N., Stuart D.I.,
 RA Jones E.Y., Screaton G.R.;
 RT "Structure of the TRAIL-DR5 complex reveals mechanisms conferring
 RT specificity in apoptotic initiation.";
 RL Nat. Struct. Biol. 6:1048-1053(1999).
 RN [6]
 RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 114-281.
 RX MEDLINE=99413670; PubMed=10485660;
 RA Cha S.-S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C.,

RA Sung Y.C., Oh B.-H.;
 RT "2.8 A resolution crystal structure of human TRAIL, a cytokine with
 RT selective antitumor activity.";
 RL Immunity 11:253-261(1999).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF10A/TRAILR1,
 CC TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and
 CC possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity
 CC may be modulated by binding to the decoy receptors
 CC TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot
 CC induce apoptosis.
 CC -!- COFACTOR: Binds 1 zinc ion and one anionic solvent molecule per
 CC trimer.
 CC -!- SUBUNIT: Homotrimer.
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein (Potential).
 CC -!- TISSUE SPECIFICITY: WIDESPREAD; MOST PREDOMINANT IN SPLEEN, LUNG
 CC AND PROSTATE.
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; U37518; AAC50332.1; -.
 DR EMBL; U57059; AAB01233.1; -.
 DR EMBL; BC032722; AAH32722.1; -.
 DR PDB; 1D0G; 22-OCT-99.
 DR PDB; 1D4V; 01-NOV-99.
 DR PDB; 1D2Q; 11-FEB-00.
 DR PDB; 1DG6; 26-SEP-01.
 DR Genew; HGNC:11925; TNFSF10.
 DR MIM; 603598; -.
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0005625; C:soluble fraction; TAS.
 DR GO; GO:0005102; F:receptor binding; TAS.
 DR GO; GO:0007267; P:cell-cell signaling; TAS.
 DR GO; GO:0006917; P:induction of apoptosis; TAS.
 DR GO; GO:0007165; P:signal transduction; TAS.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Apoptosis; Transmembrane; Signal-anchor; Metal-binding;
 KW Zinc; 3D-structure.
 FT DOMAIN 1 17 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 18 38 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 39 281 EXTRACELLULAR (POTENTIAL).
 FT METAL 230 230 ZINC.
 FT STRAND 123 127

```

FT    TURN          130    131
FT    TURN          137    139
FT    STRAND        149    150
FT    STRAND        163    165
FT    STRAND        167    170
FT    TURN          171    172
FT    STRAND        173    176
FT    STRAND        180    193
FT    STRAND        205    213
FT    STRAND        220    228
FT    STRAND        237    250
FT    TURN          252    253
FT    STRAND        255    260
FT    HELIX         263    265
FT    STRAND        266    267
FT    TURN          270    272
FT    STRAND        274    281
SQ    SEQUENCE      281 AA; 32509 MW;  DDAAAF78DAAB2F6D CRC64;

```

```

Query Match          14.9%;  Score 251.5;  DB 1;  Length 281;
Best Local Similarity 24.1%;  Pred. No. 2.3e-14;
Matches 71;  Conservative 61;  Mismatches 117;  Indels 45;  Gaps 10;

```

```

Qy      42 PAASRSMFVALLGLGLGQVCSVALFFYFRAQMD--PNRISEDGTHCIYRILRLHENADF 99
      |:  ::  :  ::  |  |  :|  :  ||  ::  :  :  |:  |  |  |  |  |  |  |
Db      10 PSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMMDKYSKSGIACF-----LKED--- 61

Qy     100 QDTTLESQDTKLIPDSCRRIKQAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDLAKRSK 159
      |:  :  |  :  :  |  ::|  :  :  :|  :  :  :  |  :  :  :  :  :  :  :
Db      62 -DSYWDPNDEESMNSPCWQVKW-----QLRQLVRKMILRTSEETI-----STVQEKQ 107

Qy     160 LEAQPF-----AHLT-----INATDIPSGSHKVSL----SSWYHDR-GWAKISNM 199
      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Db     108 QNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNL 167

Qy     200 TFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEY LQLMVYVTKTSIKIPSSHTLMKGG 259
      ||:|:|:|:|  |||:|:|  ||  |  :  |  :  :|  |  :  |  :  |  |  |||
Db     168 HLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYT-SYPDPILLMKSA 226

Qy     260 STKYWSGNSEFHFYSINVG GFFKLRSGEEISIEVSNPSLLDPDQDATYFGAFKV 313
      ||  ::|:|  |||  ||  |:|:  :  |  :  |:|  |:|  |  |:|:|  |||  |
Db     227 RNSCWSKDAEYGLYSIQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLV 280

```

RESULT 5

TN10_MOUSE

```

ID    TN10_MOUSE      STANDARD;      PRT;      291 AA.
AC    P50592;
DT    01-OCT-1996 (Rel. 34, Created)
DT    01-OCT-1996 (Rel. 34, Last sequence update)
DT    28-FEB-2003 (Rel. 41, Last annotation update)
DE    Tumor necrosis factor ligand superfamily member 10 (TNF-related
DE    apoptosis inducing ligand) (TRAIL protein).
GN    TNFSF10 OR TRAIL.
OS    Mus musculus (Mouse).
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

```

```

OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=96111955; PubMed=8777713;
RA   Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.-P.,
RA   Nicholl J.K., Sutherland G.R., Davis-Smith T., Rauch C., Smith C.A.,
RA   Goodwin R.G.;
RT   "Identification and characterization of a new member of the TNF
RT   family that induces apoptosis.";
RL   Immunity 3:673-682(1995).
CC   -!- FUNCTION: Cytokine that binds to TNFRSF10A/TRAILR1,
CC       TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and
CC       possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity
CC       may be modulated by binding to the decoy receptors
CC       TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot
CC       induce apoptosis.
CC   -!- SUBUNIT: Homotrimer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Type II membrane protein (Potential).
CC   -!- TISSUE SPECIFICITY: WIDESPREAD.
CC   -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC   -----
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   -----
DR   EMBL; U37522; AAC52345.1; -.
DR   HSSP; P50591; 1D0G.
DR   MGD; MGI:107414; Tnfsf10.
DR   InterPro; IPR006052; TNF_family.
DR   InterPro; IPR008983; TNF_like.
DR   InterPro; IPR003636; TNF_subf.
DR   Pfam; PF00229; TNF; 1.
DR   ProDom; PD002012; TNF_subf; 1.
DR   SMART; SM00207; TNF; 1.
DR   PROSITE; PS00251; TNF_1; 1.
DR   PROSITE; PS50049; TNF_2; 1.
KW   Cytokine; Transmembrane; Signal-anchor; Apoptosis.
FT   DOMAIN            1      17      CYTOPLASMIC (POTENTIAL).
FT   TRANSMEM          18      38      SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT                                     (POTENTIAL).
FT   DOMAIN            39     291     EXTRACELLULAR (POTENTIAL).
FT   CARBOHYD           52      52      N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ   SEQUENCE          291 AA;  33477 MW;  3FEACAB9F0D7D802 CRC64;

Query Match              14.7%;  Score 248;  DB 1;  Length 291;
Best Local Similarity    25.4%;  Pred. No. 4.9e-14;
Matches    79;  Conservative    52;  Mismatches 100;  Indels    80;  Gaps    13;

Qy      46 RSMFVALLGLG-LGQVVCSVALFFYFRAQMD--PNRISEDGTHCIYRILRLHENADFQDT 102
        | | : :: | | | : || :| : | : | | : : || |:
Db      17 RMMVICIVLLQVLLQAVSVAVTYMYFTNEMKQLQDNYSKIGLACFSK-----TDEDFWDS 71

Qy      103 TLESQDTKLIPDSCRRIK-----QAQF-----GAVOKEL 131

```

```

      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
Db      72 T----DGEILNRPC LQVKRQLYQLIEEVTLR T FQDTISTVPEKQLSTPPLPRGGRPQKVA 127
Qy      132 QHIVGSQH IRAEKAMVDG SWLDLAKRSKLEA QPFAHLTINATDIPSGSHKVSLS SWYHDR 191
      || |   | : | : :   : | | |   |
Db      128 AHITGITR-RSNSALI-----PISKDGKTLGQ-----KIESWESSR 162
Qy      192 -GWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYL-----QLMVYV 242
      | : : : : | || : : : | : | || : : | | |   | : : : | | : |
Db      163 KGHSFLNHVLF R NGELVIEQEGLYIYSQTYFRFQEAED--ASKMVSKDKV R TKQLVQYI 220
Qy      243 TKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVG GFFKLRS GEEISIEVSNPSLLDPD 302
      | : |   | || |   || : : | || | | : | : | : | | |
Db      221 YKYT-SYPDP I VLMKSARNSCWSRDAEYGLYSIQGGLFELKKNDRI FVSVTNEHIMDL D 279
Qy      303 QDATYFGAFKV 313
      | : | : | | | :
Db      280 QEASFFGAFLI 290

```

RESULT 6

TNF6_PIG

```

ID      TNF6_PIG          STANDARD;          PRT;    282 AA.
AC      Q9BEA8; Q95M04; Q95N10;
DT      28-FEB-2003 (Rel. 41, Created)
DT      28-FEB-2003 (Rel. 41, Last sequence update)
DT      10-OCT-2003 (Rel. 42, Last annotation update)
DE      Tumor necrosis factor ligand superfamily member 6 (FAS antigen
DE      ligand).
GN      TNFSF6 OR FASL.
OS      Sus scrofa (Pig).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OX      NCBI_TaxID=9823;
RN      [1]
RP      SEQUENCE FROM N.A.
RX      MEDLINE=21322533; PubMed=11429161;
RA      Muneta Y., Shimoji Y., Inumaru S., Mori Y.;
RT      "Molecular cloning, characterization, and expression of porcine Fas
RT      ligand (CD95 ligand).";
RL      J. Interferon Cytokine Res. 21:305-312(2001).
RN      [2]
RP      SEQUENCE FROM N.A.
RC      STRAIN=Guanxi bama miniature pig;
RA      Zhu N., Young Y.;
RT      "Molecular cloning and characterization of porcine Fas ligand cDNA.";
RL      Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN      [3]
RP      SEQUENCE FROM N.A.
RC      TISSUE=Lymphoid;
RA      Tsuyuki S., Kono M., Bloom E.T.;
RT      "Cloning and potential utility of porcine Fas ligand: overexpression
RT      in porcine cells protects them from attack by human cytolytic cells.";
RL      Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN      [4]
RP      SEQUENCE FROM N.A.
RC      STRAIN=Landrace x Large Yorkshire white; TISSUE=Thymocytes;

```

RX MEDLINE=21653191; PubMed=11792426;
 RA Motegi-Ishiyama Y., Nakajima Y., Hoka S., Takagaki Y.;
 RT "Porcine Fas-ligand gene: genomic sequence analysis and comparison
 RT with human gene.";
 RL Mol. Immunol. 38:581-586(2002).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that
 CC transduces the apoptotic signal into cells. May be involved in
 CC cytotoxic T cell mediated apoptosis and in T cell development.
 CC TNFRSF6/FAS-mediated apoptosis may have a role in the induction of
 CC peripheral tolerance, in the antigen-stimulated suicide of mature
 CC T cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3
 CC modulates its effects (By similarity).
 CC -!- SUBUNIT: Homotrimer (Probable).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein and secreted (By
 CC similarity).
 CC -!- INDUCTION: By IL-18.
 CC -!- PTM: The soluble form derives from the membrane form by
 CC proteolytic processing (By similarity).
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AB027297; BAB40919.1; -.
 DR EMBL; AY033634; AAK56449.1; -.
 DR EMBL; AF397407; AAK84408.1; -.
 DR EMBL; AB069764; BAB64291.1; -.
 DR HSSP; P01375; 4TSV.
 DR InterPro; IPR008064; Fas_ligand.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01681; FASLIGAND.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor.
 FT CHAIN 1 282 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, MEMBRANE FORM.
 FT CHAIN 131 282 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, SOLUBLE FORM (BY SIMILARITY).
 FT DOMAIN 1 82 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 83 103 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 104 282 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 4 70 PRO-RICH.
 FT DOMAIN 45 56 POLY-PRO.
 FT SITE 130 131 CLEAVAGE (BY SIMILARITY).

FT DISULFID 203 234 POTENTIAL.
 FT CARBOHYD 185 185 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 251 251 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 261 261 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CONFLICT 5 5 F -> L (IN REF. 4).
 FT CONFLICT 57 57 T -> P (IN REF. 2).
 SQ SEQUENCE 282 AA; 31756 MW; 6743DAA1145671FB CRC64;

Query Match 11.9%; Score 200; DB 1; Length 282;
 Best Local Similarity 23.0%; Pred. No. 6.5e-10;
 Matches 76; Conservative 42; Mismatches 90; Indels 122; Gaps 14;

QY 22 PGAPHEGPLHAPPPAPHPQPPAA---SRSM-----FVA 51
 || | | ||| | || :
 Db 37 PGRP--GQRRPPPPPPPPPPPTLLPSRPLPPLPPPSLKKKRDHNAGLCLLVMMFFMVLVA 94
 QY 52 LLGLGLGQVVCVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKL 111
 |:|||| :| | : : | |:| : |
 Db 95 LVGLGLG-----MFQLFHLQKE-----LTELRESASQRHT----- 124
 QY 112 IPDSCRRIKQAFQGAQVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLT-- 169
 : | : :| :: :|| | : ||||
 Db 125 -----ESSLEKQIGHPNLPSEKK-----ELRKVAHLTGK 153
 QY 170 INATDIPSGSHKVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSG 229
 |: || | | :| : : | |::| | |::: : || :
 Db 154 PNSRSIP-----LEWEDTYGIALVSGVKYMKGSLVINDTGLYFVYSKVYFRGQYCN- 204
 QY 230 DLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKY-----WSGNSEFHFYSINVGGFFKL 283
 : | || |: | : | ||:| | : :| : | |
 Db 205 ---NQPLSHKVY-TRNS-RYPQDLVLMEGKMMNYCTTGQMWARSS-----YLGAVFNL 252
 QY 284 RSGEEISIEVSNPSLLDPDQDATYFGAFKV 313
 | : : : || ||:: : : |:|| : :
 Db 253 TSADHLYVNVSELSLVNFEESKTFFGLYKL 282

RESULT 7

TNF6_HUMAN

ID TNF6_HUMAN STANDARD; PRT; 281 AA.
 AC P48023; Q9BZP9;
 DT 01-FEB-1996 (Rel. 33, Created)
 DT 01-FEB-1996 (Rel. 33, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Tumor necrosis factor ligand superfamily member 6 (FAS antigen ligand)
 DE (Apoptosis antigen ligand) (APTL) (CD178 antigen).
 GN TNFSF6 OR FASL OR APT1LG1.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RX MEDLINE=95105731; PubMed=7528780;
 RA Alderson M.;
 RT "Fas ligand mediates activation-induced cell death in human T
 RT lymphocytes.";

RL J. Exp. Med. 181:71-77(1995).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RX MEDLINE=95127560; PubMed=7826947;
 RA Takahashi T., Tanaka M., Inazawa J., Abe T., Suda T., Nagata S.;
 RT "Human Fas ligand: gene structure, chromosomal location and species
 RT specificity.";
 RL Int. Immunol. 6:1567-1574(1994).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RA Schaetzlein C.E., Poehlmann R., Philippson P., Eibel H.;
 RL Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RX MEDLINE=95071350; PubMed=7980502;
 RA Mita E., Hayashi N., Iio S., Takehara T., Hijioka T., Kasahara A.,
 RA Fusamoto H., Kamada T.;
 RT "Role of Fas ligand in apoptosis induced by hepatitis C virus
 RT infection.";
 RL Biochem. Biophys. Res. Commun. 204:468-474(1994).
 RN [5]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Leukocyte;
 RA Zeytun A., Nagarkatti M., Nagarkatti P.S.;
 RT "Isolation and characterization of a new naturally occurring variant of
 RT human Fas ligand that is expressed only in membrane bound form.";
 RL Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
 RN [6]
 RP SEQUENCE FROM N.A.
 RA Wilkinson J.;
 RL Submitted (MAY-1997) to the EMBL/GenBank/DDBJ databases.
 RN [7]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Blood;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [8]
 RP SEQUENCE OF 1-10 FROM N.A.

RC TISSUE=Blood;
 RA Matsumura M., Nakanishi Y., Ohba Y.;
 RL Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
 RN [9]
 RP CHARACTERIZATION, AND MUTAGENESIS OF PRO-206; TYR-218 AND PHE-275.
 RX MEDLINE=97373583; PubMed=9228058;
 RA Schneider P., Bodmer J.-L., Holler N., Mattmann C., Scuderi P.,
 RA Terskikh A., Peitsch M.C., Tschopp J.;
 RT "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.";
 RL J. Biol. Chem. 272:18827-18833(1997).
 RN [10]
 RP PROCESSING.
 RX MEDLINE=98087475; PubMed=9427603;
 RA Tanaka M., Itai T., Adachi M., Nagata S.;
 RT "Downregulation of Fas ligand by shedding.";
 RL Nat. Med. 4:31-36(1998).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that
 CC transduces the apoptotic signal into cells. May be involved in
 CC cytotoxic T cell mediated apoptosis and in T cell development.
 CC TNFRSF6/FAS-mediated apoptosis may have a role in the induction of
 CC peripheral tolerance, in the antigen-stimulated suicide of mature
 CC T cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3
 CC modulates its effects.
 CC -!- SUBUNIT: Homotrimer (Probable).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein. May be released
 CC into the extracellular fluid, probably by cleavage from the cell
 CC surface.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=P48023-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=P48023-2; Sequence=VSP_006443, VSP_006444;
 CC -!- PTM: N-glycosylated.
 CC -!- PTM: The soluble form derives from the membrane form by
 CC proteolytic processing.
 CC -!- DISEASE: Defects in TNFSF6 are a cause of autoimmune
 CC lymphoproliferative syndrome (ALPS) [MIM:601859]; also known as
 CC Canale-Smith syndrome (CSS). ALPS is a childhood syndrome
 CC involving hemolytic anemia and thrombocytopenia with massive
 CC lymphadenopathy and splenomegaly.
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -!- DATABASE: NAME=PROW; NOTE=PROW 2:59-69(2001);
 CC WWW="http://www.ncbi.nlm.nih.gov/prow/guide/333879674_g.htm".
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X89102; CAA61474.1; -.
 DR EMBL; U08137; AAC50071.1; -.
 DR EMBL; U11821; AAC50124.1; -.
 DR EMBL; D38122; BAA07320.1; -.

DR EMBL; AF288573; AAG60017.1; -.
 DR EMBL; Z96050; CAB09424.1; -.
 DR EMBL; BC017502; AAH17502.1; -.
 DR EMBL; AB013303; BAA32542.1; -.
 DR PIR; I38707; I38707.
 DR HSSP; P01375; 1TNF.
 DR Genew; HGNC:11936; TNFSF6.
 DR MIM; 134638; -.
 DR MIM; 601859; -.
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0005102; F:receptor binding; TAS.
 DR GO; GO:0007267; P:cell-cell signaling; TAS.
 DR GO; GO:0006917; P:induction of apoptosis; TAS.
 DR GO; GO:0007165; P:signal transduction; TAS.
 DR InterPro; IPR008064; Fas_ligand.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01681; FASLIGAND.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor;
 KW Alternative splicing; Antigen.
 FT CHAIN 1 281 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, MEMBRANE FORM.
 FT CHAIN 130 281 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, SOLUBLE FORM.
 FT DOMAIN 1 80 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 81 102 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 103 281 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 4 70 PRO-RICH.
 FT DOMAIN 45 65 POLY-PRO.
 FT SITE 129 130 CLEAVAGE.
 FT DISULFID 202 233 POTENTIAL.
 FT CARBOHYD 184 184 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 250 250 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 260 260 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT VARSPLIC 117 127 STSQMHTASSL -> ATPVHPLKKRS (in isoform
 FT 2).
 FT /FTId=VSP_006443.
 FT VARSPLIC 128 281 Missing (in isoform 2).
 FT /FTId=VSP_006444.
 FT MUTAGEN 206 206 P->D,F,R: LOWERS BINDING TO TNFRSF6 AND
 FT REDUCES CYTOTOXICITY MORE THAN 100-FOLD.
 FT MUTAGEN 218 218 Y->F,R: LOWERS BINDING TO TNFRSF6 AND
 FT ABOLISHES CYTOTOXICITY.
 FT MUTAGEN 275 275 F->L: ABOLISHES BINDING TO TNFRSF6 AND
 FT CYTOTOXICITY.
 SQ SEQUENCE 281 AA; 31485 MW; A8A6EB358246E9BB CRC64;

Query Match 11.2%; Score 189; DB 1; Length 281;

Best Local Similarity 21.7%; Pred. No. 5.8e-09;
Matches 69; Conservative 43; Mismatches 98; Indels 108; Gaps 11;

```

QY      22 PGAPHEGPLHAPPPAP----HQPPAASRS-----MFVALLGLGLGQVVCS 63
      | |  ||  ||| |  ||  |  : |||:||||
Db      46 PPPPPPPPLPPPPPPPLPPLPLPPLKKRGNHSTGLCLLMFFMVLVALVGLGLG----- 100

QY      64 VALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAF 123
      :| | |  | | :| :| :
Db     101 --MFQLFHLQ-----KELAELESTSQMHTA----- 124

QY     124 QGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLT--INATDIPSGSHK 181
      ::|:: |  | | : ||| | : :|
Db     125 -SSLEKQIGH-----PSPPEKKELRKVAHLTGKSNSRSMP----- 159

QY     182 VSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLIMVY 241
      |  |  :| : : | |::| : |::| : : ||  :  | |
Db     160 ---LEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNN-----LPLSHK 210

QY     242 VTKTSIKIPSSHTLMKGGSTKY-----WSGNSEFHFYSINVGFFKLRSGEEISIEVSN 295
      |  : | |  :|:|  |  | : :|  :| | | : : : ||
Db     211 VYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSS-----YLGAVENLTSADHLYVNVSE 263

QY     296 PSLLDPDQDATYFGAFKV 313
      ||:: :: |::| :|:
Db     264 LSLVNFEESQTFFGLYKL 281

```

RESULT 8

TNF6_MACMU

```

ID   TNF6_MACMU          STANDARD;          PRT;   280 AA.
AC   Q9MYL6; Q9BDM5;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   28-FEB-2003 (Rel. 41, Last annotation update)
DE   Tumor necrosis factor ligand superfamily member 6 (FAS antigen ligand)
DE   (CD95L protein).
GN   TNFSF6 OR FASL OR CD95L.
OS   Macaca mulatta (Rhesus macaque),
OS   Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey), and
OS   Macaca nemestrina (Pig-tailed macaque).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC   Cercopithecinae; Macaca.
OX   NCBI_TaxID=9544, 9541, 9545;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   SPECIES=M.mulatta; TISSUE=Lymphocytes;
RX   MEDLINE=21383618; PubMed=11491535;
RA   Villinger F., Bostik P., Mayne A.E., King C.L., Genain C.P.,
RA   Weiss W.R., Ansari A.A.;
RT   "Cloning, sequencing, and homology analysis of nonhuman primate
RT   Fas/Fas-ligand and co-stimulatory molecules.";
RL   Immunogenetics 53:315-328(2001).
RN   [2]
RP   SEQUENCE FROM N.A.
RC   SPECIES=M.mulatta, M.fascicularis, and M.nemestrina;

```

RA Kirii Y., Inoue T., Yoshino K.;
 RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
 CC -!- FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that
 CC transduces the apoptotic signal into cells. May be involved in
 CC cytotoxic T cell mediated apoptosis and in T cell development.
 CC TNFRSF6/FAS-mediated apoptosis may have a role in the induction of
 CC peripheral tolerance, in the antigen-stimulated suicide of mature
 CC T cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3
 CC modulates its effects (By similarity).
 CC -!- SUBUNIT: Homotrimer (Potential).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein and secreted (By
 CC similarity).
 CC -!- PTM: The soluble form derives from the membrane form by
 CC proteolytic processing (By similarity).
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF344856; AAK37539.1; -.
 DR EMBL; AB035138; BAA90294.1; -.
 DR EMBL; AB035139; BAA90295.1; -.
 DR EMBL; AB035140; BAA90296.1; -.
 DR HSSP; P01375; 4TSV.
 DR InterPro; IPR008064; Fas_ligand.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01681; FASLIGAND.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor.
 FT CHAIN 1 280 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, MEMBRANE FORM.
 FT CHAIN 129 280 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, SOLUBLE FORM (BY SIMILARITY).
 FT DOMAIN 1 80 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 81 101 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 102 280 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 4 69 PRO-RICH.
 FT DOMAIN 45 64 POLY-PRO.
 FT SITE 128 129 CLEAVAGE (BY SIMILARITY).
 FT DISULFID 201 232 POTENTIAL.
 FT CARBOHYD 183 183 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 249 249 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 259 259 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CONFLICT 60 60 S -> P (IN REF. 1).
SQ SEQUENCE 280 AA; 31367 MW; F0B284D61A132EB4 CRC64;

Query Match 11.0%; Score 186; DB 1; Length 280;
Best Local Similarity 22.1%; Pred. No. 1e-08;
Matches 69; Conservative 44; Mismatches 103; Indels 96; Gaps 11;

```
Qy      22 PGAPHEGPHLHAPPPAP----HQPPAASRS-----MFVALLGLGLGQVVCS 63
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      45 P P P P P P P P L P P P P P S P L P P L P L P P L K K R G N H S T G L C L L V M F F M V L V A L V G L G L G ---- 99

Qy      64 VALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAF 123
      : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db     100 --MFQLFHLQ-----KELAE LRESTSQKHTA----- 123

Qy     124 QGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLT--INATDIPSGSHK 181
      : : | : | | | | | | | | | | | | | | | | | | | | | |
Db     124 -SSLEKQIGH-----PSPPEKKEQRKVAHLTGKPNRSRSM----- 158

Qy     182 VSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMVY 241
      | | | | | : | : : | | : : | | : : | | : : | | | | | |
Db     159 ---LEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFR-----GQSCTN-LPLSHK 209

Qy     242 VTKTSIKIPSSHTLMKGGSTKYWSCNSEFHFYSINVGGFFKLRSGEIEISIEVSNPSLLDP 301
      | : | | : | : | | : : : | : | | | : : : | | | : |
Db     210 VYMRNSKYPQDLVMMEGKMMSYCT-TGQMWAHSSYLGAVFNLTADHLYVNVSELSLVNF 268

Qy     302 DQDATYFGAFKV 313
      : : | : | | : | :
Db     269 EESQTFFGLYKL 280
```

RESULT 9

TNF6_MOUSE

ID TNF6_MOUSE STANDARD; PRT; 279 AA.
AC P41047; Q61217; Q9R1F2;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 6 (FAS antigen
DE ligand).
GN TNFSF6 OR FASL OR APT1LG1 OR GLD.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM FASL).
RX MEDLINE=94185175; PubMed=7511063;
RA Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G.,
RA Suda T., Nagata S.;
RT "Generalized lymphoproliferative disease in mice, caused by a point
RT mutation in the Fas ligand."
RL Cell 76:969-976(1994).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM FASL), AND 3D-STRUCTURE MODELING.
RC STRAIN=C57BL/6;

RX MEDLINE=95388076; PubMed=7544870;
 RA Peitsch M.J., Tschopp J.J.;
 RT "Comparative molecular modelling of the Fas-ligand and other members
 RT of the TNF family.";
 RL Mol. Immunol. 32:761-772(1995).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM FASL).
 RX MEDLINE=95196085; PubMed=7889405;
 RA Lynch D.H., Watson M.L., Alderson M.R., Baum P.R., Miller R.E.,
 RA Tough T., Gibson M., Davis-Smith T., Smith C.A., Hunter K.;
 RT "The mouse Fas-ligand gene is mutated in gld mice and is part of a
 RT TNF family gene cluster.";
 RL Immunity 1:131-136(1994).
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM FASL).
 RC STRAIN=BALB/c;
 RA Fenner M.H., Shioda T., Isselbacher K.J.;
 RT "Mus musculus Balb/c Fas ligand differs from 129/SV Fas ligand in
 RT two amino acids.";
 RL Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
 RN [5]
 RP SEQUENCE FROM N.A. (ISOFORM FASLS).
 RC STRAIN=C3H; TISSUE=Spleen;
 RX MEDLINE=20021694; PubMed=10552956;
 RA Ayroldi E., D'Adamio F., Zollo O., Agostini M., Moraca R.,
 RA Cannarile L., Migliorati G., Delfino D.V., Riccardi C.;
 RT "Cloning and expression of a short Fas ligand: A new alternatively
 RT spliced product of the mouse Fas ligand gene.";
 RL Blood 94:3456-3467(1999).
 RN [6]
 RP CHARACTERIZATION OF VARIANT GLD.
 RX MEDLINE=96091792; PubMed=7495745;
 RA Hahne M., Peitsch M.C., Irmeler M., Schroeter M., Lowin B.,
 RA Rousseau M., Bron C., Renno T., French L., Tschopp J.;
 RT "Characterization of the non-functional Fas ligand of gld mice.";
 RL Int. Immunol. 7:1381-1386(1995).
 RN [7]
 RP VARIANTS ALA-184 AND GLY-218.
 RC STRAIN=C57BL/6, C3H, MRL, SJL, NOD, NZB, NZW, BALB/c, DBA/1, and
 RC DBA/2;
 RX MEDLINE=97268671; PubMed=9108079;
 RA Kayagaki N., Yamaguchi N., Nagao F., Matsuo S., Maeda H., Okumura K.,
 RA Yagita H.;
 RT "Polymorphism of murine Fas ligand that affects the biological
 RT activity.";
 RL Proc. Natl. Acad. Sci. U.S.A. 94:3914-3919(1997).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that
 CC transduces the apoptotic signal into cells. May be involved in
 CC cytotoxic T cell mediated apoptosis and in T cell development.
 CC TNFRSF6/FAS-mediated apoptosis may have a role in the induction of
 CC peripheral tolerance, in the antigen-stimulated suicide of mature
 CC T cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3
 CC modulates its effects (By similarity).
 CC -!- SUBUNIT: Homotrimer (Probable).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein (isoform FASL);
 CC Secreted (isoforms FASL and FASLS).
 CC -!- ALTERNATIVE PRODUCTS:

```

CC      Event=Alternative splicing; Named isoforms=2;
CC      Name=FasL;
CC      IsoId=P41047-1; Sequence=Displayed;
CC      Name=FasLS;
CC      IsoId=P41047-2; Sequence=VSP_006445;
CC      -!- PTM: The soluble form derives from the membrane form by
CC      proteolytic processing (By similarity).
CC      -!- DISEASE: A deficiency in this protein is the cause of generalized
CC      lymphoproliferation disease phenotype (gld). Gld mice present
CC      lymphadenopathy and autoantibody production. The phenotype is
CC      recessively inherited.
CC      -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
DR      EMBL; U06948; AAA17800.1; -.
DR      EMBL; U10984; AAA19778.1; -.
DR      EMBL; S76752; AAB33780.1; -.
DR      EMBL; U58995; AAB02915.1; -.
DR      EMBL; AF119335; AAD52106.1; -.
DR      PIR; A53062; A53062.
DR      HSSP; P01375; 4TSV.
DR      MGD; MGI:99255; Tnfsf6.
DR      InterPro; IPR008064; Fas_ligand.
DR      InterPro; IPR006053; TNF_abc.
DR      InterPro; IPR006052; TNF_family.
DR      InterPro; IPR008983; TNF_like.
DR      InterPro; IPR003636; TNF_subf.
DR      Pfam; PF00229; TNF; 1.
DR      PRINTS; PR01681; FASLIGAND.
DR      PRINTS; PR01234; TNECROSISFCT.
DR      ProDom; PD002012; TNF_subf; 1.
DR      SMART; SM00207; TNF; 1.
DR      PROSITE; PS00251; TNF_1; 1.
DR      PROSITE; PS50049; TNF_2; 1.
KW      Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor;
KW      Disease mutation; Polymorphism; Alternative splicing.
FT      CHAIN          1      279      TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT                                     MEMBER 6, MEMBRANE FORM.
FT      CHAIN          128     279      TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT                                     MEMBER 6, SOLUBLE FORM (BY SIMILARITY).
FT      DOMAIN          1       78      CYTOPLASMIC (POTENTIAL).
FT      TRANSMEM        79     100      SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT                                     (POTENTIAL).
FT      DOMAIN          101     279      EXTRACELLULAR (POTENTIAL).
FT      DOMAIN           4       69      PRO-RICH.
FT      DOMAIN          45       51      POLY-PRO.
FT      SITE            127     128      CLEAVAGE (BY SIMILARITY).
FT      DISULFID        200     231      POTENTIAL.
FT      CARBOHYD        117     117      N-LINKED (GLCNAC. . .) (POTENTIAL).
FT      CARBOHYD        182     182      N-LINKED (GLCNAC. . .) (POTENTIAL).

```

FT CARBOHYD 248 248 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 258 258 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT VARSPLIC 1 210 Missing (in isoform FasLS).
 FT /FTId=VSP_006445.
 FT VARIANT 184 184 T -> A (IN STRAINS BALB/C AND DBA;
 FT ENHANCES CYTOTOXICITY).
 FT VARIANT 218 218 E -> G (IN STRAINS BALB/C AND DBA;
 FT ENHANCES CYTOTOXICITY).
 FT VARIANT 273 273 F -> L (IN GLD; ABOLISHES BINDING OF FASL
 FT TO ITS RECEPTOR).
 SQ SEQUENCE 279 AA; 31442 MW; 37972E2728E0A1CA CRC64;

Query Match 10.9%; Score 184.5; DB 1; Length 279;
 Best Local Similarity 21.7%; Pred. No. 1.4e-08;
 Matches 70; Conservative 45; Mismatches 106; Indels 101; Gaps 11;

Qy 13 RGSEEMGGGPGAPHEGPLHAPPPAPHPQ-----PAASRSMFVALLGLGL 57
 || :: | | | | | | | | : |||:|:|
 Db 38 RGPDQRRPPPPPPVSPPLPPSQPLPLPLPLTPLKKKDHNTNLWLPVVFVFMVLVALVGMGL 97

 Qy 58 GQVVCVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDQTLESQDTKLIPDSCR 117
 | :|:: |
 Db 98 G-----MYQLFHL----- 105

 Qy 118 RIKQAFQGA VQKELQHI--VGSQHRA---EKAMVDGSWLDLAKRSKLEAQPFAHLTINA 172
 ||| : :|:: || : : | | : ||| |
 Db 106 -----QKELAE LREFTNQSLKVSSF EKQIANPS----TPSEKKEPRSV AHLTGN- 150

 Qy 173 TDIPSGSHKVSLS-SWYHDRGWAKISNMFTSNGKLIVNQDGFYYLYANICFRHHETSGDL 231
 | |: | | || : : | :|:| :| :|:| :| :| :
 Db 151 -----PHSRSI PLEWEDTYGTALISGVKYKKGGLVINETGLYFVYSKVYFRGQSCN--- 201

 Qy 232 ATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGFFKLRSGEEISI 291
 : | ||: : | | ||: | : : :| :| | | : : :
 Db 202 -NQPLNHKVYMRNS--KYPEDLVLME EKRLNYCT-TGQIWAHSSYLGA VFNLT SADHLYV 257

 Qy 292 EVSNPSLLDPDQDATYFGAFKV 313
 :| ||:: : :|:| :|:
 Db 258 NISQLSLINFEEKSTFFGLYKL 279

RESULT 10

TNF6_CERTO

ID TNF6_CERTO STANDARD; PRT; 280 AA.
 AC Q9BDN1;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Tumor necrosis factor ligand superfamily member 6 (FAS antigen ligand)
 DE (CD95L protein).
 GN TNFSF6 OR FASL OR CD95L.
 OS Cercopithecus torquatus atys (Red-crowned mangabey) (Sooty mangabey).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
 OC Cercopithecinae; Cercopithecus.
 OX NCBI_TaxID=9531;
 RN [1]

RP SEQUENCE FROM N.A.
 RC TISSUE=Lymphocytes;
 RX MEDLINE=21383618; PubMed=11491535;
 RA Villinger F., Bostik P., Mayne A.E., King C.L., Genain C.P.,
 RA Weiss W.R., Ansari A.A.;
 RT "Cloning, sequencing, and homology analysis of nonhuman primate
 RT Fas/Fas-ligand and co-stimulatory molecules.";
 RL Immunogenetics 53:315-328(2001).
 CC -!- FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that
 CC transduces the apoptotic signal into cells. May be involved in
 CC cytotoxic T cell mediated apoptosis and in T cell development.
 CC TNFRSF6/FAS-mediated apoptosis may have a role in the induction of
 CC peripheral tolerance, in the antigen-stimulated suicide of mature
 CC T cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3
 CC modulates its effects (By similarity).
 CC -!- SUBUNIT: Homotrimer (Probable).
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein and secreted (By
 CC similarity).
 CC -!- PTM: The soluble form derives from the membrane form by
 CC proteolytic processing (By similarity).
 CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF344847; AAK37606.1; -.
 DR HSSP; P01375; 4TSV.
 DR InterPro; IPR008064; Fas_ligand.
 DR InterPro; IPR006053; TNF_abc.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.
 DR InterPro; IPR003636; TNF_subf.
 DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01681; FASLIGAND.
 DR PRINTS; PR01234; TNECROSISFCT.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor.
 FT CHAIN 1 280 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, MEMBRANE FORM.
 FT CHAIN 129 280 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 6, SOLUBLE FORM (BY SIMILARITY).
 FT DOMAIN 1 80 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 81 101 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 102 280 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 4 69 PRO-RICH.
 FT DOMAIN 45 64 POLY-PRO.
 FT SITE 128 129 CLEAVAGE (BY SIMILARITY).
 FT DISULFID 201 232 POTENTIAL.

FT CARBOHYD 183 183 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 249 249 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 259 259 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 280 AA; 31407 MW; 729EA60067B7D398 CRC64;

Query Match 10.8%; Score 182.5; DB 1; Length 280;
 Best Local Similarity 22.4%; Pred. No. 2.1e-08;
 Matches 70; Conservative 44; Mismatches 100; Indels 99; Gaps 12;

Qy 22 PGAPHEGPLHAPPPPAPHQPP-----AASRS-----MFVALLGLGLGQVVC 62
 | | | | | | | | : | : | | | | |
 Db 46 P P P P P P P L -- P P P P P P L P P L P L P P L K K R G N H S T G L C L L V M F F M V L V A L V G L G L G ---- 99
 Qy 63 SVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQA 122
 : | | | | : | | : : : | :
 Db 100 ---MFQLFHLQ-----KELAE LRESTSQKHTA----- 123
 Qy 123 FQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFHAHLT--INATDIPSGSH 180
 : : : | : : | : | : | | | | : : |
 Db 124 --SSLEKQIGH-----PSPPEKKEQRKVAHLTGKPNRSRSM----- 158
 Qy 181 KVSLSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYQLQMV 240
 | | : : : | : : : | : : : : | | | |
 Db 159 ----LEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFR-----GQSCTN-LPLSH 208
 Qy 241 YVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEIEISIEVSNPSLLD 300
 | : | | : | : | : : | : | : : | : : : | : : :
 Db 209 KVYMRNSKYPQDLVMMEGKMMSYCT-TGQMWAHSSYLGA VFNLTSTDHLYVNVSELSLVN 267
 Qy 301 PDQDATYFGAFKV 313
 : : | : | : :
 Db 268 FEESQTFFGLYKL 280

RESULT 11

TNF5_BOVIN

ID TNF5_BOVIN STANDARD; PRT; 261 AA.

AC P51749;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Tumor necrosis factor ligand superfamily member 5 (CD40 ligand) (TNF-related activation protein) (TRAP) (T cell antigen GP39).

GN TNFSF5 OR CD40LG OR CD40L.

OS Bos taurus (Bovine).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;

OC Bovidae; Bovinae; Bos.

OX NCBI_TaxID=9913;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Blood;

RX MEDLINE=96006582; PubMed=7590981;

RA Mertens B.E.L.C., Muriuki M., Gaidulis L.;

RT "Cloning of two members of the TNF-superfamily in cattle: CD40 ligand and tumor necrosis factor alpha.";

RL Immunogenetics 42:430-431(1995).

CC -!- FUNCTION: Cytokine that binds to TNFRSF5. Mediates B-cell
CC proliferation in the absence of co-stimulus as well as IgE
CC production in the presence of IL-4. Involved in immunoglobulin
CC class switching (By similarity).
CC -!- SUBUNIT: Homotrimer (By similarity).
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Also exists as an
CC extracellular soluble form (By similarity).
CC -!- PTM: The soluble form derives from the membrane form by
CC proteolytic processing (By similarity).
CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----

DR EMBL; Z48469; CAA88363.1; -.
DR PIR; S53090; S53090.
DR HSSP; P29965; 1ALY.
DR GO; GO:0016021; C:integral to membrane; ISS.
DR GO; GO:0005174; F:CD40 receptor binding; ISS.
DR GO; GO:0042100; P:B-cell proliferation; ISS.
DR GO; GO:0006954; P:inflammatory response; ISS.
DR GO; GO:0007159; P:leukocyte cell adhesion; ISS.
DR GO; GO:0030168; P:platelet activation; ISS.
DR InterPro; IPR003263; TNF_5.
DR InterPro; IPR006052; TNF_family.
DR InterPro; IPR008983; TNF_like.
DR InterPro; IPR003636; TNF_subf.
DR Pfam; PF00229; TNF; 1.
DR PRINTS; PR01702; CD40LIGAND.
DR ProDom; PD008600; TNF_5; 1.
DR ProDom; PD002012; TNF_subf; 1.
DR SMART; SM00207; TNF; 1.
DR PROSITE; PS00251; TNF_1; 1.
DR PROSITE; PS50049; TNF_2; 1.
KW Cytokine; Transmembrane; Glycoprotein; Signal-anchor.

FT	CHAIN	1	261	TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT				MEMBER 5, MEMBRANE FORM.
FT	CHAIN	113	261	TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT				MEMBER 5, SOLUBLE FORM (BY SIMILARITY).
FT	DOMAIN	1	22	CYTOPLASMIC (POTENTIAL).
FT	TRANSMEM	23	46	SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT				(POTENTIAL).
FT	DOMAIN	47	261	EXTRACELLULAR (POTENTIAL).
FT	SITE	112	113	CLEAVAGE (BY SIMILARITY).
FT	DISULFID	178	218	POTENTIAL.
FT	CARBOHYD	240	240	N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ	SEQUENCE	261 AA;	29242 MW;	8491FEFB30A787FD CRC64;

Query Match 10.5%; Score 176.5; DB 1; Length 261;
Best Local Similarity 24.2%; Pred. No. 6.3e-08;
Matches 70; Conservative 54; Mismatches 122; Indels 43; Gaps 13;

CC proteolytic processing (By similarity).
CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U03470; AAC52129.1; -.
DR PIR; A49266; A49266.
DR HSSP; P01375; 4TSV.
DR InterPro; IPR008064; Fas_ligand.
DR InterPro; IPR006053; TNF_abc.
DR InterPro; IPR006052; TNF_family.
DR InterPro; IPR008983; TNF_like.
DR InterPro; IPR003636; TNF_subf.
DR Pfam; PF00229; TNF; 1.
DR PRINTS; PR01681; FASLIGAND.
DR PRINTS; PR01234; TNECROSISFCT.
DR ProDom; PD002012; TNF_subf; 1.
DR SMART; SM00207; TNF; 1.
DR PROSITE; PS00251; TNF_1; 1.
DR PROSITE; PS50049; TNF_2; 1.
KW Cytokine; Apoptosis; Transmembrane; Glycoprotein; Signal-anchor.
FT CHAIN 1 278 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT MEMBER 6, MEMBRANE FORM.
FT CHAIN 127 278 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
FT MEMBER 6, SOLUBLE FORM (BY SIMILARITY).
FT DOMAIN 1 77 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 78 99 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT (POTENTIAL).
FT DOMAIN 100 278 EXTRACELLULAR (POTENTIAL).
FT DOMAIN 4 69 PRO-RICH.
FT DOMAIN 45 58 POLY-PRO.
FT SITE 126 127 CLEAVAGE (BY SIMILARITY).
FT DISULFID 199 230 POTENTIAL.
FT CARBOHYD 116 116 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 247 247 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 257 257 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 278 AA; 31140 MW; 2898E18A862CEAC6 CRC64;

Query Match 10.4%; Score 175.5; DB 1; Length 278;
Best Local Similarity 20.3%; Pred. No. 8.4e-08;
Matches 64; Conservative 47; Mismatches 106; Indels 99; Gaps 10;

Qy 21 GPGAPHEGPLHAPPPPHQPPAASRSM-----FVALLGLGL 57
 ||| | |||:| ||: : |||:|:|
Db 39 GPGQRRPPP--PPPPPSPLPPPSQPPPLPLPLSPLKKKDNIELWLPVIFFMVLVALVGMGL 96

Qy 58 GQVVC SVALFFYFRAQMDPNRI SEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCR 117
 | :: | | : : | | : | : : | |:: : :
Db 97 G-----MYQLFHLQKELAE LREFTNHSL-RVSSF EKQIANPSTPSETKKPRSV----- 143

Qy 118 RIKQAFQGA VQKELQHIVGSQH IRAEKAMVDG SWLDLAKRSKLEAQPF AHLTINATDIPS 177

```

                                     |||| |
Db      144 -----AHLTGNPR----- 151
Qy      178 GSHKVSLSWYHDRGWAKISNMFTSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQ 237
        | : | | | | | : : | | : | | : | : | | : : |
Db      152 -SRSIPL-EWEDTYGTALISGVKYKKGGLVINEAGLYFVYSKVYFRGQSCN----SQPLS 205
Qy      238 LMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEESIEVSNPS 297
        ||: : | | ||: | : : : | | | : : : | |
Db      206 HKVYM--RNFKYPGDLVLMEEKKLNICT-TGQIAHSSYLGAVERNLTVDHLYVNISQLS 262
Qy      298 LLDPDQDATYFGAFKV 313
        |:: :: |::| ::|
Db      263 LINFEESKTFFGLYKL 278

```

RESULT 13

TNF5_CALJA

```

ID      TNF5_CALJA      STANDARD;      PRT;      261 AA.
AC      Q9BDN3;
DT      28-FEB-2003 (Rel. 41, Created)
DT      28-FEB-2003 (Rel. 41, Last sequence update)
DT      28-FEB-2003 (Rel. 41, Last annotation update)
DE      Tumor necrosis factor ligand superfamily member 5 (CD40 ligand) (CD40-
DE      L) (CD154 protein).
GN      TNFSF5 OR CD40LG OR CD40L.
OS      Callithrix jacchus (Common marmoset).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae;
OC      Callithrix.
OX      NCBI_TaxID=9483;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      TISSUE=Lymphocytes;
RX      MEDLINE=21383618; PubMed=11491535;
RA      Villinger F., Bostik P., Mayne A.E., King C.L., Genain C.P.,
RA      Weiss W.R., Ansari A.A.;
RT      "Cloning, sequencing, and homology analysis of nonhuman primate
RT      Fas/Fas-ligand and co-stimulatory molecules.";
RL      Immunogenetics 53:315-328(2001).
CC      -!- FUNCTION: Cytokine that binds to TNFRSF5. Mediates B-cell
CC      proliferation in the absence of co-stimulus as well as IgE
CC      production in the presence of IL-4. Involved in immunoglobulin
CC      class switching (By similarity).
CC      -!- SUBUNIT: Homotrimer (By similarity).
CC      -!- SUBCELLULAR LOCATION: Type II membrane protein. Also exists as an
CC      extracellular soluble form (By similarity).
CC      -!- PTM: The soluble form derives from the membrane form by
CC      proteolytic processing (By similarity).
CC      -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

CC or send an email to license@isb-sib.ch).

Query Match 10.1%; Score 169.5; DB 1; Length 261;
Best Local Similarity 24.6%; Pred. No. 2.5e-07;
Matches 71; Conservative 55; Mismatches 120; Indels 43; Gaps 15;

RESULT 14

TNF5_AOTTR

ID TNF5_AOTTR STANDARD; PRT; 261 AA.
AC Q9BDM3;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Tumor necrosis factor ligand superfamily member 5 (CD40 ligand) (CD40-
DE L) (CD154 protein).
GN TNFSF5 OR CD40LG OR CD40L.
OS Aotus trivirgatus (Night monkey) (Douroucoulis).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Aotinae; Aotus.
OX NCBI_TaxID=9505;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymphocytes;
RX MEDLINE=21383618; PubMed=11491535;
RA Villinger F., Bostik P., Mayne A.E., King C.L., Genain C.P.,
RA Weiss W.R., Ansari A.A.;
RT "Cloning, sequencing, and homology analysis of nonhuman primate
RT Fas/Fas-ligand and co-stimulatory molecules.";
RL Immunogenetics 53:315-328(2001).
CC -!- FUNCTION: Cytokine that binds to TNFRSF5. Mediates B-cell
CC proliferation in the absence of co-stimulus as well as IgE
CC production in the presence of IL-4. Involved in immunoglobulin
CC class switching (By similarity).
CC -!- SUBUNIT: Homotrimer (By similarity).
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Also exists as an
CC extracellular soluble form (By similarity).
CC -!- PTM: The soluble form derives from the membrane form by
CC proteolytic processing (By similarity).
CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF344860; AAK37542.1; -.
DR HSSP; P29965; 1ALY.
DR GO; GO:0016021; C:integral to membrane; ISS.
DR GO; GO:0005174; F:CD40 receptor binding; ISS.
DR GO; GO:0042100; P:B-cell proliferation; ISS.
DR GO; GO:0006954; P:inflammatory response; ISS.
DR GO; GO:0007159; P:leukocyte cell adhesion; ISS.
DR GO; GO:0030168; P:platelet activation; ISS.
DR InterPro; IPR003263; TNF_5.
DR InterPro; IPR006052; TNF_family.
DR InterPro; IPR008983; TNF_like.
DR InterPro; IPR003636; TNF_subf.

DR Pfam; PF00229; TNF; 1.
 DR PRINTS; PR01702; CD40LIGAND.
 DR ProDom; PD008600; TNF_5; 1.
 DR ProDom; PD002012; TNF_subf; 1.
 DR SMART; SM00207; TNF; 1.
 DR PROSITE; PS00251; TNF_1; 1.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Cytokine; Transmembrane; Glycoprotein; Signal-anchor.
 FT CHAIN 1 261 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 5, MEMBRANE FORM.
 FT CHAIN 113 261 TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY
 FT MEMBER 5, SOLUBLE FORM (BY SIMILARITY).
 FT DOMAIN 1 22 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 23 43 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 44 261 EXTRACELLULAR (POTENTIAL).
 FT SITE 112 113 CLEAVAGE (BY SIMILARITY).
 FT DISULFID 178 218 POTENTIAL.
 FT CARBOHYD 240 240 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 261 AA; 29357 MW; 85E1588B507901B5 CRC64;

Query Match 9.9%; Score 167.5; DB 1; Length 261;
 Best Local Similarity 24.4%; Pred. No. 3.8e-07;
 Matches 71; Conservative 55; Mismatches 122; Indels 43; Gaps 15;

Qy 31 HAPPPPAPHQPPAASRSMFVALLGLGL-GQVVCVALFFYFRAQMDPNRISEDGTHCIYR 89
 | | | : | : | : | : | : | : | : | : | : | :
 Db 6 HQPAPRSAATGLPVSMKIFMYLLTVFLITQMIGSALFAVYLHRRLD--KIEDE----- 56
 Qy 90 ILRLHENADFQDT--TLESQDTKLIPDSCRRIKQAFQGAVQKELQHIVGSQHIRAEKAMV 147
 |||: | | : : | : | | | : | : | : | : | :
 Db 57 -RNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFV-KDIM-----LNKEEKKK 107
 Qy 148 DGSWLDLAKRSKLEAQPF AHLTINATDIPSGSHKVSLSWYHDRGWAKISN--MTFSNGK 205
 : | : : | : | | : | : | : | : | : | : | : | : | : | : | : | :
 Db 108 ENSF-EMQKGDQ-NPQIAAHVISEAS-----SKTTSVLQW-AEKGYYTMSNNLVTLENGK 159
 Qy 206 -LIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPS--SHTLMKGGSTK 262
 | | : | ||: || : | : : | : : | : | : | : | : | : | : | :
 Db 160 QLTVKRQGLYYIYAQVTFCSNREASSQAP-----FIASLCLKPPNRFERILLRAANTH 212
 Qy 263 YWSGNSEFHFYSINVGGFFKLRSGEESISIEVSNPSLLDPDQDATYFGAFKV 313
 | | : | | : | : | : | : | : | : | : | : | : | : | : | :
 Db 213 --SSAKPCGQQSIHLGGIFELQPGASVFVNVDPSQVSHGTGFTSFGLLKL 261

RESULT 15

TNF5_HUMAN

ID TNF5_HUMAN STANDARD; PRT; 261 AA.
 AC P29965;
 DT 01-APR-1993 (Rel. 25, Created)
 DT 01-APR-1993 (Rel. 25, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Tumor necrosis factor ligand superfamily member 5 (CD40 ligand) (CD40-
 DE L) (TNF-related activation protein) (TRAP) (T cell antigen Gp39)
 DE (CD154 antigen).
 GN TNFSF5 OR CD40LG OR CD40L OR TRAP.

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93076854; PubMed=1280226;
 RA Graf D., Korthaeuer U., Mages H.W., Senger G., KroczeK R.A.;
 RT "Cloning of TRAP, a ligand for CD40 on human T cells.";
 RL Eur. J. Immunol. 22:3191-3194(1992).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93049181; PubMed=1385114;
 RA Hollenbaugh D., Grosmaire L.S., Kullas C.D., Chalupny J.N.,
 RA Braesch-Andersen S., Noelle R.J., Stamenkovic I., Ledbetter J.A.,
 RA Aruffo A.;
 RT "The human T cell antigen gp39, a member of the TNF gene family, is a
 RT ligand for the CD40 receptor: expression of a soluble form of gp39
 RT with B cell co-stimulatory activity.";
 RL EMBO J. 11:4313-4321(1992).
 RN [3]
 RP SEQUENCE FROM N.A., AND VARIANTS HIGM1 128-ARG-GLY-129 AND PRO-235.
 RX MEDLINE=93145330; PubMed=7678782;
 RA Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A.,
 RA Nonoyama S., Bajorath J., Grosmaire L.S., Stenkamp R., Neubauer M.,
 RA Roberts R.L., Noelle R.J., Ledbetter J.A., Francke U., Ochs H.D.;
 RT "The CD40 ligand, gp39, is defective in activated T cells from
 RT patients with X-linked hyper-IgM syndrome.";
 RL Cell 72:291-300(1993).
 RN [4]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93094757; PubMed=1281209;
 RA Spriggs M.K., Armitage R.J., Strockbine L., Clifford K.N.,
 RA Macduff B.M., Sato T.A., Maliszewski C.R., Fanslow W.C.;
 RT "Recombinant human CD40 ligand stimulates B cell proliferation and
 RT immunoglobulin E secretion.";
 RL J. Exp. Med. 176:1543-1550(1992).
 RN [5]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93138085; PubMed=7678552;
 RA Gauchat J.F.M., Aubry J.-P., Mazzei G.J., Life P., Jomotte T.,
 RA Elson G., Bonnefoy J.Y.;
 RT "Human CD40-ligand: molecular cloning, cellular distribution and
 RT regulation of expression by factors controlling IgE production.";
 RL FEBS Lett. 315:259-266(1993).
 RN [6]
 RP SEQUENCE FROM N.A.
 RA Shimadzu M., Terasaki H., Ninomiya R., Shimizu S., Nunoi H.,
 RA Matsuda I.;
 RL Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
 RN [7]
 RP SEQUENCE OF 113-117, AND PROCESSING.
 RX MEDLINE=96198042; PubMed=8626375;
 RA Pietravalle F., Lecoanet-Henchoz S., Blasey H., Aubry J.-P., Elson G.,
 RA Edgerton M.D., Bonnefoy J.-Y., Gauchat J.-F.;
 RT "Human native soluble CD40L is a biologically active trimer, processed
 RT inside microsomes.";

RL J. Biol. Chem. 271:5965-5967(1996).
 RN [8]
 RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 116-261.
 RX MEDLINE=96131874; PubMed=8589998;
 RA Karpsusas M., Hsu Y.-M., Wang J.-H., Thompson J., Lederman S.,
 RA Chess L., Thomas D.;
 RT "2-A crystal structure of an extracellular fragment of human CD40
 RT ligand.";
 RL Structure 3:1031-1039(1995).
 RN [9]
 RP 3D-STRUCTURE MODELING OF COMPLEX WITH CD40.
 RX MEDLINE=98266353; PubMed=9605317;
 RA Singh J., Garber E., van Vlijmen H., Karpsusas M., Hsu Y.-M.,
 RA Zheng Z., Naismith J.H., Thomas D.;
 RT "The role of polar interactions in the molecular recognition of CD40L
 RT with its receptor CD40.";
 RL Protein Sci. 7:1124-1135(1998).
 RN [10]
 RP VARIANTS HIGM1 ARG-36 AND GLY-140.
 RX MEDLINE=93156839; PubMed=7679206;
 RA Korthaeuer U., Graf D., Mages H.W., Briere F., Padayachee M.,
 RA Malcolm S., Ugazio A.G., Notarangelo L.D., Levinsky R.J.,
 RA Kroczeck R.A.;
 RT "Defective expression of T-cell CD40 ligand causes X-linked
 RT immunodeficiency with hyper-IgM.";
 RL Nature 361:539-541(1993).
 RN [11]
 RP VARIANT HIGM1 GLU-123.
 RX MEDLINE=93156840; PubMed=8094231;
 RA Disanto J.P., Bonnefoy J.Y., Gauchat J.F.M., Fischer A.,
 RA de Saint Basile G.;
 RT "CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM.";
 RL Nature 361:541-543(1993).
 RN [12]
 RP VARIANTS HIGM1 PRO-155; ASP-211 AND VAL-227.
 RX MEDLINE=93174270; PubMed=7679801;
 RA Allen R.C., Armitage R.J., Conley M.E., Rosenblatt H., Jenkins N.A.,
 RA Copeland N.G., Bedell M.A., Edelhoff S., Distech C.M.,
 RA Simoneaux D.K., Fanslow W.C., Belmont J.W., Spriggs M.K.;
 RT "CD40 ligand gene defects responsible for X-linked hyper-IgM
 RT syndrome.";
 RL Science 259:990-993(1993).
 RN [13]
 RP VARIANTS HIGM1 ALA-126; ARG-140 AND GLU-144.
 RX MEDLINE=95233438; PubMed=7717401;
 RA Macchi P., Villa A., Strina D., Sacco M.G., Morali F., Brugnani D.,
 RA Giliani S., Mantuano E., Fasth A., Andersson B., Zegers B.J.M.,
 RA Cavagni G., Reznick I., Levy J., Zan-Bar I., Porat Y., Airo P.,
 RA Plebani A., Vezzoni P., Notarangelo L.D.;
 RT "Characterization of nine novel mutations in the CD40 ligand gene in
 RT patients with X-linked hyper IgM syndrome of various ancestry.";
 RL Am. J. Hum. Genet. 56:898-906(1995).
 RN [14]
 RP VARIANTS HIGM1 PRO-155 AND VAL-227, AND VARIANT ARG-219.
 RX MEDLINE=96133533; PubMed=8550833;
 RA Lin Q., Rohrer J., Allen R.C., Larche M., Greene J.M., Shigeoka A.O.,
 RA Gatti R.A., Derauf D.C., Belmont J.W., Conley M.E.;

RT "A single strand conformation polymorphism study of CD40 ligand.
RT Efficient mutation analysis and carrier detection for X-linked hyper
RT IgM syndrome.";
RL J. Clin. Invest. 97:196-201(1996).
RN [15]
RP VARIANTS HIGM1 ARG-36; CYS-140; SER-231; MET-254 AND GLY-227 DEL.
RX MEDLINE=97295077; PubMed=9150729;
RA Nonoyama S., Shimadzu M., Toru H., Seyama K., Nunoi H., Neubauer M.,
RA Yata J.-I., Och H.D.;
RT "Mutations of the CD40 ligand gene in 13 Japanese patients with
RT X-linked hyper-IgM syndrome.";
RL Hum. Genet. 99:624-627(1997).
CC -!- FUNCTION: Mediates B-cell proliferation in the absence of co-
CC stimulus as well as IgE production in the presence of IL-4.
CC Involved in immunoglobulin class switching.
CC -!- SUBUNIT: Homotrimer.
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Also exists as an
CC extracellular soluble form.
CC -!- TISSUE SPECIFICITY: Specifically expressed on activated CD4+
CC T-lymphocytes.
CC -!- PTM: The soluble form derives from the membrane form by
CC proteolytic processing.
CC -!- DISEASE: Defects in TNFSF5 are the cause of X-linked
CC immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]. HIGM1
CC is an immunoglobulin isotype switch defect characterized by
CC elevated concentrations of serum IgM and decreased amounts of all
CC other isotypes. Affected males present at an early age (usually
CC within the first year of life) recurrent bacterial and
CC opportunistic infections, including pneumocystis carinii pneumonia
CC and intractable diarrhea due to cryptosporidium infection. Despite
CC substitution treatment with intravenous immunoglobulin, the
CC overall prognosis is rather poor, with a death rate of about 10%
CC before adolescence.
CC -!- SIMILARITY: Belongs to the tumor necrosis factor family.
CC -!- DATABASE: NAME=CD40Lbase;
CC NOTE=European CD40L defect database (mutation db);
CC WWW="http://www.expasy.org/cd40lbase/";
CC FTP="ftp://ftp.expasy.org/databases/cd40lbase".
CC -!- DATABASE: NAME=PROW; NOTE=CD guide CD154 entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cd154.htm".

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----

DR EMBL; X68550; CAA48554.1; -.
DR EMBL; Z15017; CAA78737.1; -.
DR EMBL; X67878; CAA48077.1; -.
DR EMBL; L07414; AAA35662.1; -.
DR EMBL; D31797; BAA06599.1; -.
DR EMBL; D31793; BAA06599.1; JOINED.
DR EMBL; D31794; BAA06599.1; JOINED.
DR EMBL; D31795; BAA06599.1; JOINED.

DR EMBL; D31796; BAA06599.1; JOINED.
 DR PIR; S28017; I53476.
 DR PDB; 1ALY; 17-SEP-97.
 DR PDB; 1I9R; 22-MAY-02.
 DR Genew; HGNC:11935; TNFSF5.
 DR MIM; 300386; -.
 DR MIM; 308230; -.
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0005625; C:soluble fraction; TAS.
 DR GO; GO:0005174; F:CD40 receptor binding; IPI.
 DR GO; GO:0006916; P:anti-apoptosis; IDA.
 DR GO; GO:0042100; P:B-cell proliferation; IDA.
 DR GO; GO:0006954; P:inflammatory response; IDA.
 DR GO; GO:0045190; P:isotype switching; ISS.
 DR GO; GO:0007159; P:leukocyte cell adhesion; NAS.
 DR GO; GO:0030168; P:platelet activation; IDA.
 DR GO; GO:0007165; P:signal transduction; ISS.
 DR InterPro; IPR003263; TNF_5.
 DR InterPro; IPR006052; TNF_family.
 DR InterPro; IPR008983; TNF_like.

Query Match 9.4%; Score 158.5; DB 1; Length 261;
 Best Local Similarity 24.5%; Pred. No. 2.3e-06;
 Matches 68; Conservative 53; Mismatches 113; Indels 43; Gaps 15;

Qy	45	SRSMFVALLGLGL-GQVVC	SVALFFYFRAQMDPNRI	SEDGTHCIYRILRLHEN	ADFQDT-	102
		: : : ::	:: : ::	:		
Db	20	SMKIFMYLLTVFLITQM	IGSALFAVYLHRRLD--	KIEDE-----	RNLHEDFVFMKTI	69
Qy	103	-TLESQDTKLIPDSCRRI	KQAFQGA	VQKELQHIVGSQHIRA	EKAMVDG	SWLDLAKRSKLE 161
		: : : ::	: : : : :: :			
Db	70	QRCNTGERSLSLLNCEE	IKSQFEGFV-KDIM--	-----	LNKEETKKENSF-	EMQKGDQ-N 119
Qy	162	AQPFAHLTINATDIPSG	SHKVSLS	SWYHDRGWAKISN--	MTFSNGK-LIV	NQDGFYYLYA 218
		: : : : :	: :			
Db	120	PQIAAHVISEAS-----	SKTTSVLQW-AEKGY	TMSNNLV	TLENGKQLTVKRQ	GLYYIYA 173
Qy	219	NICFRHHETSGDLATE	YLQLMVY	TKTSIKIPS--	SHTLMKGGSTKY	WSGNSEFHFYSIN 276
		: : : :: :	: : :			
Db	174	QVTFCSNREASSQAP-----	FIASLCLKSPGRFER	ILLRAANTH--	SSAKPCGQQSIH	224
Qy	277	VGGFFKLRS	GEEISIEVSNPSLLD	PDQDATYFGAFKV		313
		: :: : : :: :	:			
Db	225	LGGVFELQPGASVFN	VTDP	SQVSHGTGFTSFGL	LKL	261

Search completed: September 15, 2004, 08:32:55
 Job time : 25 secs